JP2009107947A - Agent for treating diabetes, containing pyrazolyl 5-thioglucoside compound as active ingredient - Google Patents
Agent for treating diabetes, containing pyrazolyl 5-thioglucoside compound as active ingredient Download PDFInfo
- Publication number
- JP2009107947A JP2009107947A JP2007279690A JP2007279690A JP2009107947A JP 2009107947 A JP2009107947 A JP 2009107947A JP 2007279690 A JP2007279690 A JP 2007279690A JP 2007279690 A JP2007279690 A JP 2007279690A JP 2009107947 A JP2009107947 A JP 2009107947A
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- alkyl group
- hydrogen atom
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 156
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 39
- 239000004480 active ingredient Substances 0.000 title claims abstract description 25
- 125000003226 pyrazolyl group Chemical group 0.000 title claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 34
- -1 piperazino Chemical group 0.000 claims description 81
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 58
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 44
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 39
- 239000003814 drug Substances 0.000 claims description 38
- 229940124597 therapeutic agent Drugs 0.000 claims description 24
- 125000005037 alkyl phenyl group Chemical group 0.000 claims description 21
- 125000001424 substituent group Chemical group 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 230000003449 preventive effect Effects 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims description 8
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 3
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 125000004434 sulfur atom Chemical group 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims 5
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 22
- 239000008103 glucose Substances 0.000 abstract description 18
- 201000009104 prediabetes syndrome Diseases 0.000 abstract description 14
- 208000002705 Glucose Intolerance Diseases 0.000 abstract description 13
- 230000002401 inhibitory effect Effects 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 8
- 239000003795 chemical substances by application Substances 0.000 abstract description 7
- 238000010521 absorption reaction Methods 0.000 abstract description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 2
- 108091006277 SLC5A1 Proteins 0.000 abstract 1
- 102000058090 Sodium-Glucose Transporter 1 Human genes 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 111
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 90
- 239000000243 solution Substances 0.000 description 44
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 42
- 238000006243 chemical reaction Methods 0.000 description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 39
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 38
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 33
- 238000003786 synthesis reaction Methods 0.000 description 33
- 230000015572 biosynthetic process Effects 0.000 description 32
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- 239000002904 solvent Substances 0.000 description 30
- 239000000203 mixture Substances 0.000 description 28
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- 238000010898 silica gel chromatography Methods 0.000 description 24
- 238000004519 manufacturing process Methods 0.000 description 23
- 230000002829 reductive effect Effects 0.000 description 23
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 19
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 18
- 238000005481 NMR spectroscopy Methods 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 18
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 17
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 16
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 239000003112 inhibitor Substances 0.000 description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 15
- 239000000843 powder Substances 0.000 description 15
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 15
- 238000005160 1H NMR spectroscopy Methods 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 14
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 13
- 239000002585 base Substances 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 229910052763 palladium Inorganic materials 0.000 description 9
- 150000003217 pyrazoles Chemical class 0.000 description 9
- 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 8
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 8
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 8
- 229910000024 caesium carbonate Inorganic materials 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 125000001841 imino group Chemical group [H]N=* 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 239000012298 atmosphere Substances 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 101000716688 Homo sapiens Sodium/glucose cotransporter 1 Proteins 0.000 description 6
- 101000716682 Homo sapiens Sodium/glucose cotransporter 2 Proteins 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 125000002947 alkylene group Chemical group 0.000 description 6
- ZGJLJEMLZMXNFD-UHFFFAOYSA-N but-3-enamide Chemical compound NC(=O)CC=[CH] ZGJLJEMLZMXNFD-UHFFFAOYSA-N 0.000 description 6
- 229910000019 calcium carbonate Inorganic materials 0.000 description 6
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 6
- 102000052194 human SLC5A1 Human genes 0.000 description 6
- 102000052543 human SLC5A2 Human genes 0.000 description 6
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 210000000813 small intestine Anatomy 0.000 description 6
- WRLSNQXIGKWPGJ-UHFFFAOYSA-N 2-methylpropanamide Chemical group C[C](C)C(N)=O WRLSNQXIGKWPGJ-UHFFFAOYSA-N 0.000 description 5
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 5
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 230000009102 absorption Effects 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 238000010511 deprotection reaction Methods 0.000 description 5
- 239000002274 desiccant Substances 0.000 description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- 108010011459 Exenatide Proteins 0.000 description 4
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 4
- 238000006751 Mitsunobu reaction Methods 0.000 description 4
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102100037202 Sodium/myo-inositol cotransporter 2 Human genes 0.000 description 4
- 101710090560 Sodium/myo-inositol cotransporter 2 Proteins 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- PVEOYINWKBTPIZ-UHFFFAOYSA-N but-3-enoic acid Chemical compound OC(=O)CC=C PVEOYINWKBTPIZ-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- IJJLRUSZMLMXCN-SLPGGIOYSA-N (2r,3r,4s,5r)-2,3,4,6-tetrahydroxy-5-sulfanylhexanal Chemical class OC[C@@H](S)[C@@H](O)[C@H](O)[C@@H](O)C=O IJJLRUSZMLMXCN-SLPGGIOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 235000019743 Choline chloride Nutrition 0.000 description 3
- 208000002249 Diabetes Complications Diseases 0.000 description 3
- 206010012655 Diabetic complications Diseases 0.000 description 3
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 3
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 102000000070 Sodium-Glucose Transport Proteins Human genes 0.000 description 3
- 108010080361 Sodium-Glucose Transport Proteins Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 239000000883 anti-obesity agent Substances 0.000 description 3
- 229940125710 antiobesity agent Drugs 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 3
- 229960003178 choline chloride Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000006264 debenzylation reaction Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 3
- 229960001519 exenatide Drugs 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- HOVAGTYPODGVJG-UHFFFAOYSA-N methyl beta-galactoside Natural products COC1OC(CO)C(O)C(O)C1O HOVAGTYPODGVJG-UHFFFAOYSA-N 0.000 description 3
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- LFQULJPVXNYWAG-UHFFFAOYSA-N sodium;phenylmethanolate Chemical compound [Na]OCC1=CC=CC=C1 LFQULJPVXNYWAG-UHFFFAOYSA-N 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 2
- ZHMVQPQIFCBPRQ-QKYBYQKWSA-N (2R,3R,4S,5S,6R)-2-[[4-[[4-(2-aminoethoxy)-2-methylphenyl]methyl]-5-propan-2-yl-1H-pyrazol-3-yl]oxy]-6-(hydroxymethyl)thiane-3,4,5-triol Chemical compound C=1C=C(OCCN)C=C(C)C=1CC1=C(C(C)C)NN=C1O[C@@H]1S[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZHMVQPQIFCBPRQ-QKYBYQKWSA-N 0.000 description 2
- QUBGNANSBUZBTA-QKYBYQKWSA-N (2R,3R,4S,5S,6R)-2-[[4-[[4-(2-hydroxyethoxy)-2-methylphenyl]methyl]-5-propan-2-yl-1H-pyrazol-3-yl]oxy]-6-(hydroxymethyl)thiane-3,4,5-triol Chemical compound C=1C=C(OCCO)C=C(C)C=1CC1=C(C(C)C)NN=C1O[C@@H]1S[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QUBGNANSBUZBTA-QKYBYQKWSA-N 0.000 description 2
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 2
- 102000004277 11-beta-hydroxysteroid dehydrogenases Human genes 0.000 description 2
- 108090000874 11-beta-hydroxysteroid dehydrogenases Proteins 0.000 description 2
- ZIOBGZDFMKCKGZ-UHFFFAOYSA-N 2-amino-2-methylpropanamide Chemical compound CC(C)(N)C(N)=O ZIOBGZDFMKCKGZ-UHFFFAOYSA-N 0.000 description 2
- SRFCAWATPLCLMG-UHFFFAOYSA-N 3-[3-ethoxy-1-[[4-[(2-phenyl-1,3-thiazol-4-yl)methoxy]phenyl]methyl]pyrazol-4-yl]propanoic acid Chemical compound C1=C(CCC(O)=O)C(OCC)=NN1CC(C=C1)=CC=C1OCC1=CSC(C=2C=CC=CC=2)=N1 SRFCAWATPLCLMG-UHFFFAOYSA-N 0.000 description 2
- WZFZJEPHYDDFCT-UHFFFAOYSA-N 3-chloro-2-methyl-n-[4-[2-(3-oxomorpholin-4-yl)ethyl]-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CCN2C(COCC2)=O)=CS1 WZFZJEPHYDDFCT-UHFFFAOYSA-N 0.000 description 2
- WHJJAQSRKKNNKR-UHFFFAOYSA-N 4-[[2-methyl-4-(2-phenylmethoxyethoxy)phenyl]methyl]-5-propan-2-yl-1,2-dihydropyrazol-3-one Chemical compound N1NC(=O)C(CC=2C(=CC(OCCOCC=3C=CC=CC=3)=CC=2)C)=C1C(C)C WHJJAQSRKKNNKR-UHFFFAOYSA-N 0.000 description 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 2
- CJEBRBLABFHOMD-SHPGVJHPSA-N CC1=C(C=CC(=C1)OCCO)CC2=C(NN=C2O[C@H]3[C@@H]([C@H]([C@@H]([C@H](S3)COC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C)C(C)C Chemical compound CC1=C(C=CC(=C1)OCCO)CC2=C(NN=C2O[C@H]3[C@@H]([C@H]([C@@H]([C@H](S3)COC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C)C(C)C CJEBRBLABFHOMD-SHPGVJHPSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 229940127193 DGAT1 inhibitor Drugs 0.000 description 2
- 238000007341 Heck reaction Methods 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 229940126557 INCB13739 Drugs 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 2
- 108010019598 Liraglutide Proteins 0.000 description 2
- 108010075639 MAP Kinase Kinase Kinase 5 Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102100033127 Mitogen-activated protein kinase kinase kinase 5 Human genes 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000019280 Pancreatic lipases Human genes 0.000 description 2
- 108050006759 Pancreatic lipases Proteins 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 229960002632 acarbose Drugs 0.000 description 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic acid anhydride Natural products CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 239000003524 antilipemic agent Substances 0.000 description 2
- 229960004676 antithrombotic agent Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- MVCQKIKWYUURMU-UHFFFAOYSA-N cetilistat Chemical compound C1=C(C)C=C2C(=O)OC(OCCCCCCCCCCCCCCCC)=NC2=C1 MVCQKIKWYUURMU-UHFFFAOYSA-N 0.000 description 2
- 229950002397 cetilistat Drugs 0.000 description 2
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- SVABQOITNJTVNJ-UHFFFAOYSA-N diphenyl-2-pyridylphosphine Chemical compound C1=CC=CC=C1P(C=1N=CC=CC=1)C1=CC=CC=C1 SVABQOITNJTVNJ-UHFFFAOYSA-N 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 230000004190 glucose uptake Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 229960002600 icosapent ethyl Drugs 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- HOVAGTYPODGVJG-ZFYZTMLRSA-N methyl alpha-D-glucopyranoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HOVAGTYPODGVJG-ZFYZTMLRSA-N 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 229950005805 monteplase Drugs 0.000 description 2
- 108010075698 monteplase Proteins 0.000 description 2
- BDQCDIWFPIDPQU-NDEPHWFRSA-N n-methyl-5-[4-[1-[(1r)-3-oxospiro[2-benzofuran-1,3'-pyrrolidine]-1'-carbonyl]cyclopropyl]phenyl]pyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC=C1C1=CC=C(C2(CC2)C(=O)N2C[C@@]3(CC2)C2=CC=CC=C2C(=O)O3)C=C1 BDQCDIWFPIDPQU-NDEPHWFRSA-N 0.000 description 2
- 229960000698 nateglinide Drugs 0.000 description 2
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 238000007410 oral glucose tolerance test Methods 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 229940116369 pancreatic lipase Drugs 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 229960002797 pitavastatin Drugs 0.000 description 2
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229910003446 platinum oxide Inorganic materials 0.000 description 2
- 125000006410 propenylene group Chemical group 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- UAOCLDQAQNNEAX-ABMICEGHSA-N remogliflozin etabonate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)OCC)O[C@H]1OC1=NN(C(C)C)C(C)=C1CC1=CC=C(OC(C)C)C=C1 UAOCLDQAQNNEAX-ABMICEGHSA-N 0.000 description 2
- 229960004937 saxagliptin Drugs 0.000 description 2
- 108010033693 saxagliptin Proteins 0.000 description 2
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 2
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 1
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
- XZYQYQOGFSNLEZ-YERJVIMESA-N (2R,3R,4S,5S,6R)-2-[[4-[[4-[2-[bis(2-phenylmethoxyethyl)amino]ethoxy]-2-methylphenyl]methyl]-5-propan-2-yl-1H-pyrazol-3-yl]oxy]-6-(hydroxymethyl)thiane-3,4,5-triol Chemical compound C=1C=C(OCCN(CCOCC=2C=CC=CC=2)CCOCC=2C=CC=CC=2)C=C(C)C=1CC1=C(C(C)C)NN=C1O[C@@H]1S[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XZYQYQOGFSNLEZ-YERJVIMESA-N 0.000 description 1
- MWKUBHOAIGDNBY-IOLXHVLYSA-N (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[[4-[[2-methyl-4-(2-phenylmethoxyethoxy)phenyl]methyl]-5-propan-2-yl-1H-pyrazol-3-yl]oxy]thiane-3,4,5-triol Chemical compound C=1C=C(OCCOCC=2C=CC=CC=2)C=C(C)C=1CC1=C(C(C)C)NN=C1O[C@@H]1S[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O MWKUBHOAIGDNBY-IOLXHVLYSA-N 0.000 description 1
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 description 1
- DMYZJLOWGSRVKP-RTBURBONSA-N (2r,4r)-1-n-(4-chlorophenyl)-4-hydroxy-2-n-[4-(3-oxomorpholin-4-yl)phenyl]pyrrolidine-1,2-dicarboxamide Chemical compound N1([C@H](C[C@H](C1)O)C(=O)NC=1C=CC(=CC=1)N1C(COCC1)=O)C(=O)NC1=CC=C(Cl)C=C1 DMYZJLOWGSRVKP-RTBURBONSA-N 0.000 description 1
- GYIYAOUGKJSCCG-HTRCEHHLSA-N (2s,3r)-2-[(6-aminopyridin-3-yl)methyl]-3-sulfanylbutanoic acid Chemical compound C[C@@H](S)[C@H](C(O)=O)CC1=CC=C(N)N=C1 GYIYAOUGKJSCCG-HTRCEHHLSA-N 0.000 description 1
- JSYGLDMGERSRPC-FQUUOJAGSA-N (2s,4s)-4-fluoro-1-[2-[[(1r,3s)-3-(1,2,4-triazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C1[C@@H](F)C[C@@H](C#N)N1C(=O)CN[C@H]1C[C@@H](CN2N=CN=C2)CC1 JSYGLDMGERSRPC-FQUUOJAGSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- VMDKRSNUUUUARH-MQDBWYGVSA-N (3s)-4-[[(2s)-1-[[(2s)-2-[[(2s)-3-(1h-indol-3-yl)-2-[[2-[[(2s)-2-[[2-(4-sulfooxyphenyl)acetyl]amino]hexanoyl]amino]acetyl]amino]propanoyl]amino]hexanoyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(methylamino)-4-oxobutanoic acid Chemical compound N([C@@H](CCCC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCC)C(=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC)C(=O)CC1=CC=C(OS(O)(=O)=O)C=C1 VMDKRSNUUUUARH-MQDBWYGVSA-N 0.000 description 1
- BMHZAHGTGIZZCT-LJQANCHMSA-N (4r)-2-[(4-bromo-2-fluorophenyl)methyl]-6-fluorospiro[isoquinoline-4,3'-pyrrolidine]-1,2',3,5'-tetrone Chemical compound C1([C@]2(C(NC(=O)C2)=O)C2=O)=CC(F)=CC=C1C(=O)N2CC1=CC=C(Br)C=C1F BMHZAHGTGIZZCT-LJQANCHMSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- VLSDXINSOMDCBK-BQYQJAHWSA-N (E)-1,1'-azobis(N,N-dimethylformamide) Chemical compound CN(C)C(=O)\N=N\C(=O)N(C)C VLSDXINSOMDCBK-BQYQJAHWSA-N 0.000 description 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- WTAPZWXVSZMMDG-UHFFFAOYSA-N 1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1C=CC(=O)C=CC1=CC=CC=C1 WTAPZWXVSZMMDG-UHFFFAOYSA-N 0.000 description 1
- UGRMITBWUVWUEB-UHFFFAOYSA-N 1-$l^{1}-oxidanyl-3-methylbenzene Chemical group CC1=CC=CC([O])=C1 UGRMITBWUVWUEB-UHFFFAOYSA-N 0.000 description 1
- KMXPHBJUGYLXDM-UHFFFAOYSA-N 1-(7-hydroxy-6,6-dimethyl-7,8-dihydropyrano[2,3-f][2,1,3]benzoxadiazol-8-yl)piperidin-2-one Chemical compound OC1C(C)(C)OC2=CC3=NON=C3C=C2C1N1CCCCC1=O KMXPHBJUGYLXDM-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- YLRBJYMANQKEAW-UHFFFAOYSA-N 1-bromo-4-(bromomethyl)benzene Chemical compound BrCC1=CC=C(Br)C=C1 YLRBJYMANQKEAW-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- 125000004825 2,2-dimethylpropylene group Chemical group [H]C([H])([H])C(C([H])([H])[H])(C([H])([H])[*:1])C([H])([H])[*:2] 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- NMRWDFUZLLQSBN-UHFFFAOYSA-N 2,4-dichloro-n-(3,5-dichloro-4-quinolin-3-yloxyphenyl)benzenesulfonamide Chemical compound ClC1=CC(Cl)=CC=C1S(=O)(=O)NC(C=C1Cl)=CC(Cl)=C1OC1=CN=C(C=CC=C2)C2=C1 NMRWDFUZLLQSBN-UHFFFAOYSA-N 0.000 description 1
- DDTQLPXXNHLBAB-UHFFFAOYSA-N 2-(4-chlorophenyl)-2-[3-(trifluoromethyl)phenoxy]acetic acid Chemical compound C=1C=C(Cl)C=CC=1C(C(=O)O)OC1=CC=CC(C(F)(F)F)=C1 DDTQLPXXNHLBAB-UHFFFAOYSA-N 0.000 description 1
- CMLUGNQVANVZHY-POURPWNDSA-N 2-[1-[2-[(3r,5s)-1-(3-acetyloxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-5h-4,1-benzoxazepin-3-yl]acetyl]piperidin-4-yl]acetic acid Chemical compound COC1=CC=CC([C@@H]2C3=CC(Cl)=CC=C3N(CC(C)(C)COC(C)=O)C(=O)[C@@H](CC(=O)N3CCC(CC(O)=O)CC3)O2)=C1OC CMLUGNQVANVZHY-POURPWNDSA-N 0.000 description 1
- ODYDHBPMKYCXOZ-QKYBYQKWSA-N 2-[2-[3-methyl-4-[[5-propan-2-yl-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)thian-2-yl]oxy-1H-pyrazol-4-yl]methyl]phenoxy]ethyl]guanidine Chemical compound C=1C=C(OCCN=C(N)N)C=C(C)C=1CC1=C(C(C)C)NN=C1O[C@@H]1S[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ODYDHBPMKYCXOZ-QKYBYQKWSA-N 0.000 description 1
- QBMWXMFMIMDQML-JZWLZXDTSA-N 2-[2-[3-methyl-4-[[5-propan-2-yl-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)thian-2-yl]oxy-1H-pyrazol-4-yl]methyl]phenoxy]ethylamino]acetamide Chemical compound C=1C=C(OCCNCC(N)=O)C=C(C)C=1CC1=C(C(C)C)NN=C1O[C@@H]1S[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QBMWXMFMIMDQML-JZWLZXDTSA-N 0.000 description 1
- NSVFSAJIGAJDMR-UHFFFAOYSA-N 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxido-1,3,2-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate Chemical compound CC=1NC(C)=C(C(=O)OCCN(CC=2C=CC=CC=2)C=2C=CC=CC=2)C(C=2C=C(C=CC=2)[N+]([O-])=O)C=1P1(=O)OCC(C)(C)CO1 NSVFSAJIGAJDMR-UHFFFAOYSA-N 0.000 description 1
- BHCOXAHSKHZKSC-UHFFFAOYSA-N 2-amino-2-methyl-1-(4-methylpiperazin-1-yl)propan-1-one Chemical compound CN1CCN(C(=O)C(C)(C)N)CC1 BHCOXAHSKHZKSC-UHFFFAOYSA-N 0.000 description 1
- UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 description 1
- HUGNLEZLTOVJLD-UHFFFAOYSA-N 2-bromo-3-methylphenol Chemical compound CC1=CC=CC(O)=C1Br HUGNLEZLTOVJLD-UHFFFAOYSA-N 0.000 description 1
- FWOHDAGPWDEWIB-UHFFFAOYSA-N 2-bromoethoxymethylbenzene Chemical compound BrCCOCC1=CC=CC=C1 FWOHDAGPWDEWIB-UHFFFAOYSA-N 0.000 description 1
- ROJNYKZWTOHRNU-UHFFFAOYSA-N 2-chloro-4,5-difluoro-n-[[2-methoxy-5-(methylcarbamoylamino)phenyl]carbamoyl]benzamide Chemical compound CNC(=O)NC1=CC=C(OC)C(NC(=O)NC(=O)C=2C(=CC(F)=C(F)C=2)Cl)=C1 ROJNYKZWTOHRNU-UHFFFAOYSA-N 0.000 description 1
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 1
- JCCBZCMSYUSCFM-UHFFFAOYSA-N 2-chlorobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1Cl JCCBZCMSYUSCFM-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- YZQLWPMZQVHJED-UHFFFAOYSA-N 2-methylpropanethioic acid S-[2-[[[1-(2-ethylbutyl)cyclohexyl]-oxomethyl]amino]phenyl] ester Chemical compound C=1C=CC=C(SC(=O)C(C)C)C=1NC(=O)C1(CC(CC)CC)CCCCC1 YZQLWPMZQVHJED-UHFFFAOYSA-N 0.000 description 1
- BCSVCWVQNOXFGL-UHFFFAOYSA-N 3,4-dihydro-4-oxo-3-((5-trifluoromethyl-2-benzothiazolyl)methyl)-1-phthalazine acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=NC2=CC(C(F)(F)F)=CC=C2S1 BCSVCWVQNOXFGL-UHFFFAOYSA-N 0.000 description 1
- IQQYLBIFFAFHPD-UHFFFAOYSA-N 3-(iminomethylideneamino)propan-1-amine;hydrochloride Chemical compound Cl.NCCCN=C=N IQQYLBIFFAFHPD-UHFFFAOYSA-N 0.000 description 1
- MDBARDSTXONTFS-MNDUUMEHSA-N 3-[3-[3-methyl-4-[[5-propan-2-yl-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1h-pyrazol-4-yl]methyl]phenoxy]propylamino]propanamide Chemical compound C=1C=C(OCCCNCCC(N)=O)C=C(C)C=1CC1=C(C(C)C)NN=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O MDBARDSTXONTFS-MNDUUMEHSA-N 0.000 description 1
- DGENZVKCTGIDRZ-UHFFFAOYSA-N 3-[4-[(3-phenoxyphenyl)methylamino]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1NCC1=CC=CC(OC=2C=CC=CC=2)=C1 DGENZVKCTGIDRZ-UHFFFAOYSA-N 0.000 description 1
- MCFBUIIRFZBRCU-UHFFFAOYSA-N 4-[1-[5-[6-(trifluoromethyl)-1h-benzimidazol-2-yl]pyridin-2-yl]piperidin-4-yl]oxycyclohexane-1-carboxylic acid Chemical compound C1CC(C(=O)O)CCC1OC1CCN(C=2N=CC(=CC=2)C=2NC3=CC(=CC=C3N=2)C(F)(F)F)CC1 MCFBUIIRFZBRCU-UHFFFAOYSA-N 0.000 description 1
- JRHNIQQUVJOPQC-AQNFWKISSA-N 4-methyl-7-[(2r,3r,4s,5s)-3,4,5-trihydroxythian-2-yl]oxychromen-2-one Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1O[C@@H]1SC[C@@H](O)[C@H](O)[C@H]1O JRHNIQQUVJOPQC-AQNFWKISSA-N 0.000 description 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- MPLLLQUZNJSVTK-UHFFFAOYSA-N 5-[3-[4-[2-(4-fluorophenyl)ethoxy]phenyl]propyl]furan-2-carboxylic acid Chemical compound O1C(C(=O)O)=CC=C1CCCC(C=C1)=CC=C1OCCC1=CC=C(F)C=C1 MPLLLQUZNJSVTK-UHFFFAOYSA-N 0.000 description 1
- AJJISMLYIMQAKP-OAHLLOKOSA-N 5-[4-[(2r)-4-(3-fluoro-4-methylsulfonylphenoxy)butan-2-yl]piperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(CC2)[C@H](C)CCOC=2C=C(F)C(=CC=2)S(C)(=O)=O)=N1 AJJISMLYIMQAKP-OAHLLOKOSA-N 0.000 description 1
- BKYKPTRYDKTTJY-UHFFFAOYSA-N 6-chloro-3-(cyclopentylmethyl)-1,1-dioxo-3,4-dihydro-2H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1CCCC1 BKYKPTRYDKTTJY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 108010093583 ART123 Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- PTQXTEKSNBVPQJ-UHFFFAOYSA-N Avasimibe Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1CC(=O)NS(=O)(=O)OC1=C(C(C)C)C=CC=C1C(C)C PTQXTEKSNBVPQJ-UHFFFAOYSA-N 0.000 description 1
- 108010028845 BIM 23190 Proteins 0.000 description 1
- 108700001281 BIM 51077 Proteins 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000002081 C09CA05 - Tasosartan Substances 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- VDTFJRMLGCUYLW-SHPGVJHPSA-N CC1=C(C=CC(=C1)OCCN)CC2=C(NN=C2O[C@H]3[C@@H]([C@H]([C@@H]([C@H](S3)COC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C)C(C)C Chemical compound CC1=C(C=CC(=C1)OCCN)CC2=C(NN=C2O[C@H]3[C@@H]([C@H]([C@@H]([C@H](S3)COC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C)C(C)C VDTFJRMLGCUYLW-SHPGVJHPSA-N 0.000 description 1
- 108010055448 CJC 1131 Proteins 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 1
- 229940122820 Cannabinoid receptor antagonist Drugs 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 108090000201 Carboxypeptidase B2 Proteins 0.000 description 1
- 102100035023 Carboxypeptidase B2 Human genes 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- BMOVQUBVGICXQN-UHFFFAOYSA-N Clinofibrate Chemical compound C1=CC(OC(C)(CC)C(O)=O)=CC=C1C1(C=2C=CC(OC(C)(CC)C(O)=O)=CC=2)CCCCC1 BMOVQUBVGICXQN-UHFFFAOYSA-N 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 125000003535 D-glucopyranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@@]([H])(O[H])[C@]1([H])O[H] 0.000 description 1
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 description 1
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 1
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 1
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- VXLCNTLWWUDBSO-UHFFFAOYSA-N Ethiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)NC(CC)NC2=C1 VXLCNTLWWUDBSO-UHFFFAOYSA-N 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- 102100023374 Forkhead box protein M1 Human genes 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 102100026148 Free fatty acid receptor 1 Human genes 0.000 description 1
- 102000027487 Fructose-Bisphosphatase Human genes 0.000 description 1
- 108010017464 Fructose-Bisphosphatase Proteins 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 229940100607 GPR119 agonist Drugs 0.000 description 1
- 229940125827 GPR40 agonist Drugs 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102400000442 Ghrelin-28 Human genes 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- 102000030595 Glucokinase Human genes 0.000 description 1
- 108010021582 Glucokinase Proteins 0.000 description 1
- 229940121931 Gluconeogenesis inhibitor Drugs 0.000 description 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 1
- HNSCCNJWTJUGNQ-UHFFFAOYSA-N Glyclopyramide Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)NC(=O)NN1CCCC1 HNSCCNJWTJUGNQ-UHFFFAOYSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101000907578 Homo sapiens Forkhead box protein M1 Proteins 0.000 description 1
- 101000912510 Homo sapiens Free fatty acid receptor 1 Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 239000003458 I kappa b kinase inhibitor Substances 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
- 102000029828 Melanin-concentrating hormone receptor Human genes 0.000 description 1
- 108010047068 Melanin-concentrating hormone receptor Proteins 0.000 description 1
- 101710151321 Melanostatin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- OKJHGOPITGTTIM-DEOSSOPVSA-N Naveglitazar Chemical compound C1=CC(C[C@H](OC)C(O)=O)=CC=C1OCCCOC(C=C1)=CC=C1OC1=CC=CC=C1 OKJHGOPITGTTIM-DEOSSOPVSA-N 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 102400000064 Neuropeptide Y Human genes 0.000 description 1
- 108090000742 Neurotrophin 3 Proteins 0.000 description 1
- 102100029268 Neurotrophin-3 Human genes 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- KUEUWHJGRZKESU-UHFFFAOYSA-N Niceritrol Chemical compound C=1C=CN=CC=1C(=O)OCC(COC(=O)C=1C=NC=CC=1)(COC(=O)C=1C=NC=CC=1)COC(=O)C1=CC=CN=C1 KUEUWHJGRZKESU-UHFFFAOYSA-N 0.000 description 1
- VRAHPESAMYMDQI-UHFFFAOYSA-N Nicomol Chemical compound C1CCC(COC(=O)C=2C=NC=CC=2)(COC(=O)C=2C=NC=CC=2)C(O)C1(COC(=O)C=1C=NC=CC=1)COC(=O)C1=CC=CN=C1 VRAHPESAMYMDQI-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 101100516956 Oryza sativa subsp. japonica NPR2 gene Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- UJEWTUDSLQGTOA-UHFFFAOYSA-N Piretanide Chemical compound C=1C=CC=CC=1OC=1C(S(=O)(=O)N)=CC(C(O)=O)=CC=1N1CCCC1 UJEWTUDSLQGTOA-UHFFFAOYSA-N 0.000 description 1
- CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 description 1
- 229940127315 Potassium Channel Openers Drugs 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 102100040918 Pro-glucagon Human genes 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- JLRNKCZRCMIVKA-UHFFFAOYSA-N Simfibrate Chemical compound C=1C=C(Cl)C=CC=1OC(C)(C)C(=O)OCCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 JLRNKCZRCMIVKA-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229940127504 Somatostatin Receptor Agonists Drugs 0.000 description 1
- 229940123051 Somatostatin receptor agonist Drugs 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- OSZSMFQZURNRHS-RQICVUQASA-N [(2r,3s,4s,5r)-3,4,5-triacetyloxy-6-hydroxythian-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1SC(O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O OSZSMFQZURNRHS-RQICVUQASA-N 0.000 description 1
- BQBIFIXRYFBGAT-WIMVFMHDSA-N [4-[[5-propan-2-yl-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)thian-2-yl]oxy-1H-pyrazol-4-yl]methyl]phenyl]urea Chemical compound C=1C=C(NC(N)=O)C=CC=1CC1=C(C(C)C)NN=C1O[C@@H]1S[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O BQBIFIXRYFBGAT-WIMVFMHDSA-N 0.000 description 1
- FUMLKAFCVQJVEZ-UHFFFAOYSA-N [bromo(nitro)methyl]benzene Chemical compound [O-][N+](=O)C(Br)C1=CC=CC=C1 FUMLKAFCVQJVEZ-UHFFFAOYSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229960001466 acetohexamide Drugs 0.000 description 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
- FKCBLVCOSCZFHV-UHFFFAOYSA-N acetonitrile;ethanol Chemical compound CCO.CC#N FKCBLVCOSCZFHV-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- MKOMESMZHZNBIZ-UHFFFAOYSA-M alagebrium Chemical compound [Cl-].CC1=C(C)SC=[N+]1CC(=O)C1=CC=CC=C1 MKOMESMZHZNBIZ-UHFFFAOYSA-M 0.000 description 1
- 229960004733 albiglutide Drugs 0.000 description 1
- OGWAVGNOAMXIIM-UHFFFAOYSA-N albiglutide Chemical compound O=C(O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)CNC(=O)C(N)CC=1(N=CNC=1))CCC(=O)O)C(O)C)CC2(=CC=CC=C2))C(O)C)CO)CC(=O)O)C(C)C)CO)CO)CC3(=CC=C(O)C=C3))CC(C)C)CCC(=O)O)CCC(=O)N)C)C)CCCCN)CCC(=O)O)CC4(=CC=CC=C4))C(CC)C)C)CC=6(C5(=C(C=CC=C5)NC=6)))CC(C)C)C(C)C)CCCCN)CCCNC(=N)N OGWAVGNOAMXIIM-UHFFFAOYSA-N 0.000 description 1
- 239000003288 aldose reductase inhibitor Substances 0.000 description 1
- 229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 229960003318 alteplase Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000001858 anti-Xa Effects 0.000 description 1
- 230000001887 anti-feedant effect Effects 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
- 229960003856 argatroban Drugs 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 229950010046 avasimibe Drugs 0.000 description 1
- KGSXMPPBFPAXLY-UHFFFAOYSA-N azilsartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NOC(=O)N1 KGSXMPPBFPAXLY-UHFFFAOYSA-N 0.000 description 1
- IIOPLILENRZKRV-UHFFFAOYSA-N azosemide Chemical compound C=1C=CSC=1CNC=1C=C(Cl)C(S(=O)(=O)N)=CC=1C1=NN=N[N]1 IIOPLILENRZKRV-UHFFFAOYSA-N 0.000 description 1
- 229960004988 azosemide Drugs 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- QQFYLZXBFWWJHR-UHFFFAOYSA-M benzyl(triethyl)phosphanium;bromide Chemical compound [Br-].CC[P+](CC)(CC)CC1=CC=CC=C1 QQFYLZXBFWWJHR-UHFFFAOYSA-M 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 229960002890 beraprost Drugs 0.000 description 1
- YTCZZXIRLARSET-VJRSQJMHSA-M beraprost sodium Chemical compound [Na+].O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC([O-])=O YTCZZXIRLARSET-VJRSQJMHSA-M 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 108010055460 bivalirudin Proteins 0.000 description 1
- 229960001500 bivalirudin Drugs 0.000 description 1
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
- 229960004111 buformin Drugs 0.000 description 1
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229960004064 bumetanide Drugs 0.000 description 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- GDDSFMMICZTVCA-UHFFFAOYSA-L calcium;2-carboxyphenolate;3,7-dimethylpurine-2,6-dione Chemical compound [Ca+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.CN1C(=O)NC(=O)C2=C1N=CN2C GDDSFMMICZTVCA-UHFFFAOYSA-L 0.000 description 1
- ZQNPDAVSHFGLIQ-UHFFFAOYSA-N calcium;hydrate Chemical compound O.[Ca] ZQNPDAVSHFGLIQ-UHFFFAOYSA-N 0.000 description 1
- 229960004349 candesartan cilexetil Drugs 0.000 description 1
- 239000003536 cannabinoid receptor antagonist Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 229960001523 chlortalidone Drugs 0.000 description 1
- 239000003753 cholecystokinin receptor stimulating agent Substances 0.000 description 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 1
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 description 1
- 229960004588 cilostazol Drugs 0.000 description 1
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 1
- 229950003072 clinofibrate Drugs 0.000 description 1
- 229960002492 clobenzorex Drugs 0.000 description 1
- LRXXRIXDSAEIOR-ZDUSSCGKSA-N clobenzorex Chemical compound C([C@H](C)NCC=1C(=CC=CC=1)Cl)C1=CC=CC=C1 LRXXRIXDSAEIOR-ZDUSSCGKSA-N 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229960003206 cyclopenthiazide Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003850 dabigatran Drugs 0.000 description 1
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 description 1
- 229940018872 dalteparin sodium Drugs 0.000 description 1
- 229960003834 dapagliflozin Drugs 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 229960005227 delapril Drugs 0.000 description 1
- WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 108010073652 desirudin Proteins 0.000 description 1
- 229960000296 desirudin Drugs 0.000 description 1
- XYWBJDRHGNULKG-OUMQNGNKSA-N desirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 XYWBJDRHGNULKG-OUMQNGNKSA-N 0.000 description 1
- 229960004597 dexfenfluramine Drugs 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229940125542 dual agonist Drugs 0.000 description 1
- 229950003102 efonidipine Drugs 0.000 description 1
- 229950000269 emiglitate Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 description 1
- 229950010170 epalrestat Drugs 0.000 description 1
- CHNUOJQWGUIOLD-UHFFFAOYSA-N epalrestate Natural products C=1C=CC=CC=1C=C(C)C=C1SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960004563 eprosartan Drugs 0.000 description 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
- 229960003199 etacrynic acid Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- NWWORXYTJRPSMC-QKPAOTATSA-N ethyl 4-[2-[(2r,3r,4r,5s)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]ethoxy]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1OCCN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1 NWWORXYTJRPSMC-QKPAOTATSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 229960001582 fenfluramine Drugs 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 229940049370 fibrinolysis inhibitor Drugs 0.000 description 1
- WAAPEIZFCHNLKK-PELKAZGASA-N fidarestat Chemical compound C([C@@H](OC1=CC=C(F)C=C11)C(=O)N)[C@@]21NC(=O)NC2=O WAAPEIZFCHNLKK-PELKAZGASA-N 0.000 description 1
- 229950007256 fidarestat Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 229960001318 fondaparinux Drugs 0.000 description 1
- KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- AIWAEWBZDJARBJ-PXUUZXDZSA-N fz7co35x2s Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)CCN1C(C=CC1=O)=O)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 AIWAEWBZDJARBJ-PXUUZXDZSA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 125000005640 glucopyranosyl group Chemical group 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 229950002888 glyclopyramide Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229940095529 heparin calcium Drugs 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 229960003313 hydroflumethiazide Drugs 0.000 description 1
- DMDGGSIALPNSEE-UHFFFAOYSA-N hydroflumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O DMDGGSIALPNSEE-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 229960004569 indapamide Drugs 0.000 description 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 229960002479 isosorbide Drugs 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 229960004408 lepirudin Drugs 0.000 description 1
- OTQCKZUSUGYWBD-BRHMIFOHSA-N lepirudin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 OTQCKZUSUGYWBD-BRHMIFOHSA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 229960001093 lixisenatide Drugs 0.000 description 1
- 108010004367 lixisenatide Proteins 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- ANEBWFXPVPTEET-UHFFFAOYSA-N manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 description 1
- 229960003963 manidipine Drugs 0.000 description 1
- 229960000299 mazindol Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- FWMHZWMPUWAUPL-NDEPHWFRSA-N methyl (4s)-3-[3-[4-(3-acetamidophenyl)piperidin-1-yl]propylcarbamoyl]-4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,4-dihydropyrimidine-5-carboxylate Chemical compound N1([C@H](C(=C(NC1=O)COC)C(=O)OC)C=1C=C(F)C(F)=CC=1)C(=O)NCCCN(CC1)CCC1C1=CC=CC(NC(C)=O)=C1 FWMHZWMPUWAUPL-NDEPHWFRSA-N 0.000 description 1
- 229960003404 mexiletine Drugs 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 229950002259 minalrestat Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- OQJBFFCUFALWQL-UHFFFAOYSA-N n-(piperidine-1-carbonylimino)piperidine-1-carboxamide Chemical compound C1CCCCN1C(=O)N=NC(=O)N1CCCCC1 OQJBFFCUFALWQL-UHFFFAOYSA-N 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229950002774 nateplase Drugs 0.000 description 1
- 229950003494 naveglitazar Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 230000032064 neurotrophin production Effects 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- 229960000827 niceritrol Drugs 0.000 description 1
- 229950001071 nicomol Drugs 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- MVPQUSQUURLQKF-MCPDASDXSA-E nonasodium;(2s,3s,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3s,4s,5r,6r)-2-carboxylato-4,5-dimethoxy-6-[(2r,3r,4s,5r,6s)-6-methoxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-4,5-di Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)O[C@@H]1[C@@H](OS([O-])(=O)=O)[C@@H](OC)O[C@H](COS([O-])(=O)=O)[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@@H]2[C@@H]([C@@H](OS([O-])(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](OC)[C@H](O[C@@H]4[C@@H]([C@@H](OC)[C@H](OC)[C@@H](COS([O-])(=O)=O)O4)OC)[C@H](O3)C([O-])=O)OC)[C@@H](COS([O-])(=O)=O)O2)OS([O-])(=O)=O)[C@H](C([O-])=O)O1 MVPQUSQUURLQKF-MCPDASDXSA-E 0.000 description 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229950005036 odiparcil Drugs 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 229940125395 oral insulin Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- JRTYPQGPARWINR-UHFFFAOYSA-N palladium platinum Chemical compound [Pd].[Pt] JRTYPQGPARWINR-UHFFFAOYSA-N 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- MFPRYDMAZLLTGM-IJDGSQHYSA-N pegmusirudin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC1=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCNC(=O)OCCOCC)C(=O)N2)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)=O)CCCCNC(=O)OCCOCC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=C(O)C=C1 MFPRYDMAZLLTGM-IJDGSQHYSA-N 0.000 description 1
- 229950001482 pegmusirudin Drugs 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000003873 peroxisome proliferator activated receptor gamma antagonist Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960003243 phenformin Drugs 0.000 description 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 125000000109 phenylethoxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])O* 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003003 phosphines Chemical class 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229960001085 piretanide Drugs 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229960005483 polythiazide Drugs 0.000 description 1
- 229920000046 polythiazide Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 229960003611 pramlintide Drugs 0.000 description 1
- 108010029667 pramlintide Proteins 0.000 description 1
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- XTRUQJBVQBUKSQ-UHFFFAOYSA-N propan-2-yl 4-[1-(2-fluoro-4-methylsulfonylphenyl)pyrazolo[3,4-d]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC2=C1C=NN2C1=CC=C(S(C)(=O)=O)C=C1F XTRUQJBVQBUKSQ-UHFFFAOYSA-N 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- LHZWKWCEAXQUMX-UHFFFAOYSA-N psn-632,408 Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OCC1=NC(C=2C=CN=CC=2)=NO1 LHZWKWCEAXQUMX-UHFFFAOYSA-N 0.000 description 1
- HDOUGSFASVGDCS-UHFFFAOYSA-N pyridin-3-ylmethanamine Chemical compound NCC1=CC=CN=C1 HDOUGSFASVGDCS-UHFFFAOYSA-N 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- HNWCOANXZNKMLR-UHFFFAOYSA-N pyridoxamine dihydrochloride Chemical compound Cl.Cl.CC1=NC=C(CO)C(CN)=C1O HNWCOANXZNKMLR-UHFFFAOYSA-N 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000030558 renal glucose absorption Effects 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 1
- CRPGRUONUFDYBG-UHFFFAOYSA-N risarestat Chemical compound C1=C(OCC)C(OCCCCC)=CC=C1C1C(=O)NC(=O)S1 CRPGRUONUFDYBG-UHFFFAOYSA-N 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 229950005789 sarpogrelate Drugs 0.000 description 1
- FFYNAVGJSYHHFO-UHFFFAOYSA-N sarpogrelate Chemical compound COC1=CC=CC(CCC=2C(=CC=CC=2)OCC(CN(C)C)OC(=O)CCC(O)=O)=C1 FFYNAVGJSYHHFO-UHFFFAOYSA-N 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229960004058 simfibrate Drugs 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229950005481 sipoglitazar Drugs 0.000 description 1
- 229960004034 sitagliptin Drugs 0.000 description 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 1
- WSRBRQQGWDWSON-UHFFFAOYSA-M sodium;3,7-dimethylpurine-2,6-dione;2-hydroxybenzoate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O.CN1C(=O)NC(=O)C2=C1N=CN2C WSRBRQQGWDWSON-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940033331 soy sterol Drugs 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960000651 tasosartan Drugs 0.000 description 1
- ADXGNEYLLLSOAR-UHFFFAOYSA-N tasosartan Chemical compound C12=NC(C)=NC(C)=C2CCC(=O)N1CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 ADXGNEYLLLSOAR-UHFFFAOYSA-N 0.000 description 1
- WRGVLTAWMNZWGT-VQSPYGJZSA-N taspoglutide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 WRGVLTAWMNZWGT-VQSPYGJZSA-N 0.000 description 1
- 229950007151 taspoglutide Drugs 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- WGRQANOPCQRCME-PMACEKPBSA-N teneligliptin Chemical compound O=C([C@H]1NC[C@H](C1)N1CCN(CC1)C1=CC(=NN1C=1C=CC=CC=1)C)N1CCSC1 WGRQANOPCQRCME-PMACEKPBSA-N 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- QKSQWQOAUQFORH-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonylimino]carbamate Chemical compound CC(C)(C)OC(=O)N=NC(=O)OC(C)(C)C QKSQWQOAUQFORH-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 229960003069 tolrestat Drugs 0.000 description 1
- LUBHDINQXIHVLS-UHFFFAOYSA-N tolrestat Chemical compound OC(=O)CN(C)C(=S)C1=CC=CC2=C(C(F)(F)F)C(OC)=CC=C21 LUBHDINQXIHVLS-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- CMSGWTNRGKRWGS-NQIIRXRSSA-N torcetrapib Chemical compound COC(=O)N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CMSGWTNRGKRWGS-NQIIRXRSSA-N 0.000 description 1
- 229950004514 torcetrapib Drugs 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- 229960004813 trichlormethiazide Drugs 0.000 description 1
- LMJSLTNSBFUCMU-UHFFFAOYSA-N trichlormethiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(C(Cl)Cl)NS2(=O)=O LMJSLTNSBFUCMU-UHFFFAOYSA-N 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- 229960001254 vildagliptin Drugs 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960000883 warfarin potassium Drugs 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 229960001522 ximelagatran Drugs 0.000 description 1
- ZXIBCJHYVWYIKI-PZJWPPBQSA-N ximelagatran Chemical compound C1([C@@H](NCC(=O)OCC)C(=O)N2[C@@H](CC2)C(=O)NCC=2C=CC(=CC=2)C(\N)=N\O)CCCCC1 ZXIBCJHYVWYIKI-PZJWPPBQSA-N 0.000 description 1
- SXONDGSPUVNZLO-UHFFFAOYSA-N zenarestat Chemical compound O=C1N(CC(=O)O)C2=CC(Cl)=CC=C2C(=O)N1CC1=CC=C(Br)C=C1F SXONDGSPUVNZLO-UHFFFAOYSA-N 0.000 description 1
- 229950006343 zenarestat Drugs 0.000 description 1
- 229910000166 zirconium phosphate Inorganic materials 0.000 description 1
- 229950005346 zopolrestat Drugs 0.000 description 1
Abstract
Description
本発明は、腎臓でのグルコース再吸収に関わるナトリウム依存性グルコース共輸送体1(SGLT1)の阻害活性を有するピラゾリル 5−チオグルコシド化合物に関する。 The present invention relates to a pyrazolyl 5-thioglucoside compound having an inhibitory activity on sodium-dependent glucose cotransporter 1 (SGLT1) involved in glucose reabsorption in the kidney.
糖尿病に罹患すると、空腹時の血糖値は126mg/dL以上を示す。また、空腹時の血糖値が正常であっても、食事の後に140〜200mg/dLという高い血糖値を示す場合には、耐糖能異常(以下、IGT(impaired glucose tolerance)という。)と診断される。IGTから糖尿病の発症を遅らせることは、心血管障害のリスクを低減させると考えられ、それを示す幾つかの知見が得られている。例えば、1997年に中国で行われたDa Qing IGT and Diabetes Studyでは、ダイエットや運動を行うことでIGTから2型糖尿病への移行を有意に抑制したと報告されている(非特許文献1参照)。また、薬剤治療が有効な例として、糖の加水分解酵素を阻害し、小腸からの糖の吸収を遅延させるα−グルコシダ−ゼ阻害剤アカルボ−スを投与すると、IGTから2型糖尿病への移行を抑制し、さらに高血圧の発症も有意に抑制することが報告されている(非特許文献2参照)。 When suffering from diabetes, the fasting blood glucose level is 126 mg / dL or more. Moreover, even if the fasting blood glucose level is normal, if it shows a high blood glucose level of 140 to 200 mg / dL after meal, it is diagnosed as abnormal glucose tolerance (hereinafter referred to as IGT (impaired glucose tolerance)). The Delaying the onset of diabetes from IGT is thought to reduce the risk of cardiovascular disorders and several findings have been obtained. For example, in Da Qing IGT and Diabetes Study conducted in China in 1997, it was reported that the transition from IGT to type 2 diabetes was significantly suppressed by performing diet and exercise (see Non-Patent Document 1). . As an effective example of drug treatment, the transition from IGT to type 2 diabetes occurs when an α-glucosidase inhibitor acarbose that inhibits sugar hydrolase and delays the absorption of sugar from the small intestine is administered. In addition, it has been reported that the onset of hypertension is also significantly suppressed (see Non-Patent Document 2).
この様なことから、糖尿病の発症を抑えるには、食事療法、運動及び薬物療法によってIGTをコントロ−ルすることが重要である。 For this reason, it is important to control IGT by diet, exercise and drug therapy in order to suppress the onset of diabetes.
哺乳動物の小腸上皮には高い頻度でナトリウム依存性グルコ−ス共輸送体1(SGLT1)が発現している。このSGLT1は小腸において、ナトリウムに依存し、グルコ−ス又はガラクト−スの能動輸送を司っていることが知られている。そこで、食事由来のグルコ−ス吸収を抑制し、IGTの予防または治療を行うというコンセプトに基づき、SGLT1活性を阻害するグリコシド化合物が報告されている(特許文献1〜6参照)。 Sodium-dependent glucose cotransporter 1 (SGLT1) is frequently expressed in the small intestinal epithelium of mammals. SGLT1 is known to depend on sodium in the small intestine and to control active transport of glucose or galactose. Therefore, glycoside compounds that inhibit SGLT1 activity have been reported based on the concept of suppressing dietary glucose absorption and preventing or treating IGT (see Patent Documents 1 to 6).
また、腎臓には高頻度にナトリウム依存性グルコ−ス共輸送体2(SGLT2)が発現しており、糸球体で一旦濾過されたグルコ−スはSGLT2を介して再吸収される(非特許文献3参照)。そして、SGLT2阻害剤は、尿への糖***を促進し、血糖低下作用を招来するので、新たな糖尿病治療薬の標的分子と考えられるようになった(非特許文献4参照)。このような背景から、SGLT2阻害剤が研究されヘテロアリ−ル 5−チオグルコシド誘導体が提供されている(特許文献7参照)。 In addition, sodium-dependent glucose cotransporter 2 (SGLT2) is frequently expressed in the kidney, and glucose once filtered by glomeruli is reabsorbed via SGLT2 (Non-patent Document). 3). And since SGLT2 inhibitor accelerates | stimulates the glucose excretion to urine and brings about the hypoglycemic effect | action, it came to be considered as a target molecule of a new diabetes therapeutic drug (refer nonpatent literature 4). Against this background, SGLT2 inhibitors have been studied and heteroaryl 5-thioglucoside derivatives have been provided (see Patent Document 7).
しかしながら、従来SGLT1阻害活性を有するチオグルコシド誘導体は知られていなかった。 However, a thioglucoside derivative having SGLT1 inhibitory activity has not been known.
本発明は、選択的にSGLT1活性を阻害し、消化管からのグルコース吸収を抑制することで、IGTをコントロールする新規なピラゾリル 5−チオ−β−D−グルコピラノシド化合物を有効成分として含有する、糖尿病の予防又は治療剤を提供することを目的とする。 The present invention comprises a novel pyrazolyl 5-thio-β-D-glucopyranoside compound that controls IGT by selectively inhibiting SGLT1 activity and suppressing glucose absorption from the gastrointestinal tract as an active ingredient. It aims at providing the preventive or therapeutic agent of this.
本発明者らは前記課題を解決するために鋭意研究した結果、ある種のピラゾール誘導体を5−チオグルコシル化した化合物が、優れたSGLT1活性阻害作用を有することを見出し、本発明を完成するに至った。 As a result of diligent research to solve the above-mentioned problems, the present inventors have found that a compound obtained by 5-thioglucosylating a certain pyrazole derivative has an excellent SGLT1 activity inhibitory action, thereby completing the present invention. It came.
以下に、本発明のピラゾリル 5−チオグルコシド誘導体(以下、「本発明化合物」という)の態様を述べる。 Hereinafter, embodiments of the pyrazolyl 5-thioglucoside derivative of the present invention (hereinafter referred to as “the compound of the present invention”) will be described.
(1)本発明の態様は、下記式(I)で表されるピラゾリル 5−チオグルコシド化合物若しくはその製薬学的に許容される塩又はそれらの水和物を有効成分として含有する、糖尿病の予防又は治療剤に関する。 (1) The aspect of this invention prevents the diabetes which contains the pyrazolyl 5-thioglucoside compound or its pharmaceutically acceptable salt represented by following formula (I), or those hydrates as an active ingredient. Or it relates to a therapeutic agent.
式(I)中、Zは、C1-6アルキル基であり、
R1、R2及びR3は同一または異なって、水素原子、ハロゲン原子、C1-6アルコキシ基またはC1-6アルキル基であり、
Yは単結合、C1-6アルキレン基、C2-6アルケニレン基または−O−(CH2)n−(nは1から4の整数を示す)であり、
Qは水酸基、−OC1-4アルキルフェニル、−N(RA)RBまたは−CONHRCである、
但し、Qが水酸基、−OC1-4アルキルフェニルまたは−NH2のとき、Yは単結合ではない、
RA及びRBは同一または異なって、水素原子、−CONHRD(RDは水素原子または、水酸基及びピリジル基からなる群から選択される置換基で置換されてもよいC1-6アルキル基を示す)、−C(=NH)NHRE(REは水素原子、または−CO2C1-4アルキルフェニルである)、あるいは、C1-6アルキル基(該C1-6アルキル基は、水酸基、−CONH2及び−OC1-4アルキルフェニルからなる群から選択される置換基で置換されてもよい)であり、
RCは水酸基及び−CON(RF)RGからなる群より選択される置換基で置換されたC1-6アルキル基であり、
RF及びRGは、同一または異なって、水素原子またはC1-6アルキル基であるか、あるいはRF及びRGが結合している窒素原子と一緒になって、さらに環構成原子として、酸素原子、硫黄原子及び窒素原子から選択されるヘテロ原子を含んでも良い5〜6員のヘテロシクロアルキル基(該ヘテロシクロアルキル基は水酸基で置換されても良いC1-6アルキル基で置換されてもよい)を形成してもよい。
In formula (I), Z is a C 1-6 alkyl group,
R 1 , R 2 and R 3 are the same or different and are a hydrogen atom, a halogen atom, a C 1-6 alkoxy group or a C 1-6 alkyl group,
Y is a single bond, a C 1-6 alkylene group, a C 2-6 alkenylene group or —O— (CH 2 ) n — (n represents an integer of 1 to 4);
Q is a hydroxyl group, a -OC 1-4 alkyl phenyl, -N (R A) R B or -CONHR C,
Provided that when Q is a hydroxyl group, —OC 1-4 alkylphenyl or —NH 2 , Y is not a single bond,
R A and R B are the same or different and are a hydrogen atom, —CONHR D (R D is a hydrogen atom or a C 1-6 alkyl group which may be substituted with a substituent selected from the group consisting of a hydroxyl group and a pyridyl group. ), —C (═NH) NHR E (R E is a hydrogen atom, or —CO 2 C 1-4 alkylphenyl), or a C 1-6 alkyl group (the C 1-6 alkyl group is Which may be substituted with a substituent selected from the group consisting of a hydroxyl group, —CONH 2 and —OC 1-4 alkylphenyl),
R C is a C 1-6 alkyl group substituted with a substituent selected from the group consisting of a hydroxyl group and —CON (R F ) RG ;
R F and R G are the same or different and are a hydrogen atom or a C 1-6 alkyl group, or together with the nitrogen atom to which R F and R G are bonded, A 5- to 6-membered heterocycloalkyl group which may contain a heteroatom selected from an oxygen atom, a sulfur atom and a nitrogen atom (the heterocycloalkyl group is substituted with a C 1-6 alkyl group which may be substituted with a hydroxyl group) May be formed).
なお、ピラゾール環の点線は、環構成窒素原子に水素原子が結合する位置によって、互変異性体が存在することを示しているが、下記に示す具体的化合物では、便宜上、どちらか一方の異性体のみを示す。 The dotted line of the pyrazole ring indicates that a tautomer exists depending on the position at which a hydrogen atom is bonded to the ring nitrogen atom. However, in the specific compound shown below, for the sake of convenience, either isomer is present. Only the body is shown.
(2)本発明の他の態様は、YがC1-6アルキレン基、C2-6アルケニレン基または−O−(CH2)n−(nは2から4の整数である)である、前記態様(1)記載のピラゾリル 5−チオグルコシド化合物若しくはその製薬学的に許容される塩又はそれらの水和物を有効成分として含有する、糖尿病の予防又は治療剤に関する。 (2) In another embodiment of the present invention, Y is a C 1-6 alkylene group, a C 2-6 alkenylene group or —O— (CH 2 ) n — (n is an integer of 2 to 4). The present invention relates to a preventive or therapeutic agent for diabetes containing the pyrazolyl 5-thioglucoside compound of the above aspect (1) or a pharmaceutically acceptable salt thereof or a hydrate thereof as an active ingredient.
(3)本発明の他の態様は、Qが−N(RA)RB(RA及びRBは前記態様(1)で定義したとおりである)である、前記態様(1)または(2)に記載のピラゾリル 5−チオグルコシド化合物若しくはその製薬学的に許容される塩又はそれらの水和物を有効成分として含有する、糖尿病の予防又は治療剤に関する。 (3) In another embodiment of the present invention, Q is -N (R A ) R B (wherein R A and R B are as defined in the above embodiment (1)). The present invention relates to a preventive or therapeutic agent for diabetes containing the pyrazolyl 5-thioglucoside compound or a pharmaceutically acceptable salt thereof or a hydrate thereof as described in 2).
(4)本発明の他の態様は、RAが−CONHRD(RDは水酸基及びピリジル基からなる群から選択される置換基で置換されてもよいC1-6アルキル基である)であり、RBが水素原子である、前記態様(3)に記載のピラゾリル 5−チオグルコシド化合物若しくはその製薬学的に許容される塩又はそれらの水和物を有効成分として含有する、糖尿病の予防又は治療剤に関する。 (4) In another embodiment of the present invention, R A is —CONHR D (R D is a C 1-6 alkyl group which may be substituted with a substituent selected from the group consisting of a hydroxyl group and a pyridyl group). Diabetes prevention comprising, as an active ingredient, the pyrazolyl 5-thioglucoside compound or the pharmaceutically acceptable salt or hydrate thereof according to the above aspect (3), wherein R B is a hydrogen atom Or it relates to a therapeutic agent.
(5)本発明の他の態様は、RAが−C(=NH)NHRE(REは水素原子、または−CO2C1-4アルキルフェニルである)であり、RBが水素原子である、前記態様(3)に記載のピラゾリル 5−チオグルコシド化合物若しくはその製薬学的に許容される塩又はそれらの水和物を有効成分として含有する、糖尿病の予防又は治療剤に関する。 (5) In another embodiment of the present invention, R A is —C (═NH) NHR E (R E is a hydrogen atom or —CO 2 C 1-4 alkylphenyl), and R B is a hydrogen atom. It is related with the preventive or therapeutic agent of diabetes which contains the pyrazolyl 5-thioglucoside compound or its pharmaceutically acceptable salt as described in said aspect (3), or those hydrates as an active ingredient.
(6)本発明の他の態様は、RA及びRBが同一または異なって、水素原子、またはC1-6アルキル基(該C1-6アルキル基は、水酸基、−CONH2及び−OC1-4アルキルフェニルからなる群から選択される置換基で置換されてもよい)である前記態様(3)に記載のピラゾリル 5−チオグルコシド化合物若しくはその製薬学的に許容される塩又はそれらの水和物を有効成分として含有する、糖尿病の予防又は治療剤に関する。 (6) In another embodiment of the present invention, R A and R B are the same or different, and a hydrogen atom or a C 1-6 alkyl group (the C 1-6 alkyl group is a hydroxyl group, —CONH 2 and —OC) A pyrazolyl 5-thioglucoside compound or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, which may be substituted with a substituent selected from the group consisting of 1-4 alkylphenyl) The present invention relates to a preventive or therapeutic agent for diabetes containing a hydrate as an active ingredient.
(7)本発明の他の態様は、Qが−CONHRC(RCは前記態様(1)で定義したとおりである)である、前記態様(1)または(2)に記載のピラゾリル 5−チオグルコシド化合物若しくはその製薬学的に許容される塩又はそれらの水和物を有効成分として含有する、糖尿病の予防又は治療剤に関する。 (7) In another embodiment of the present invention, Q is —CONHR C (wherein R C is as defined in the above embodiment (1)), and pyrazolyl according to the above embodiment (1) or (2) The present invention relates to a preventive or therapeutic agent for diabetes containing a thioglucoside compound or a pharmaceutically acceptable salt thereof or a hydrate thereof as an active ingredient.
(8)本発明の他の態様は、RCが水酸基及び−CONH2からなる群より選択される1〜4個の置換基で置換されたC1-6アルキル基であるか、または、−CO−ピペラジノ(該ピペラジノは、水酸基で置換されても良いC1-6アルキル基で置換されてもよい)で置換されたC1-6アルキル基である(ここで、RCが−NH−に結合する各C1-6アルキル基の炭素原子は3級である)、前記態様(7)記載のピラゾリル 5−チオグルコシド化合物若しくはその製薬学的に許容される塩又はそれらの水和物を有効成分として含有する、糖尿病の予防又は治療剤に関する。 (8) In another embodiment of the present invention, R C is a C 1-6 alkyl group substituted with 1 to 4 substituents selected from the group consisting of a hydroxyl group and —CONH 2 , or — A C 1-6 alkyl group substituted with CO-piperazino (wherein piperazino may be substituted with a C 1-6 alkyl group which may be substituted with a hydroxyl group) (where R C is —NH— The carbon atom of each C 1-6 alkyl group bonded to is a tertiary), the pyrazolyl 5-thioglucoside compound of the above-mentioned embodiment (7), or a pharmaceutically acceptable salt thereof, or a hydrate thereof. The present invention relates to an agent for preventing or treating diabetes, which is contained as an active ingredient.
(9)本発明の他の態様は、YはC1-6アルキレン基又はC2-6アルケニレン基である、前記態様(7)または(8)記載のピラゾリル 5−チオグルコシド化合物若しくはその製薬学的に許容される塩又はそれらの水和物を有効成分として含有する、糖尿病の予防又は治療剤に関する。 (9) In another embodiment of the present invention, Y is a C 1-6 alkylene group or a C 2-6 alkenylene group, and the pyrazolyl 5-thioglucoside compound or the pharmaceutical preparation thereof according to the above embodiment (7) or (8) The present invention relates to a preventive or therapeutic agent for diabetes, which contains a pharmaceutically acceptable salt or hydrate thereof as an active ingredient.
(10)本発明の他の態様は、
R1、R2及びR3は同一または異なって、水素原子、またはC1-6アルキル基であり、
Yは、−O−(CH2)n−(nは1から4の整数である)であり、
Qは、水酸基、−OC1-4アルキルフェニル、又は−N(RA)RBであり、
RA及びRBは、同一又は異なって、水素原子、−CONH2で置換されたC1-6アルキル基、−CONHRD(RDは、水酸基で置換されたC1-6アルキル基である)、あるいは−C(=NH)NHRE(REは、水素原子または−CO2C1-4アルキルフェニルである)である、前記態様(1)に記載のピラゾリル 5−チオグルコシド化合物若しくはその製薬学的に許容される塩又はそれらの水和物を有効成分として含有する、糖尿病の予防又は治療剤に関する。
(10) Another aspect of the present invention is:
R 1 , R 2 and R 3 are the same or different and each represents a hydrogen atom or a C 1-6 alkyl group;
Y is -O- (CH 2) n- (n is an integer of 1 to 4),
Q is a hydroxyl group, —OC 1-4 alkylphenyl, or —N (R A ) R B ;
R A and R B are the same or different and are a hydrogen atom, a C 1-6 alkyl group substituted with —CONH 2 , or —CONHR D (R D is a C 1-6 alkyl group substituted with a hydroxyl group. Or a pyrazolyl 5-thioglucoside compound according to the above aspect (1) or —C (═NH) NHR E (R E is a hydrogen atom or —CO 2 C 1-4 alkylphenyl) The present invention relates to a preventive or therapeutic agent for diabetes, which contains a pharmaceutically acceptable salt or a hydrate thereof as an active ingredient.
本発明の化合物は、SGLT1活性を選択的に阻害するので、糖尿病患者の治療だけでなく、食前血糖が正常域であっても食後高血糖がみられる、境界型(糖尿病予備群)の患者の治療もすることができ、これにより糖尿病への移行予防をすることができる。 Since the compound of the present invention selectively inhibits SGLT1 activity, not only treatment of diabetic patients but also post-prandial hyperglycemia even when pre-prandial blood glucose is in the normal range, patients of borderline type (pre-diabetes group) It can also be treated, thereby preventing the transition to diabetes.
本発明において使用する用語を以下に定義する。 The terms used in the present invention are defined below.
「C1-6アルキル基」とは、炭素原子を1−6個有する直鎖状又は分枝状のアルキル基を意味する。例えば、メチル基、エチル基、n−プロピル基、イソプロピル基、n−ブチル基、イソブチル基、tert−ブチル基、sec−ブチル基、n−ペンチル基、n−ヘキシル基が挙げられる。 The “C 1-6 alkyl group” means a linear or branched alkyl group having 1-6 carbon atoms. For example, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, tert-butyl group, sec-butyl group, n-pentyl group, and n-hexyl group can be mentioned.
「C1-6アルコキシ基」とは、炭素原子を1−6個有する直鎖状又は分枝状のアルコキシ基を意味し、C1-4アルコキシ基が好ましい。C1-4アルコキシ基としては、例えば、メトキシ基、エトキシ基、プロポキシ基、イソプロポキシ基、n−ブトキシ基、イソブトキシ基、tert−ブトキシ基が挙げられる。 The “C 1-6 alkoxy group” means a linear or branched alkoxy group having 1-6 carbon atoms, and a C 1-4 alkoxy group is preferable. Examples of the C 1-4 alkoxy group include a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, an n-butoxy group, an isobutoxy group, and a tert-butoxy group.
「ハロゲン原子」とは、フッ素原子、塩素原子、臭素原子又はヨウ素原子である。 The “halogen atom” is a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
「−OC1-4アルキルフェニル」とは、C1-4アルコキシ基とフェニルが複合した形態を有する基である。例えば、ベンジルオキシ基、フェニルエチルオキシ基が挙げられる。 The “—OC 1-4 alkylphenyl” is a group having a form in which a C 1-4 alkoxy group and phenyl are combined. Examples include a benzyloxy group and a phenylethyloxy group.
「C1-6アルキレン基」とは、炭素数1〜6個からなる、直鎖または分岐状の2価の飽和炭化水素である。例えば、メチレン、エチレン、トリメチレン、テトラメチレン、2−メチルプロピレン、2,2−ジメチルプロピレン等が挙げられる。 The “C 1-6 alkylene group” is a linear or branched divalent saturated hydrocarbon having 1 to 6 carbon atoms. Examples include methylene, ethylene, trimethylene, tetramethylene, 2-methylpropylene, 2,2-dimethylpropylene and the like.
「C2-6アルケニレン基」とは、二重結合を含む炭素数2〜6個からなる、直鎖または分岐状の2価の不飽和炭化水素である。例えば、エチレン、プロペニレン、2−ブチニレン等が挙げられ、中でもプロペニレンが好ましい。 The “C 2-6 alkenylene group” is a linear or branched divalent unsaturated hydrocarbon composed of 2 to 6 carbon atoms including a double bond. For example, ethylene, propenylene, 2-butynylene and the like can be mentioned, among which propenylene is preferable.
「水酸基及びピリジル基からなる群から選択される置換基で置換されてもよいC1-6アルキル基」とは、C1-6アルキル基上の水素原子が、水酸基及びピリジル基から選択される一つ以上の基(好ましくは1〜3個)によって置換されてもよいC1-6アルキル基を示す。例えば、メチル基、エチル基、イソプロピル基、ピリジン−3−イルメチル基、ヒドロキシメチル基、ヒドロキシエチル基、2−ヒドロキシ−1,1−ジメチルエチル基、1,3−ジヒドロキシ−2−ヒドロキシメチルプロパン−2−イル基が挙げられる。 “C 1-6 alkyl group optionally substituted with a substituent selected from the group consisting of a hydroxyl group and a pyridyl group” means that the hydrogen atom on the C 1-6 alkyl group is selected from a hydroxyl group and a pyridyl group. A C 1-6 alkyl group which may be substituted with one or more groups (preferably 1 to 3) is shown. For example, methyl group, ethyl group, isopropyl group, pyridin-3-ylmethyl group, hydroxymethyl group, hydroxyethyl group, 2-hydroxy-1,1-dimethylethyl group, 1,3-dihydroxy-2-hydroxymethylpropane- A 2-yl group is mentioned.
「水酸基、−CONH2及び−OC1-4アルキルフェニルからなる群から選択される置換基で置換されてもよいC1-6アルキル基」とは、C1-6アルキル基上の水素原子が、水酸基、−CONH2及び−OC1-4アルキルフェニルからなる群から選択される1つ以上(好ましくは1〜3個)の基によって置換されてもよいC1-6アルキル基を示す。例えば、メチル基、エチル基、イソプロピル基、ベンジルオキシエチル基、ヒドロキシメチル基、ヒドロキシエチル基、2−ヒドロキシ−1,1−ジメチルエチル基、1,3−ヒドロキシ−2−メチルプロパン−2−イル基、カルバモイルメチル基、カルバモイルメチル基、2−カルバモイルエチル基、2−カルバモイル−2−メチルエチル基が挙げられる。 “C 1-6 alkyl group optionally substituted with a substituent selected from the group consisting of a hydroxyl group, —CONH 2 and —OC 1-4 alkylphenyl” means that a hydrogen atom on the C 1-6 alkyl group is , A C 1-6 alkyl group which may be substituted by one or more (preferably 1 to 3) groups selected from the group consisting of hydroxyl group, —CONH 2 and —OC 1-4 alkylphenyl. For example, methyl group, ethyl group, isopropyl group, benzyloxyethyl group, hydroxymethyl group, hydroxyethyl group, 2-hydroxy-1,1-dimethylethyl group, 1,3-hydroxy-2-methylpropan-2-yl Group, carbamoylmethyl group, carbamoylmethyl group, 2-carbamoylethyl group, 2-carbamoyl-2-methylethyl group.
「水酸基及び−CON(RF)RGからなる群より選択された置換基で置換されたC1-6アルキル基」とは、C1-6アルキル基上の水素原子が、水酸基または−CON(RF)RGからなる群より選択される置換基(好ましくは1〜4個、より好ましくは1〜3個)によって置換されているC1-6アルキル基を示す。例えば、ヒドロキシメチル基、ヒドロキシエチル基、2−ヒドロキシ−1,1−ジメチルエチル基、1,3−ヒドロキシ−2−メチルプロパン−2−イル基、カルバモイルメチル基が挙げられる。 “C 1-6 alkyl group substituted with a substituent selected from the group consisting of a hydroxyl group and —CON (R F ) RG ” means that a hydrogen atom on a C 1-6 alkyl group is a hydroxyl group or —CON (R F ) A C 1-6 alkyl group substituted with a substituent selected from the group consisting of R G (preferably 1 to 4, more preferably 1 to 3). Examples thereof include a hydroxymethyl group, a hydroxyethyl group, a 2-hydroxy-1,1-dimethylethyl group, a 1,3-hydroxy-2-methylpropan-2-yl group, and a carbamoylmethyl group.
「結合している窒素原子と一緒になって形成し、さらに環構成原子として、酸素原子、硫黄原子及び窒素原子から選択されるヘテロ原子を含んでも良い5〜6員のヘテロシクロアルキル基(該ヘテロシクロアルキル基は水酸基で置換されてもよいC1-6アルキル基で置換されてもよい)」の例としては、1−ピロリジニル基、ピペリジノ基、1−ピペラジニル基、モルホリノ基、チオモルホリノ基、4−メチル−1−ピペラジニル基等が挙げられる。 “5- to 6-membered heterocycloalkyl group which is formed together with the nitrogen atom to which it is bonded, and may further contain a heteroatom selected from an oxygen atom, a sulfur atom and a nitrogen atom as a ring-constituting atom ( Examples of “heterocycloalkyl group may be substituted with a hydroxyl group and optionally substituted with a C 1-6 alkyl group” include 1-pyrrolidinyl group, piperidino group, 1-piperazinyl group, morpholino group, and thiomorpholino group. , 4-methyl-1-piperazinyl group and the like.
「水酸基で置換されてもよいC1-6アルキル基」とは、少なくとも1個(好ましくは1〜4個、より好ましくは1〜3個)の水酸基によって置換されてもよいC1-6アルキル基を意味し、例えば、ヒドロキシメチル基、ヒドロキシエチル基、2−ヒドロキシ−1,1−ジメチルエチル基、1,3−ジヒドロキシ−2−メチルプロパン−2−イル基、1,3−ジヒドロキシ−2−ヒドロキシメチルプロパン−2−イル基が挙げられる。 The "be a C 1-6 alkyl group substituted by hydroxyl group", at least one (preferably 1 to 4, more preferably 1 to 3) C 1-6 alkyl optionally substituted by hydroxyl group of Group, for example, hydroxymethyl group, hydroxyethyl group, 2-hydroxy-1,1-dimethylethyl group, 1,3-dihydroxy-2-methylpropan-2-yl group, 1,3-dihydroxy-2 -Hydroxymethylpropan-2-yl group.
「製薬学的に許容される塩」とは、アルカリ金属類、アルカリ土類金属類、アンモニウム、アルキルアンモニウムなどとの塩、鉱酸又は有機酸との塩であり、例えば、ナトリウム塩、カリウム塩、カルシウム塩、アンモニウム塩、アルミニウム塩、トリエチルアンモニウム塩、酢酸塩、プロピオン酸塩、酪酸塩、ぎ酸塩、トリフルオロ酢酸塩、マレイン酸塩、酒石酸塩、クエン酸塩、ステアリン酸塩、コハク酸塩、エチルコハク酸塩、ラクトビオン酸塩、グルコン酸塩、グルコヘプトン酸塩、安息香酸塩、メタンスルホン酸塩、エタンスルホン酸塩、2−ヒドロキシエタンスルホン酸塩、ベンゼンスルホン酸塩、パラトルエンスルホン酸塩、ラウリル硫酸塩、リンゴ酸塩、アスパラギン酸塩、グルタミン酸塩、アジピン酸塩、システインとの塩、N−アセチルシステインとの塩、塩酸塩、臭化水素酸塩、リン酸塩、硫酸塩、よう化水素酸塩、ニコチン酸塩、シュウ酸塩、ピクリン酸塩、チオシアン酸塩、ウンデカン酸塩、アクリル酸ポリマーとの塩、カルボキシビニルポリマーとの塩が挙げられる。 “Pharmaceutically acceptable salt” is a salt with an alkali metal, alkaline earth metal, ammonium, alkylammonium, or the like, a salt with a mineral acid or an organic acid, such as a sodium salt or potassium salt. , Calcium salt, ammonium salt, aluminum salt, triethylammonium salt, acetate, propionate, butyrate, formate, trifluoroacetate, maleate, tartrate, citrate, stearate, succinic acid Salt, ethyl succinate, lactobionate, gluconate, glucoheptonate, benzoate, methanesulfonate, ethanesulfonate, 2-hydroxyethanesulfonate, benzenesulfonate, paratoluenesulfonate With, lauryl sulfate, malate, aspartate, glutamate, adipate, cysteine , Salts with N-acetylcysteine, hydrochloride, hydrobromide, phosphate, sulfate, hydroiodide, nicotinate, oxalate, picrate, thiocyanate, undecanoate And a salt with an acrylic acid polymer and a salt with a carboxyvinyl polymer.
「水和物」とは、本発明の化合物又はその塩の製薬学的に許容される水和物である。本発明の化合物又はその塩は、大気にさらされ、あるいは再結晶することなどにより、水分を吸収し、吸着水がつく場合や、水和物となる場合がある。本発明における水和物には、そのような水和物も含まれる。 “Hydrate” is a pharmaceutically acceptable hydrate of the compound of the present invention or a salt thereof. The compound of the present invention or a salt thereof may be exposed to air or recrystallized to absorb moisture and form adsorbed water, or may become a hydrate. The hydrate in the present invention includes such a hydrate.
本発明の化合物はキラル中心を有することがあるので、種々なジアステレオマー形又はエナンチオマー形として存在する。また、本発明の化合物の一部は、例えば、ケト−エノール互変異性体としても存在する。また、本発明の化合物の一部は、幾何異性体(E体、Z体)としても存在する。したがって、本発明の化合物は、上記全ての個々の異性体並びにこれらの混合物を包含する。 Since the compounds of the present invention may have chiral centers, they exist as various diastereomeric or enantiomeric forms. Some of the compounds of the present invention also exist, for example, as keto-enol tautomers. Some of the compounds of the present invention also exist as geometric isomers (E-form, Z-form). Accordingly, the compounds of this invention include all the individual isomers above as well as mixtures thereof.
本発明化合物の好ましい態様を以下にあげる。
式(I)において、Zの好ましい基は、メチル基、エチル基、プロピル基、イソプロピル基であり、より好ましくはイソプロピル基である。
Preferred embodiments of the compound of the present invention are listed below.
In formula (I), preferred groups for Z are a methyl group, an ethyl group, a propyl group, and an isopropyl group, and more preferably an isopropyl group.
R1、R2及びR3の好ましい態様は、水素原子、またはC1-4アルキル基であり、より好ましくは、水素原子、またはメチル基である。特に、R1が水素原子またはメチル基であり、R2及びR3が水素原子であることが好ましい。この場合、R1がメチル基であるときの置換位置は−Y−Qに対してメタ位であることが好ましい。 A preferred embodiment of R 1 , R 2 and R 3 is a hydrogen atom or a C 1-4 alkyl group, and more preferably a hydrogen atom or a methyl group. In particular, R 1 is preferably a hydrogen atom or a methyl group, and R 2 and R 3 are preferably hydrogen atoms. In this case, the substitution position when R 1 is a methyl group is preferably a meta position with respect to -YQ.
Yの好ましい態様はC1-4アルキレン基、C2-4アルケニレン基、あるいは−O−(CH2)n−(n=2または3)である。 A preferred embodiment of Y is a C 1-4 alkylene group, a C 2-4 alkenylene group, or —O— (CH 2 ) n — (n = 2 or 3).
Qが−NRA(RB)である場合の好ましい態様は、YがC1-4アルキレン基又はC2-4アルケニレン基であり、より好ましくは、YがC1-4アルキレン基である。 In a preferred embodiment when Q is —NR A (R B ), Y is a C 1-4 alkylene group or a C 2-4 alkenylene group, and more preferably Y is a C 1-4 alkylene group.
Qが−NRA(RB)の好ましい態様は、(1)RA及びRBは同一または異なって、水素原子、または“水酸基及び−CONH2の群から選択される1〜4個(より好ましくは1〜3個)の基で置換されてもよいC1-6アルキル基”である場合、(2)RAが−C(=NH)NH2であり、RBが水素原子である場合、(3)RAが−CONHRD(RDは水酸基で置換されているC1-6アルキル基である)であり、RBは水素原子である場合である。 A preferred embodiment in which Q is —NR A (R B ) is as follows: (1) R A and R B are the same or different and are each selected from the group consisting of hydrogen atom or “hydroxyl group and —CONH 2 group (more In the case of a “C 1-6 alkyl group which may be preferably substituted with 1 to 3 groups”, (2) R A is —C (═NH) NH 2 and R B is a hydrogen atom. In this case, (3) R A is —CONHR D (R D is a C 1-6 alkyl group substituted with a hydroxyl group), and R B is a hydrogen atom.
Qが−CONHRCである場合の好ましい態様は、1〜4個(より好ましくは1〜3個)の水酸基で置換されたC1-6アルキル基、または−CONH2、−CONHC1-4アルキル若しくは−CO−ヘテロシクロアルキル基(該ヘテロシクロアルキル基は、水酸基で置換されてもよいC1-6アルキル基で置換されてもよい)のいずれかで置換されたC1-6アルキル基である。 −CONH(RC)において、RCに定義されるC1-6アルキル基は、−NH−に結合する炭素原子が3級である場合が好ましい。 When Q is —CONHR C , a preferable embodiment is a C 1-6 alkyl group substituted with 1 to 4 (more preferably 1 to 3) hydroxyl groups, or —CONH 2 , —CONHC 1-4 alkyl. or -CO- heterocycloalkyl group (said heterocycloalkyl group, a hydroxyl group may be substituted at a C 1-6 alkyl group substituted with) by C 1-6 alkyl group substituted by either is there. In —CONH (R C ), the C 1-6 alkyl group defined for R C is preferably a case where the carbon atom bonded to —NH— is tertiary.
上記の化合物群において、より好ましい−Y−Qは、−Y−CO−NH−C1-6アルキル(該アルキルのNHに結合する炭素原子が3級であり、該アルキルは水酸基で置換されている)、−Y−CO−NH−C(CH3)2−CONH2、−Y−CO−NH−C(CH3)2−CONH−C1-6アルキル(該アルキルは水酸基で置換されてもよい)、−Y−CO−NH−C(CH3)2−CO−ピペラジノ(該ピペラジノは、水酸基で置換されてもよいC1-6アルキル基で置換されてもよい)である。ここで、Yは、プロピレン又はプロペニレン(−CH=CH−CH2−)である。 In the above compound group, -YQ is more preferably -Y-CO-NH-C 1-6 alkyl (the carbon atom bonded to NH of the alkyl is tertiary, and the alkyl is substituted with a hydroxyl group). are), - Y-CO-NH -C (CH 3) 2 -CONH 2, -Y-CO-NH-C (CH 3) 2 -CONH-C 1-6 alkyl (said alkyl substituted with a hydroxyl group Or —Y—CO—NH—C (CH 3 ) 2 —CO-piperazino (wherein the piperazino may be substituted with a C 1-6 alkyl group which may be substituted with a hydroxyl group). Here, Y is propylene or propenylene (—CH═CH—CH 2 —).
以下に、本発明化合物(I)の製造方法を例をあげて以下に詳細に説明するが、例示されたものに特に限定されない。 Although the manufacturing method of this invention compound (I) is given to the following and demonstrated in detail below, it does not specifically limit to what was illustrated.
製造法1
本発明の式(I)化合物において、Qが水酸基、−OC1-4アルキルフェニル(例えば、−OBn)又はアミノ基である化合物は以下の方法で合成できる。
Manufacturing method 1
In the compound of formula (I) of the present invention, a compound in which Q is a hydroxyl group, —OC 1-4 alkylphenyl (eg, —OBn) or an amino group can be synthesized by the following method.
ただし、P1、P2、P3及びP4は、アセチル基、ピバロイル基等のC2-6アルカノイル基又はベンゾイル基を示し、その他の記号は前記と同義である。 However, P 1, P 2, P 3 and P 4 represents an acetyl group, C 2-6 alkanoyl group or a benzoyl group such as pivaloyl group, and other symbols are as defined above.
ここに、ピラゾール誘導体1Aは国際公開WO2004/018491号に準拠して合成することができる。5−チオグルコース誘導体2Aは、国際公開WO2004/014931号に準拠して合成することができる。 Here, the pyrazole derivative 1A can be synthesized based on International Publication No. WO2004 / 018491. The 5-thioglucose derivative 2A can be synthesized based on International Publication WO2004 / 014931.
(1)工程1(光延反応)
光延反応(国際公開WO2004/089966号)によって、ピラゾール誘導体1Aと5−チオグルコース誘導体2Aからピラゾリル 5−チオ−β−D−グルコシド誘導体3Aを選択的に製造することができる。この反応における試薬として必要なホスフィン類の例としては、トリフェニルホスフィン、トリ−n−ブチルホスフィン、トリ−t−ブチルホスフィン、トリストリルホスフィンやジフェニル−2−ピリジルホスフィン等が挙げられる。中でもトリフェニルホスフィン、ジフェニル−2−ピリジルホスフィンが好ましく、トリフェニルホスフィンがより好ましい。
(1) Step 1 (Mitsunobu reaction)
The pyrazolyl 5-thio-β-D-glucoside derivative 3A can be selectively produced from the pyrazole derivative 1A and the 5-thioglucose derivative 2A by Mitsunobu reaction (International Publication WO2004 / 089966). Examples of phosphines necessary as reagents in this reaction include triphenylphosphine, tri-n-butylphosphine, tri-t-butylphosphine, tristolylphosphine, diphenyl-2-pyridylphosphine, and the like. Of these, triphenylphosphine and diphenyl-2-pyridylphosphine are preferable, and triphenylphosphine is more preferable.
アゾ試薬の例としては、ジエチルアゾジカルボキシレート、ジイソプロピルアゾジカルボキシレートやジ−tert−ブチルアゾジカルボキシレート、1,1'−アゾビス(N,N−ジメチルホルムアミド)や1,1’-(アゾジカルボニル)ジピペリジンを用いることができる。中でも、ジエチルアゾジカルボキシレート(DEAD)、ジイソプロピルアゾジカルボキシレートが好ましい。 Examples of azo reagents include diethyl azodicarboxylate, diisopropyl azodicarboxylate, di-tert-butyl azodicarboxylate, 1,1′-azobis (N, N-dimethylformamide), 1,1 ′-( Azodicarbonyl) dipiperidine can be used. Of these, diethyl azodicarboxylate (DEAD) and diisopropyl azodicarboxylate are preferable.
本反応に用いる溶媒はテトラヒドロフラン、ジオキサン、トルエン、塩化メチレン、クロロホルム、アセトニトリル、酢酸エチル、ジメチルスルホキシド、N,N−ジメチルホルムアミド等であり、好ましいのは、テトラヒドロフラン、トルエンである。 Solvents used in this reaction are tetrahydrofuran, dioxane, toluene, methylene chloride, chloroform, acetonitrile, ethyl acetate, dimethyl sulfoxide, N, N-dimethylformamide and the like, and preferred are tetrahydrofuran and toluene.
反応温度は−20℃から室温が好ましく、−5℃から+5℃がより好ましい。 The reaction temperature is preferably -20 ° C to room temperature, more preferably -5 ° C to + 5 ° C.
(2)工程2(脱ベンジル化)
上記で得られた化合物3Aをパラジウム活性炭、水酸化パラジウム、又は白金−パラジウム活性炭等の触媒を用いて水素雰囲気下にて接触水素添加することによりベンジル基を除去することができる。中でも水酸化パラジウムが触媒として好ましい。この反応に使用する溶媒としては、メタノール、エタノール、イソプロパノール、酢酸エチル、酢酸等を挙げることができる。反応温度は室温から還流温度であるが、室温が好ましい。
(2) Step 2 (debenzylation)
The benzyl group can be removed by catalytic hydrogenation of the compound 3A obtained above using a catalyst such as palladium activated carbon, palladium hydroxide, or platinum-palladium activated carbon in a hydrogen atmosphere. Of these, palladium hydroxide is preferred as the catalyst. Examples of the solvent used in this reaction include methanol, ethanol, isopropanol, ethyl acetate, acetic acid and the like. The reaction temperature is from room temperature to reflux temperature, but room temperature is preferred.
(3)工程3(アミノ基への変換)
上記で得られた化合物4Aの水酸基をアミノ基に変換し化合物5Aを得ることができる。まず、化合物4Aをトリエチルアミン、N−エチル−N,N−ジイソプロピルアミン、ピリジン、炭酸カリウム、炭酸カルシウム、炭酸セシウム等の塩基の存在下、メタンスルホニルクロリドやp−トルエンスルホニルクロリドを用いて、脱離基を導入する。この反応に使用する溶媒としては、クロロホルム、ジクロロメタン、ジエチルエーテル、テトラヒドロフラン、ジメトキシエタン、酢酸エチル等が挙げられる。反応温度は0℃から室温である。
(3) Step 3 (Conversion to amino group)
Compound 5A can be obtained by converting the hydroxyl group of compound 4A obtained above into an amino group. First, Compound 4A is eliminated using methanesulfonyl chloride or p-toluenesulfonyl chloride in the presence of a base such as triethylamine, N-ethyl-N, N-diisopropylamine, pyridine, potassium carbonate, calcium carbonate, cesium carbonate, etc. Introduce a group. Examples of the solvent used for this reaction include chloroform, dichloromethane, diethyl ether, tetrahydrofuran, dimethoxyethane, ethyl acetate and the like. The reaction temperature is from 0 ° C. to room temperature.
次に、アジ化ナトリウムを用いて、アジド基に変換することができる。この反応に使用する溶媒としては、N,N−ジメチルホルムアミド、ジメチルスルホキシド、N−メチルピロリドン、ジクロロメタン、ジエチルエーテル、テトラヒドロフラン、ジメトキシエタン、酢酸エチル等が挙げられる。反応温度は室温から還流温度である。 It can then be converted to an azide group using sodium azide. Examples of the solvent used in this reaction include N, N-dimethylformamide, dimethyl sulfoxide, N-methylpyrrolidone, dichloromethane, diethyl ether, tetrahydrofuran, dimethoxyethane, ethyl acetate and the like. The reaction temperature is from room temperature to reflux temperature.
さらに、アジド基を上記の脱ベンジル化の条件と同様な接触水素添加にてアミノ基に変換し化合物5Aが得られる。 Further, the azide group is converted to an amino group by catalytic hydrogenation under the same debenzylation conditions as described above to obtain compound 5A.
(4)工程4(P1、P2、P3及びP4の脱保護)
5−チオグルコースの保護基を適当な塩基を用いて除去し、本発明化合物(I)が得られる。この反応に使用する塩基として、ナトリウムメトキシド、ナトリウムエトキシド、ナトリウムベンジルオキシド、水酸化ナトリウム、水酸化リチウム、炭酸カリウム、炭酸セシウム、トリエチルアミン等が挙げられる。反応に適当な溶媒はメタノール、エタノール、ベンジルアルコール、水又はこれらの混合溶媒である。反応温度は0℃から室温であり、室温が好ましい。
(4) Step 4 (deprotection of P 1 , P 2 , P 3 and P 4 )
The protecting group of 5-thioglucose is removed using a suitable base to obtain the compound (I) of the present invention. Examples of the base used in this reaction include sodium methoxide, sodium ethoxide, sodium benzyl oxide, sodium hydroxide, lithium hydroxide, potassium carbonate, cesium carbonate, triethylamine and the like. Suitable solvents for the reaction are methanol, ethanol, benzyl alcohol, water or a mixed solvent thereof. The reaction temperature is from 0 ° C. to room temperature, preferably room temperature.
製造法2
製造法1の化合物5Aにおいて、Yが単結合である化合物5Bは、より好ましくは、以下の方法で合成できる。ただし、記号は前記と同義である。
Manufacturing method 2
In compound 5A of production method 1, compound 5B in which Y is a single bond is more preferably synthesized by the following method. However, the symbols are as defined above.
ここに、ピラゾール誘導体1Bは国際公開WO2004/019958号に準拠して合成することができる。 Here, the pyrazole derivative 1B can be synthesized in accordance with International Publication WO2004 / 019958.
まず、製造法1の工程1に示した光延反応により、ピラゾール誘導体1Bから化合物3Bを合成することができる。 First, the compound 3B can be synthesized from the pyrazole derivative 1B by the Mitsunobu reaction shown in Step 1 of Production Method 1.
(5)工程5(ニトロ基の還元)
化合物3Bをパラジウム活性炭、水酸化パラジウム、又は酸化白金等の触媒を用いて水素雰囲気下にて接触水素添加することによりニトロ基を還元することができる。中でも酸化白金等の白金系触媒が好ましい。この反応に使用する溶媒としては、メタノール、エタノール、イソプロパノール、酢酸エチル、酢酸等を挙げることができる。反応温度は室温から還流温度であるが、室温が好ましい。
(5) Step 5 (Reduction of nitro group)
The nitro group can be reduced by catalytically hydrogenating compound 3B under a hydrogen atmosphere using a catalyst such as palladium activated carbon, palladium hydroxide, or platinum oxide. Of these, platinum-based catalysts such as platinum oxide are preferred. Examples of the solvent used in this reaction include methanol, ethanol, isopropanol, ethyl acetate, acetic acid and the like. The reaction temperature is from room temperature to reflux temperature, but room temperature is preferred.
製造法3
本発明の式(I)化合物において、Qが−N(RA)RBであって、RAは−C(=NH)NHREであり、RBは水素原子である化合物は以下の方法で合成できる。
ただし、記号は前記と同義である。
Production method 3
In the compound of formula (I) of the present invention, Q is —N (R A ) R B , R A is —C (═NH) NHR E , and R B is a hydrogen atom. Can be synthesized.
However, the symbols are as defined above.
(6)工程6(グアニジノ基の導入)
化合物5Aからグアニジノ化試薬6Aを用いて化合物7Aに誘導することができる。この反応に使用する溶媒としては、テトラヒドロフラン、N,N−ジメチルホルムアミド、メタノール、エタノール、イソプロパノール、酢酸エチル、トルエン等が挙げられる。反応温度は室温から還流温度である。
(6) Step 6 (Introduction of guanidino group)
It can be derived from compound 5A to compound 7A using guanidino reagent 6A. Examples of the solvent used in this reaction include tetrahydrofuran, N, N-dimethylformamide, methanol, ethanol, isopropanol, ethyl acetate, toluene and the like. The reaction temperature is from room temperature to reflux temperature.
(7)工程7及び工程8(脱保護)
グアニジノ基の保護基RE、ベンジルオキシカルボニル基をナトリウムベンジルオキシドで処理することで、本発明化合物(I)(Q=−C(=NH)NHCOOBn)が得られる。さらに、ベンジルオキシカルボニル基は、製造法1の工程2に記載した脱ベンジル化と同様な方法で除去することができる。このときの好ましい触媒は水酸化パラジウムである。
(7) Step 7 and Step 8 (deprotection)
The compound (I) (Q = —C (═NH) NHCOOBn) of the present invention can be obtained by treating the protecting group R E of the guanidino group and the benzyloxycarbonyl group with sodium benzyl oxide. Furthermore, the benzyloxycarbonyl group can be removed by a method similar to the debenzylation described in Step 2 of Production Method 1. A preferred catalyst at this time is palladium hydroxide.
製造法4
本発明の式(I)化合物において、Qが−N(RA)RBであって、RAは−CONHRD、RBは水素原子である(式中、RDは水素原子または、水酸基及びピリジル基からなる群から選択される置換基で置換されてもよいC1-6アルキル基を示す)化合物は以下の方法で合成できる。ただし、下記スキーム中、他の記号は前記と同義である。
Manufacturing method 4
In the compound of formula (I) of the present invention, Q is —N (R A ) R B , R A is —CONHR D , and R B is a hydrogen atom (wherein R D is a hydrogen atom or a hydroxyl group And a compound having a C 1-6 alkyl group optionally substituted with a substituent selected from the group consisting of a pyridyl group) can be synthesized by the following method. However, in the following schemes, other symbols are as defined above.
(8)工程9(ウレイド基の構築)
化合物5Aから適当な塩基の存在下、p−ニトロフェニルクロロホルメート、トリホスゲンあるいはN,N′−カルボニルジイミダゾール(CDI)を用いて、アミンRDNH2と縮合することにより、化合物8Aに誘導することができる。適当な塩基としては、トリエチルアミン、N−エチル−N,N−ジイソプロピルアミン、ピリジン、DBU、炭酸カリウム、炭酸カルシウム、炭酸セシウム等が挙げられる。また、使用する溶媒としては、クロロホルム、ジクロロメタン、ジエチルエーテル、テトラヒドロフラン、N,N−ジメチルホルムアミド、アセトニトリル、酢酸エチル等が挙げられる。反応温度は0℃から還流温度である。
(8) Step 9 (construction of ureido group)
Derived from compound 5A to compound 8A by condensation with amine R D NH 2 using p-nitrophenyl chloroformate, triphosgene or N, N′-carbonyldiimidazole (CDI) in the presence of a suitable base. can do. Suitable bases include triethylamine, N-ethyl-N, N-diisopropylamine, pyridine, DBU, potassium carbonate, calcium carbonate, cesium carbonate and the like. Examples of the solvent to be used include chloroform, dichloromethane, diethyl ether, tetrahydrofuran, N, N-dimethylformamide, acetonitrile, ethyl acetate and the like. The reaction temperature is from 0 ° C. to reflux temperature.
(9)工程10(脱保護)
P1、P2、P3、及びP4を製造法1の工程4に記載の方法で脱保護し、本発明化合物(I)が得られる。
(9) Step 10 (deprotection)
P 1 , P 2 , P 3 and P 4 are deprotected by the method described in Step 4 of Production Method 1 to give the compound (I) of the present invention.
製造法5
本発明の式(I)化合物において、Qが−N(RA)RBであって、RA及びRBは同一または異なって、水素原子、または、C1-6アルキル基(該C1-6アルキル基は、水酸基、−CONH2及び−OC1-4アルキルフェニルからなる群から選択される置換基で置換されてもよい)である化合物は以下の方法で合成できる。下記スキーム中、L1はハロゲン原子、MeSO2O-等の脱離基を示し、その他の記号は前記と同義である。
Manufacturing method 5
In the compound of the formula (I) of the present invention, Q is —N (R A ) R B , and R A and R B are the same or different and each represents a hydrogen atom or a C 1-6 alkyl group (the C 1 -6 alkyl group may be substituted with a substituent selected from the group consisting of a hydroxyl group, —CONH 2 and —OC 1-4 alkylphenyl) can be synthesized by the following method. In the following scheme, L1 represents a leaving group such as a halogen atom or MeSO 2 O—, and the other symbols are as defined above.
(10)工程11
化合物5Aを適当な塩基の存在下、RAL1又はRBL1と反応させることにより、化合物9Aが得られる。適当な塩基としては、トリエチルアミン、N−エチル−N,N−ジイソプロピルアミン、ピリジン、DBU、炭酸カリウム、炭酸カルシウム、炭酸セシウム等が挙げられる。また、使用する溶媒としては、N,N−ジメチルホルムアミド、アセトニトリル、メタノール、エタノール、クロロホルム、ジクロロメタン、ジエチルエーテル、テトラヒドロフラン等が挙げられる。反応温度は室温から還流温度である。
(10) Step 11
Compound 9A is obtained by reacting Compound 5A with R A L1 or R B L1 in the presence of a suitable base. Suitable bases include triethylamine, N-ethyl-N, N-diisopropylamine, pyridine, DBU, potassium carbonate, calcium carbonate, cesium carbonate and the like. Moreover, as a solvent to be used, N, N-dimethylformamide, acetonitrile, methanol, ethanol, chloroform, dichloromethane, diethyl ether, tetrahydrofuran and the like can be mentioned. The reaction temperature is from room temperature to reflux temperature.
(11)工程12
化合物4Aから製造法1のアミノ基への変換と同様の条件で、化合物9Aを製造することもできる。まず、化合物4Aをトリエチルアミン、N−エチル−N,N−ジイソプロピルアミン、ピリジン、炭酸カリウム、炭酸カルシウム、炭酸セシウム等の塩基の存在下、メタンスルホニルクロリドやp−トルエンスルホニルクロリドを用いて、脱離基を導入する。この反応に使用する溶媒としては、クロロホルム、ジクロロメタン、ジエチルエーテル、テトラヒドロフラン、ジメトキシエタン、酢酸エチル等が挙げられる。反応温度は0℃から室温である。
(11) Step 12
Compound 9A can also be produced under the same conditions as in the conversion of Compound 4A to the amino group in Production Method 1. First, Compound 4A is eliminated using methanesulfonyl chloride or p-toluenesulfonyl chloride in the presence of a base such as triethylamine, N-ethyl-N, N-diisopropylamine, pyridine, potassium carbonate, calcium carbonate, cesium carbonate, etc. Introduce a group. Examples of the solvent used for this reaction include chloroform, dichloromethane, diethyl ether, tetrahydrofuran, dimethoxyethane, ethyl acetate and the like. The reaction temperature is from 0 ° C. to room temperature.
次に、トリエチルアミン、N−エチル−N,N−ジイソプロピルアミン、ピリジン、DBU、炭酸カリウム、炭酸カルシウム、炭酸セシウム等の適当な塩基の存在下、NHRARBと反応させることにより化合物9Aが得られる。この反応に使用する溶媒としては、N,N−ジメチルホルムアミド、ジメチルスルホキシド、N−メチルピロリドン、ジクロロメタン、ジエチルエーテル、テトラヒドロフラン、ジメトキシエタン、酢酸エチル等が挙げられる。反応温度は室温から還流温度である。 Next, compound 9A is obtained by reacting with NHR A R B in the presence of a suitable base such as triethylamine, N-ethyl-N, N-diisopropylamine, pyridine, DBU, potassium carbonate, calcium carbonate, cesium carbonate and the like. It is done. Examples of the solvent used in this reaction include N, N-dimethylformamide, dimethyl sulfoxide, N-methylpyrrolidone, dichloromethane, diethyl ether, tetrahydrofuran, dimethoxyethane, ethyl acetate and the like. The reaction temperature is from room temperature to reflux temperature.
(12)工程13(脱保護)
P1、P2、P3及びP4を製造法1の工程4に記載の方法で脱保護し、本発明化合物(I)が得られる。
(12) Step 13 (deprotection)
P 1 , P 2 , P 3 and P 4 are deprotected by the method described in Step 4 of Production Method 1 to give the compound (I) of the present invention.
製造法6
本発明の式(I)化合物において、Qが−CONHRCであり、YがC2-6アルキレン基、又はC2-6アルケニレン基である化合物は以下の方法で合成できる。
ただし、Y1は単結合、又はC1-4アルキレン基を示し、その他の記号は前記と同義である。
Manufacturing method 6
In the compound of formula (I) of the present invention, a compound in which Q is —CONHR C and Y is a C 2-6 alkylene group or a C 2-6 alkenylene group can be synthesized by the following method.
Y 1 represents a single bond or a C 1-4 alkylene group, and other symbols are as defined above.
ここに、ピラゾール誘導体1Cは国際公開WO2004/014932号に準拠して合成することができる。 Here, pyrazole derivative 1C can be synthesized based on International Publication WO 2004/014932.
まず、製造法1の工程1に示した光延反応により、ピラゾール誘導体1Cから化合物3Cを合成することができる。 First, the compound 3C can be synthesized from the pyrazole derivative 1C by the Mitsunobu reaction shown in Step 1 of Production Method 1.
(13)工程14(Heck反応)
化合物3Cとオレフィン酢酸10Aをパラジウム触媒とホスフィンリガンド、及び適当な塩基の存在下、Heck反応を行うことにより化合物11Aを合成することができる。このとき用いるパラジウム触媒としては、酢酸パラジウム、テトラキストリフェニルホスフィンパラジウム、ジベンジリデンアセトンパラジウム、ビストリフェニルホスフィンパラジウムクロリド、パラジウム活性炭等が挙げられる。ホスフィンリガンドとしてはトリフェニルホスフィンやトリス(2−メチルフェニル)ホスフィン等が挙げられる。また、塩基にはトリエチルアミン、N−エチル−N,N−ジイソプロピルアミン、炭酸カリウム、炭酸カルシウム、炭酸セシウム、カリウムt−ブトキシド等が用いられる。反応に用いられる溶媒としては、アセトニトリル、トルエン、テトラヒドロフラン等が挙げられる。反応温度は0℃から還流温度であるが、マイクロウェーブを用いることもある。
(13) Step 14 (Heck reaction)
Compound 11A can be synthesized by subjecting compound 3C and olefin acetic acid 10A to a Heck reaction in the presence of a palladium catalyst, a phosphine ligand, and an appropriate base. Examples of the palladium catalyst used at this time include palladium acetate, tetrakistriphenylphosphine palladium, dibenzylideneacetone palladium, bistriphenylphosphine palladium chloride, palladium activated carbon and the like. Examples of the phosphine ligand include triphenylphosphine and tris (2-methylphenyl) phosphine. As the base, triethylamine, N-ethyl-N, N-diisopropylamine, potassium carbonate, calcium carbonate, cesium carbonate, potassium t-butoxide and the like are used. Examples of the solvent used for the reaction include acetonitrile, toluene, tetrahydrofuran and the like. The reaction temperature is from 0 ° C. to reflux temperature, but microwaves may be used.
(14)工程15(アミド化)
化合物11Aとアミン(RCNH2)にて脱水縮合し、化合物12Aが得られる。この反応に使用する溶媒としては、クロロホルム、ジクロロメタン、N,N−ジメチルホルムアミド等が好ましく、脱水縮合剤としては、N,N’−ジシクロヘキシルカルボジイミド(DCC)、N−エチル−N’−3−ジメチルアミノプロピルカルボジイミド塩酸(WSC)、CDI、WSC/1−ヒドロキシベンゾトリアゾール1水和物等が好ましい。ここでの反応温度は0℃〜60℃である。
(14) Step 15 (Amidation)
Compound 12A is obtained by dehydration condensation with compound 11A and amine (R C NH 2 ). As a solvent used in this reaction, chloroform, dichloromethane, N, N-dimethylformamide and the like are preferable, and as a dehydrating condensing agent, N, N′-dicyclohexylcarbodiimide (DCC), N-ethyl-N′-3-dimethyl is used. Aminopropylcarbodiimide hydrochloride (WSC), CDI, WSC / 1-hydroxybenzotriazole monohydrate and the like are preferable. The reaction temperature here is 0 ° C to 60 ° C.
(15)工程16
化合物11Aのオレフィン部分を製造法1の工程2に示した接触水素添加を行った後に、アミン(RCNH2)と縮合することで、化合物12Bを製造することもできる。
(15) Step 16
Compound 12B can also be produced by condensing with an amine (R C NH 2 ) after performing catalytic hydrogenation as shown in Step 2 of Production Method 1 on the olefin moiety of Compound 11A.
(16)工程17(脱保護)
最後に、P1、P2、P3及びP4を製造法1の工程4に示した方法で脱保護し、本発明化合物(I)が得られる。
(16) Step 17 (deprotection)
Finally, P 1 , P 2 , P 3 and P 4 are deprotected by the method shown in Step 4 of Production Method 1 to obtain the compound (I) of the present invention.
製造法7
本発明の式(I)化合物において、Qが−CONHRCであり、Yが−O−(CH2)n−である化合物は以下の方法で合成できる。
ただし、Y1はC1-4アルキレン基を示し、L2はハロゲン原子、MeSO2O-等の脱離基を示し、その他の記号は前記と同義である。
Manufacturing method 7
In the compound of formula (I) of the present invention, a compound in which Q is —CONHR C and Y is —O— (CH 2 ) n— can be synthesized by the following method.
However, Y 1 represents a C 1-4 alkylene group, L 2 represents a leaving group such as a halogen atom or MeSO 2 O—, and other symbols are as defined above.
ここに、ピラゾール誘導体4Bは製造法1の工程1、工程2に準拠して合成することができる。 Here, the pyrazole derivative 4B can be synthesized according to Step 1 and Step 2 of Production Method 1.
(17)工程18
ピラゾール誘導体4Bを適当な塩基の存在下で、化合物13Aと反応させることにより化合物12Cを得ることができる。適当な塩基としては水素化ナトリウム、炭酸カリウム、炭酸セシウム、炭酸ナトリウム、n−ブチルリチウムが好ましく、この反応に使用する溶媒としては、テトラヒドロフラン、ジエチルエーテル、N,N−ジメチルホルムアミド、アセトン、DMSOが好ましい。ここでこの反応の温度は0℃〜60℃である。
(17) Step 18
Compound 12C can be obtained by reacting pyrazole derivative 4B with compound 13A in the presence of a suitable base. Suitable bases are preferably sodium hydride, potassium carbonate, cesium carbonate, sodium carbonate, and n-butyllithium. Solvents used in this reaction include tetrahydrofuran, diethyl ether, N, N-dimethylformamide, acetone, and DMSO. preferable. Here, the temperature of this reaction is 0 ° C to 60 ° C.
(18)工程19
P1、P2、P3及びP4を製造法1の工程4に示した方法で脱保護し、本発明化合物(I)が得られる。
(18) Step 19
P 1 , P 2 , P 3 and P 4 are deprotected by the method shown in Step 4 of Production Method 1 to obtain the compound (I) of the present invention.
本発明の化合物は、SGLT1を選択的に阻害し、小腸からの糖の吸収を抑制して、IGTを改善することができる。 The compound of the present invention can selectively inhibit SGLT1, suppress absorption of sugar from the small intestine, and improve IGT.
よって、本発明の化合物は、SGLT1阻害剤、あるいは、糖尿病、糖尿病関連疾患及び糖尿病合併症の予防又は治療剤の有効成分として用いることができる。 Therefore, the compound of the present invention can be used as an active ingredient of a SGLT1 inhibitor or a preventive or therapeutic agent for diabetes, diabetes-related diseases and diabetic complications.
ここで、「糖尿病」には、1型糖尿病、2型糖尿病の他、特定の原因によるその他の型の糖尿病が含まれる。 Here, “diabetes” includes type 1 diabetes, type 2 diabetes, and other types of diabetes caused by a specific cause.
ここで、「糖尿病関連疾患」とは、肥満、高インスリン血症、糖代謝異常、高脂質血症、高コレステロール血症、高トリグリセリド血症、脂質代謝異常、高血圧、うっ血性心不全、浮腫、高尿酸血症、痛風などが挙げられる。 Here, “diabetes-related disease” means obesity, hyperinsulinemia, glucose metabolism abnormality, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, lipid metabolism abnormality, hypertension, congestive heart failure, edema, high Examples include uricemia and gout.
ここで、「糖尿病合併症」は、急性合併症及び慢性合併症に分類される。 Here, “diabetic complications” are classified into acute complications and chronic complications.
「急性合併症」には、高血糖(ケトアシドーシスなど)、感染症(皮膚、軟部組織、胆道系、呼吸系、***など)などが挙げられる。 “Acute complications” include hyperglycemia (such as ketoacidosis), infections (such as skin, soft tissue, biliary system, respiratory system, urinary tract infection) and the like.
「慢性合併症」には、細小血管症(腎症、網膜症)、動脈硬化症(アテローム性動脈硬化症、心筋梗塞、脳梗塞、下肢動脈閉塞など)、神経障害(感覚神経、運動神経、自律神経など)、足壊疽などが挙げられる。 “Chronic complications” include microangiopathy (nephropathy, retinopathy), arteriosclerosis (atherosclerosis, myocardial infarction, cerebral infarction, lower limb arterial occlusion, etc.), neuropathy (sensory, motor, Autonomic nerves) and foot gangrene.
主要な合併症は、糖尿病網膜症、糖尿病腎症、糖尿病神経障害である。 The main complications are diabetic retinopathy, diabetic nephropathy, diabetic neuropathy.
本発明の化合物は、医薬として、全身的又は局所的に、経口投与又は非経口投与することができる。 The compound of the present invention can be administered as a pharmaceutical systemically or locally, orally or parenterally.
本発明化合物は、該化合物の作用の増強または該化合物の投与量の低減などを目的として、SGLT1及びSGLT2活性阻害薬以外のことなった作用機序の糖尿病治療剤、糖尿病性合併症治療剤、抗高脂血症剤、降圧剤、抗肥満剤、利尿剤、抗血栓剤などの薬剤( 以下、併用薬剤と略記する) と組み合わせて用いることができる。この際、本発明化合物と併用薬剤の投与時期は限定されず、これらを投与対象に対し、同時に投与してもよいし、時間差をおいて投与してもよい。さらに、本発明化合物と併用薬剤とは、それぞれの活性成分を含む2種類の製剤として投与されてもよいし、両方の活性成分を含む単一の製剤として投与されてもよい。併用薬剤の投与量は、臨床上用いられている用量を基準として適宜選択することができる。また、本発明化合物と併用薬剤の配合比は、投与対象、投与ルート、対象疾患、症状、組み合わせなどにより適宜選択することができる。例えば、投与対象がヒトである場合、本発明化合物1重量部に対し、併用薬剤を0.01〜100重量部用いればよい。 The compound of the present invention is a therapeutic agent for diabetes having a different mechanism other than SGLT1 and SGLT2 activity inhibitor, for the purpose of enhancing the action of the compound or reducing the dose of the compound, It can be used in combination with drugs such as antihyperlipidemic agents, antihypertensive agents, antiobesity agents, diuretics, antithrombotic agents (hereinafter abbreviated as concomitant drugs). In this case, the administration time of the compound of the present invention and the concomitant drug is not limited, and these may be administered to the administration subject at the same time or may be administered with a time difference. Furthermore, the compound of the present invention and the concomitant drug may be administered as two types of preparations containing each active ingredient, or may be administered as a single preparation containing both active ingredients. The dose of the concomitant drug can be appropriately selected based on the clinically used dose. The compounding ratio of the compound of the present invention and the concomitant drug can be appropriately selected depending on the administration subject, administration route, target disease, symptom, combination and the like. For example, when the administration subject is a human, the concomitant drug may be used in an amount of 0.01 to 100 parts by weight per 1 part by weight of the compound of the present invention.
なお、糖尿病治療剤としては、例えばインスリン製剤(例、ウシ、ブタの膵臓から抽出された動物インスリン製剤;大腸菌またはイーストを用い、遺伝子工学的に合成したヒトインスリン製剤;インスリン亜鉛; プロタミンインスリン亜鉛; インスリンのフラグメントまたは誘導体(例、INS−1等)、経口インスリン製剤)、インスリン抵抗性改善剤(例、ピオグリタゾンまたはその塩(好ましくは塩酸塩)、ロシグリタゾンまたはその塩(好ましくはマレイン酸塩)、リボグリタゾン(Rivoglitazone)(CS−011)(R−119702)、シポグリタザール(Sipoglitazar)(TAK−654)、メタグリダセン(Metaglidasen)(MXB−1 0 2)、ナベグリタザール(Naveglitazar)(LY−519818)、MX−6054、バラグリタゾン(Balaglitazone)(NN−2344)、T−131(AMG131)、PPARγアゴニスト、PPARγアンタゴニスト、PPARγ/αデュアルアゴニスト、α−グルコシダーゼ阻害剤(例、ボグリボース、アカルボース、ミグリトール、エミグリテート)、ビグアナイド剤(例、フェンホルミン、メトホルミン、ブホルミンまたはそれらの塩(例、塩酸塩、フマル酸塩、コハク酸塩))、インスリン分泌促進剤(スルホニルウレア剤(例、トルブタミド、グリベンクラミド、グリクラジド、クロルプロパミド、トラザミド、アセトヘキサミド、グリクロピラミド、グリメピリド、グリピザイド、グリブゾール等)、レパグリニド、セナグリニド、ナテグリニド、ミチグリニドまたはそのカルシウム塩水和物)、GPR40アゴニスト、GPR40アンタゴニスト、GLP−1受容体アゴニスト(例、GLP−1、GLP−1MR剤、リラグルチド(Liraglutide)(NN−2211)、Exenatide(AC−2993)(exendin−4)、Exenatide LAR、BIM51077、A i b (8,35)hGLP−1(7,37) NH2、CJC−1131、AVE0010、GSK-716155)、アミリンアゴニスト(例、プラムリンチド)、フォスフォチロシンフォスファターゼ阻害剤(例、バナジン酸ナトリウム)、ジペプチジルペプチダーゼIV阻害剤(例、WO02/038541に記載の化合物、NVP−DPP−278、PT−100、P32/98、ビルダグリプチン(Vildagliptin)(LAF−237)、P93/01、シタグリプチン(Sitagliptin)(MK−431)、サクサグリプチン(Saxagliptin)(BMS−477118)、SYR−322、MP−513、T−6666、GRC−8200等)、β3アゴニスト(例、AJ−9677、AZ40140等)、糖新生阻害剤(例、グリコーゲンホスホリラーゼ阻害剤、グルコース−6−ホスファターゼ阻害剤、グルカゴン拮抗剤、フルクトース−1,6−ビスホスファターゼ阻害剤)、SGLT (sodium−glucose cotransporter) 阻害剤(例、WO04/014931、WO04/089967、WO06/073197に記載の化合物、T−1095、Sergliflozin(GSK−869682)、GSK−189075、KGT−1251、KGT−1681、KGA−2727、BMS−512148、AVE2268、SAR7226等)、11β−ヒドロキシステロイドデヒドロゲナーゼ阻害薬(例、WO06/51662に記載の化合物、BVT−3498、INCB13739)、GPR119アゴニスト(例、PSN−632408、APD−668)、アディポネクチンまたはその作動薬、IKK阻害薬(例、A S−2868)、AMPK活性化薬、レプチン抵抗性改善薬、ソマトスタチン受容体作動薬、グルコキナーゼ活性化薬(例、Ro−28−1675)、膵リパーゼ阻害薬(例、オルリスタット、ATL−962)、DGAT−1阻害薬が挙げられる。 Examples of diabetes therapeutic agents include insulin preparations (eg, animal insulin preparations extracted from bovine and porcine pancreas; human insulin preparations synthesized by genetic engineering using Escherichia coli or yeast; insulin zinc; protamine insulin zinc; Insulin fragment or derivative (eg, INS-1 etc.), oral insulin preparation), insulin resistance improving agent (eg, pioglitazone or a salt thereof (preferably hydrochloride), rosiglitazone or a salt thereof (preferably maleate) Riboglitazone (CS-011) (R-11702), Sipoglitazar (TAK-654), Metaglidasen (MXB-1 0 2), Naveglitazar ) (LY-51818), MX-6054, Balaglitzone (NN-2344), T-131 (AMG131), PPARγ agonist, PPARγ antagonist, PPARγ / α dual agonist, α-glucosidase inhibitor (eg, voglibose) , Acarbose, miglitol, emiglitate), biguanides (eg, phenformin, metformin, buformin or their salts (eg, hydrochloride, fumarate, succinate)), insulin secretagogues (sulfonylurea (eg, tolbutamide) Glibenclamide, gliclazide, chlorpropamide, tolazamide, acetohexamide, glyclopyramide, glimepiride, glipizide, glybsol, etc.), repaglinide, senaglinide, nateglinide, mitigli Nido or its calcium salt hydrate), GPR40 agonist, GPR40 antagonist, GLP-1 receptor agonist (eg, GLP-1, GLP-1MR agent, Liraglutide (NN-2211), Exenatide (AC-2993) ( exendin-4), Exenatide LAR, BIM51077, A ib (8,35) hGLP-1 (7,37) NH2, CJC-1131, AVE0010, GSK-716155), amylin agonist (eg, pramlintide), phosphotyrosine phosphatase Inhibitors (eg, sodium vanadate), dipeptidyl peptidase IV inhibitors (eg, compounds described in WO02 / 038541, NVP-DPP-278, PT-100, P32 / 98, vildagliptin (Vilda liptin) (LAF-237), P93 / 01, sitagliptin (MK-431), saxagliptin (BMS-477118), SYR-322, MP-513, T-6666, GRC-8200, etc.) β3 agonist (eg, AJ-9777, AZ40140, etc.), gluconeogenesis inhibitor (eg, glycogen phosphorylase inhibitor, glucose-6-phosphatase inhibitor, glucagon antagonist, fructose-1,6-bisphosphatase inhibitor), SGLT (Sodium-glucose transporter) inhibitor (eg, compound described in WO04 / 014931, WO04 / 089967, WO06 / 073197, T-1095, Serglflozin (GSK-8696) 82), GSK-189075, KGT-1251, KGT-1681, KGA-2727, BMS-512148, AVE2268, SAR7226, etc., 11β-hydroxysteroid dehydrogenase inhibitors (eg, compounds described in WO06 / 51662, BVT-3498) , INCB13739), GPR119 agonist (eg, PSN-632408, APD-668), adiponectin or agonist thereof, IKK inhibitor (eg, AS-2868), AMPK activator, leptin resistance ameliorating agent, somatostatin receptor agonist Drugs, glucokinase activators (eg, Ro-28-1675), pancreatic lipase inhibitors (eg, orlistat, ATL-962), DGAT-1 inhibitors.
糖尿病性合併症治療剤としては、例えばアルドース還元酵素阻害剤(例、トルレスタット、エパルレスタット、ゼナレスタット、ゾポルレスタット、ミナルレスタット、フィダレスタット、CT−112)、神経栄養因子およびその増加薬(例、NGF、NT−3、BDNF、ニューロトロフィン産生・分泌促進剤)、神経再生促進薬(例、Y−128)、PKC阻害剤(例、ルボキシスタウリンメシレート(ruboxistaurin mesylate;LY−333531))、AGE阻害剤(例、ALT946、ピマゲジン、ピラトキサチン、N−フェナシルチアゾリウムブロマイド(ALT766)、ALT−711、EXO−226、ピリドリン(Pyridorin)、ピリドキサミン)、活性酸素消去薬(例、チオクト酸)、脳血管拡張剤(例、チアプリド、メキシレチン)、ソマトスタチン受容体作動薬(例、BIM23190)、アポトーシスシグナルレギュレーティングキナーゼ−1(ASK−1)阻害薬が挙げられる。 Examples of the therapeutic agent for diabetic complications include aldose reductase inhibitors (eg, tolrestat, epalrestat, zenarestat, zopolrestat, minalrestat, fidarestat, CT-112), neurotrophic factors and their increasing agents (eg, NGF). , NT-3, BDNF, neurotrophin production / secretion promoter), nerve regeneration promoter (eg, Y-128), PKC inhibitor (eg, ruboxistaurine mesylate (LY-333531)) AGE inhibitors (eg, ALT946, pimagedin, pyratoxatin, N-phenacylthiazolium bromide (ALT766), ALT-711, EXO-226, pyridorin, pyridoxamine), active oxygen scavengers (eg, thioctic acid) ), Examples thereof include cerebrovascular dilators (eg, thiaprid, mexiletine), somatostatin receptor agonists (eg, BIM23190), and apoptosis signal regulating kinase-1 (ASK-1) inhibitors.
抗高脂血症剤としては、例えばスタチン系化合物(例、プラバスタチン、シンバスタチン、ロバスタチン、アトルバスタチン、フルバスタチン、イタバスタチン、ロスバスタチン、ピタバスタチンまたはそれらの塩(例、ナトリウム塩、カルシウム塩))、スクアレン合成酵素阻害剤(例、TAK−475)、フィブラート系化合物(例、ベザフィブラート、クロフィブラート、シムフィブラート、クリノフィブラート)、ACAT阻害剤(例、アバシマイブ(Avasimibe)、エフルシマイブ(Eflucimibe))、陰イオン交換樹脂(例、コレスチラミン)、プロブコール、ニコチン酸系薬剤(例、ニコモール(nicomol)、ニセリトロール(niceritrol))、イコサペント酸エチル、植物ステロール(例、ソイステロール(soysterol)、ガンマオリザノール(γ−oryzanol))、CETP阻害薬(例、Torcetrapib、JTT−705、JTT−302、FN−VP4等)、コレステロール吸収抑制薬(例、エゼチミブ(Ezetimibe)等)が挙げられる。 Antihyperlipidemic agents include, for example, statin compounds (eg, pravastatin, simvastatin, lovastatin, atorvastatin, fluvastatin, itavastatin, rosuvastatin, pitavastatin or their salts (eg, sodium salt, calcium salt)), squalene synthesis Enzyme inhibitors (eg, TAK-475), fibrate compounds (eg, bezafibrate, clofibrate, simfibrate, clinofibrate), ACAT inhibitors (eg, avasimibe, elucimibe), anion exchange resin (Eg, cholestyramine), probucol, nicotinic acid drugs (eg, nicomol, niceritrol), ethyl icosapentate, plant sterols (eg, soy) Sterol (soysterol), gamma oryzanol (γ-oryzanol)), CETP inhibitor (eg, Torcetrapib, JTT-705, JTT-302, FN-VP4, etc.), cholesterol absorption inhibitor (eg, ezetimibe, etc.) Can be mentioned.
降圧剤としては、例えばアンジオテンシン変換酵素阻害剤(例、カプトプリル、エナラプリル、デラプリル)、アンジオテンシンII拮抗剤(例、カンデサルタン シレキセチル、ロサルタン、エプロサルタン、バルサルタン、テルミサルタン、イルベサルタン、タソサルタン、アジルザルタン(TAK−536))、カルシウム拮抗剤(例、マニジピン、ニフェジピン、アムロジピン、エホニジピン、ニカルジピン)、カリウムチャンネル開口薬(例、レブクロマカリム、L−27152、AL0671、NIP−121)、クロニジンが挙げられる。 Examples of the antihypertensive agent include angiotensin converting enzyme inhibitors (eg, captopril, enalapril, delapril), angiotensin II antagonists (eg, candesartan cilexetil, losartan, eprosartan, valsartan, telmisartan, irbesartan, tasosartan, azilsartan (TAK-536) ), Calcium antagonists (eg, manidipine, nifedipine, amlodipine, efonidipine, nicardipine), potassium channel openers (eg, lebucromakalim, L-27152, AL0671, NIP-121) and clonidine.
抗肥満剤としては、例えば中枢性抗肥満薬(例、デキスフェンフルラミン、フェンフルラミン、フェンテルミン、シブトラミン、アンフェプラモン、デキサンフェタミン、マジンドール、フェニルプロパノールアミン、クロベンゾレックス;MCH受容体拮抗薬(例、WO06/035967に記載の化合物、SB−568849; SNAP−7941、T−226296);ニューロペプチドY拮抗薬(例、CP−422935);カンナビノイド受容体拮抗薬( 例、リモナバント(Rimonabant)(SR−141716)、SR−147778);グレリン拮抗薬;11β−ヒドロキシステロイドデヒドロゲナーゼ阻害薬(例、BVT−3498、INCB13739))、膵リパーゼ阻害薬(例、オルリスタット、ATL−962)、DGAT−1阻害薬、β3アゴニスト(例、AJ−9677、AZ40140)、ペプチド性食欲抑制薬(例、レプチン、CNTF( 毛様体神経栄養因子))、コレシストキニンアゴニスト(例、リンチトリプト、FPL−15849)、摂食抑制薬(例、P−57)が挙げられる。 Examples of anti-obesity agents include central anti-obesity agents (eg, dexfenfluramine, fenfluramine, phentermine, sibutramine, amphetopramone, dexamphetamine, mazindol, phenylpropanolamine, clobenzorex; MCH receptor antagonist (Eg, compounds described in WO06 / 035967, SB-568849; SNAP-7941, T-226296); neuropeptide Y antagonists (eg, CP-422935); cannabinoid receptor antagonists (eg, rimonabant ( SR-141716), SR-147778); ghrelin antagonists; 11β-hydroxysteroid dehydrogenase inhibitors (eg, BVT-3498, INCB13739)), pancreatic lipase inhibitors (eg, orlistat, ATL-962) ), DGAT-1 inhibitor, β3 agonist (eg, AJ-9679, AZ40140), peptidic appetite suppressant (eg, leptin, CNTF (ciliary neurotrophic factor)), cholecystokinin agonist (eg, linchtripto, FPL-15849), an antifeedant (eg, P-57).
利尿剤としては、例えば、キサンチン誘導体(例、サリチル酸ナトリウムテオブロミン、サリチル酸カルシウムテオブロミン)、チアジド系製剤(例、エチアジド、シクロペンチアジド、トリクロルメチアジド、ヒドロクロロチアジド、ヒドロフルメチアジド、ベンチルヒドロクロロチアジド、ペンフルチジド、ポリチアジド、メチクロチアジド)、抗アルドステロン製剤(例、スピロノラクトン、トリアムテレン)、炭酸脱水酵素阻害剤(例、アセタゾラミド)、クロルベンゼンスルホンアミド系製剤(例、クロルタリドン、メフルシド、インダパミド)、アゾセミド、イソソルビド、エタクリン酸、ピレタニド、ブメタニド、フロセミドが挙げられる。 Examples of diuretics include xanthine derivatives (eg, sodium salicylate theobromine, calcium salicylate theobromine), thiazide preparations (eg, etiazide, cyclopenthiazide, trichloromethiazide, hydrochlorothiazide, hydroflumethiazide, benchylhydrochlorothiazide, pentfurizide, polythiazide. , Methiclotiazide), anti-aldosterone preparations (eg, spironolactone, triamterene), carbonic anhydrase inhibitors (eg, acetazolamide), chlorobenzenesulfonamide preparations (eg, chlorthalidone, mefluside, indapamide), azosemide, isosorbide, ethacrynic acid, Piretanide, bumetanide, furosemide.
抗血栓剤としては、例えば、ヘパリン(例、ヘパリンナトリウム、ヘパリンカルシウム、ダルテパリンナトリウム(dalteparin sodium)、AVE−5026) 、ワルファリン(例、ワルファリンカリウムなど) 、抗トロンビン薬(例、アルガトロバン(argatroban)、キシメラガトラン(Ximelagatran)、ダビガトラン(Dabigatran)、Odiparcil、Lepirudin、bivalirudin、Desirudin、ART−123、Idraparinux、SR−123781、AZD−0837、MCC−977、TGN−255、TGN−167、RWJ−58436、LB−30870、MPC−0920、Pegmusirudin、Org−426751等)、血栓溶解薬(例、ウロキナーゼ(urokinase)、チソキナーゼ(tisokinase)、アルテプラーゼ(alteplase)、ナテプラーゼ(nateplase)、モンテプラーゼ(monteplase)、パミテプラーゼ(pamiteplase)等)、血小板凝集抑制薬(例、塩酸チクロピジン(ticlepidine hydrochloride)、シロスタゾール(cilostazol)、イコサペント酸エチル、ベラプロストナトリウム(beraprost sodium)、塩酸サルポグレラート(sarpogrelate hydrochloride)など)、抗Xa阻害薬(例、Fondaparinux、BAY−59−7939、DU−176b、YM−150、SR−126517、Apixaban、Razaxaban、LY−517717、MLN−102、Octaparine、Otamixaban、EMD−503982、TC−10、CS−3030、AVE−3247、GSK−813893、KFA−1982等)、血漿中カルボキシペプチターゼB(または活性型thrombin−activatable fibrinolysis inhibitor[TAFIa]としても知られている)阻害薬(例、AZD−9684、EF−6265、MN−462)などが挙げられる。 Examples of the antithrombotic agent include heparin (eg, heparin sodium, heparin calcium, dalteparin sodium, AVE-5026), warfarin (eg, warfarin potassium, etc.), antithrombin drug (eg, argatroban) , Ximelagatran, Dabigatran, Odiparcil, Lepirudin, bivalirudin, Desirudin, ART-123, Idraparinux, SR-12537, TCG-9737, TCG-9737, TCG-9737, TCG-9737 -30870, MPC-0920, Pegmusirudin, Org-426751, etc.), thrombolysis Drugs (eg, urokinase, tisokinase, alteplase, nateplase, monteplase, monteplase, etc.), platelet aggregation inhibitor (eg, ticropid hydrochloride) Cilostazol, ethyl icosapentate, beraprost sodium, sarpogrelate hydrochloride, etc.), anti-Xa inhibitors (eg, Fondaparinux, BAY-59-7SR, DU-176, DU-176, DU-176, DU-176 126517, Apibaban, Razababan LY-517717, MLN-102, Octaparine, Otamixavan, EMD-503982, TC-10, CS-3030, AVE-3247, GSK-838893, KFA-1982, etc., plasma carboxypeptidase B (or active thrombin- and activable fibrinolysis inhibitor [TAFIa] inhibitors (eg, AZD-9684, EF-6265, MN-462) and the like.
本発明の化合物を医薬として提供する場合、固形剤、液剤等の種々の態様の製剤形態を適宜に採択することができる。その際、製薬学的に許容される担体を配合することも可能である。そのような担体の例としては、一般的な賦形剤、増量剤、結合剤、崩壊剤、被覆剤、糖衣剤、pH調整剤、溶解剤又は水性若しくは非水性溶媒などが挙げられる。本発明の化合物とこれらの担体から、錠剤、丸剤、カプセル剤、顆粒剤、粉剤、散剤、液剤、乳剤、懸濁剤、注射剤等を調製することができる。 When the compound of the present invention is provided as a pharmaceutical, various forms of preparations such as solid preparations and liquid preparations can be appropriately adopted. In that case, it is also possible to mix | blend a pharmaceutically acceptable carrier. Examples of such carriers include common excipients, bulking agents, binders, disintegrants, coating agents, dragees, pH adjusters, solubilizers or aqueous or non-aqueous solvents. Tablets, pills, capsules, granules, powders, powders, solutions, emulsions, suspensions, injections and the like can be prepared from the compound of the present invention and these carriers.
また、本発明の化合物は、α、β若しくはγ−シクロデキストリン又はメチル化シクロデキストリン等に包接させて、その溶解性を改善することも可能である。 Further, the solubility of the compound of the present invention can be improved by inclusion in α, β or γ-cyclodextrin or methylated cyclodextrin.
本発明の化合物の投与量は、疾患、症状、体重、年齢、性別、投与経路等により異なってくるが、成人に対し、1日当たり0.1〜1000mg/kg体重であり、0.1〜200mg/kg体重が好ましく、0.1〜10mg/kg体重がより好ましい。これを1日1回から数回に分けて投与することができる。 The dose of the compound of the present invention varies depending on the disease, symptoms, body weight, age, sex, route of administration, etc., but is 0.1 to 1000 mg / kg body weight per day for an adult, 0.1 to 200 mg. / Kg body weight is preferable, and 0.1 to 10 mg / kg body weight is more preferable. This can be administered once to several times a day.
以下に実施例及び試験例をあげて本発明をさらに詳しく説明するが、本発明はこれらの記載によって限定的に解釈されるものではない。 EXAMPLES The present invention will be described in more detail with reference to examples and test examples below, but the present invention is not construed as being limited by these descriptions.
実施例1
4−{4−[2−(ベンジルオキシ)エトキシ]−2−メチルベンジル}−5−イソプロピル−1H−ピラゾール−3−イル 5−チオ−β−D−グルコピラノシドの合成
Example 1
Synthesis of 4- {4- [2- (benzyloxy) ethoxy] -2-methylbenzyl} -5-isopropyl-1H-pyrazol-3-yl 5-thio-β-D-glucopyranoside
(1)4−{4−[2−(ベンジルオキシ)エトキシ]−2−メチルベンジル}−5−イソプロピル−1H−ピラゾール−3−イル 2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシドの合成
2,3,4,6−テトラ−O−アセチル−5−チオ−D−グルコピラノース(0.582g、1.60mmol)、4−{[4−(2−ベンジルオキシエトキシ)−2−メチルフェニル]メチル}−1,2−ジヒドロ−5−イソプロピル−3H−ピラゾール−3−オン(0.304g、0.799mmol;国際公開WO04/050122号を参考に4−ブロモ−3−メチルフェノールより合成)及びトリフェニルホスフィン(0.420g、1.60mmol)のテトラヒドロフラン(1mL)溶液に氷冷下、ジイソプロピルアゾジカルボキシレート(0.809mL、1.60mmol)の40%トルエン溶液をゆっくりと滴下した。氷冷下で30分間攪拌し、室温に昇温後、さらに3時間攪拌した。溶媒を減圧下留去し、得られた残渣をシリカゲルカラムクロマトグラフィ−(n−ヘキサン:酢酸エチル=1:1)にて2回精製した後、薄層クロマトグラフィー(クロロホルム:メタノール=50:1)にて精製し、無色ガム状物質として表題化合物(0.040g、7%)を得た。
1H NMR (300 MHz, CHLOROFORM-d) δppm 1.12 (d, J=6.99 Hz, 6 H) 1.80 (s, 3 H) 1.98 (s, 3 H) 2.02 (s, 3 H) 2.05 (s, 3 H) 2.26 (s, 3 H) 2.74 - 2.86 (m, 1 H) 3.38 - 3.59 (m, 3 H) 3.76 - 3.85 (m, 2 H) 4.05 - 4.18 (m, 3 H) 4.35 (dd, J=11.97, 4.51 Hz, 1 H) 4.63 (s, 2 H) 5.17 (t, J=9.79 Hz, 1 H) 5.37 (t, J=9.79 Hz, 1 H) 5.51 (t, J=8.86 Hz, 1 H) 5.86 (d, J=8.86 Hz, 1 H) 6.61 (dd, J=8.55, 2.49 Hz, 1 H) 6.72 (d, J=2.49 Hz, 1 H) 6.79 (d, J=8.55 Hz, 1 H) 7.21 - 7.43 (m, 5 H).
(1) 4- {4- [2- (benzyloxy) ethoxy] -2-methylbenzyl} -5-isopropyl-1H-pyrazol-3-yl 2,3,4,6-tetra-O-acetyl-5 Synthesis of -thio-β-D-glucopyranoside 2,3,4,6-tetra-O-acetyl-5-thio-D-glucopyranose (0.582 g, 1.60 mmol), 4-{[4- (2 -Benzyloxyethoxy) -2-methylphenyl] methyl} -1,2-dihydro-5-isopropyl-3H-pyrazol-3-one (0.304 g, 0.799 mmol; 4 with reference to WO 04/050122) -Synthesis from bromo-3-methylphenol) and triphenylphosphine (0.420 g, 1.60 mmol) in tetrahydrofuran (1 mL) under ice-cooling A 40% toluene solution of propyl azodicarboxylate (0.809 mL, 1.60 mmol) was slowly added dropwise. The mixture was stirred for 30 minutes under ice-cooling, warmed to room temperature, and further stirred for 3 hours. The solvent was distilled off under reduced pressure, and the resulting residue was purified twice by silica gel column chromatography (n-hexane: ethyl acetate = 1: 1) and then thin-layer chromatography (chloroform: methanol = 50: 1). To give the title compound (0.040 g, 7%) as a colorless gum.
1H NMR (300 MHz, CHLOROFORM-d) δppm 1.12 (d, J = 6.99 Hz, 6 H) 1.80 (s, 3 H) 1.98 (s, 3 H) 2.02 (s, 3 H) 2.05 (s, 3 H ) 2.26 (s, 3 H) 2.74-2.86 (m, 1 H) 3.38-3.59 (m, 3 H) 3.76-3.85 (m, 2 H) 4.05-4.18 (m, 3 H) 4.35 (dd, J = 11.97, 4.51 Hz, 1 H) 4.63 (s, 2 H) 5.17 (t, J = 9.79 Hz, 1 H) 5.37 (t, J = 9.79 Hz, 1 H) 5.51 (t, J = 8.86 Hz, 1 H ) 5.86 (d, J = 8.86 Hz, 1 H) 6.61 (dd, J = 8.55, 2.49 Hz, 1 H) 6.72 (d, J = 2.49 Hz, 1 H) 6.79 (d, J = 8.55 Hz, 1 H) ) 7.21-7.43 (m, 5 H).
(2)4−{4−[2−(ベンジルオキシ)エトキシ]−2−メチルベンジル}−5−イソプロピル−1H−ピラゾール−3−イル 5−チオ−β−D−グルコピラノシドの合成
4−{4−[2−(ベンジルオキシ)エトキシ]−2−メチルベンジル}−5−イソプロピル−1H−ピラゾール−3−イル 2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシド(0.40g、0.055mmol)のメタノール(1mL)−水(1mL)混合溶液にトリエチルアミン(2mL)を加え室温で1時間攪拌した。反応液を減圧下留去し、得られた残渣を薄層クロマトグラフィー(クロロホルム:メタノール=17:3)にて精製し、白色粉末として表題化合物(0.029g、94%)を得た。得られた化合物の構造、NMRデータ及びMSデータを表1に示す。
(2) Synthesis of 4- {4- [2- (benzyloxy) ethoxy] -2-methylbenzyl} -5-isopropyl-1H-pyrazol-3-yl 5-thio-β-D-glucopyranoside 4- {4 -[2- (Benzyloxy) ethoxy] -2-methylbenzyl} -5-isopropyl-1H-pyrazol-3-yl 2,3,4,6-tetra-O-acetyl-5-thio-β-D- Triethylamine (2 mL) was added to a mixed solution of glucopyranoside (0.40 g, 0.055 mmol) in methanol (1 mL) -water (1 mL), and the mixture was stirred at room temperature for 1 hour. The reaction solution was evaporated under reduced pressure, and the resulting residue was purified by thin layer chromatography (chloroform: methanol = 17: 3) to give the title compound (0.029 g, 94%) as a white powder. The structure, NMR data and MS data of the obtained compound are shown in Table 1.
実施例2
4−[4−(2−ヒドロキシエトキシ)−2−メチルベンジル]−5−イソプロピル−1H−ピラゾール−3−イル 5−チオ−β−D−グルコピラノシドの合成
Example 2
Synthesis of 4- [4- (2-hydroxyethoxy) -2-methylbenzyl] -5-isopropyl-1H-pyrazol-3-yl 5-thio-β-D-glucopyranoside
(1)4−[4−(2−ヒドロキシエトキシ)−2−メチルベンジル]−5−イソプロピル−1H−ピラゾール−3−イル 2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシド
2,3,4,6−テトラ−O−アセチル−5−チオ−D−グルコピラノース(51.1g、70.1mmol)、4−{[4−(2−ベンジルオキシエトキシ)−2−メチルフェニル]メチル}−1,2−ジヒドロ−5−イソプロピル−3H−ピラゾール−3−オン(26.7g、70.1mmol;国際公開WO04/050122号を参考に4−ブロモ−3−メチルフェノールより合成)及びトリフェニルホスフィン(36.8g、140mmol)のテトラヒドロフラン(175mL)溶液に氷冷下、ジイソプロピルアゾジカルボキシレート(73.8mL、140mmol)の40%トルエン溶液をゆっくりと滴下した。氷冷下で30分間攪拌し、室温に昇温後、さらに3時間攪拌した。溶媒を減圧下留去し、得られた残渣をシリカゲルカラムクロマトグラフィ−(n−ヘキサン:酢酸エチル=1:1)にて精製し、褐色ガム状物質として粗化合物(44.5g)を得た。この粗化合物(28.4g)のメタノール(156mL)溶液に20%水酸化パラジウム−活性炭素(10.2g)を加え、水素雰囲気下、室温にて一晩攪拌した。反応液をセライト濾過後、溶媒を減圧下留去し、得られた残渣をシリカゲルカラムクロマトグラフィ−(クロロホルム:メタノール=40:1)にて精製し、淡黄色粉末として表題化合物(9.53g、21%)を得た。
1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.14 (d, J=6.99 Hz, 6 H) 1.82 (s, 3 H) 1.98 (s, 3 H) 2.02 (s, 3 H) 2.05 (s, 3 H) 2.27 (s, 3 H) 2.72 - 2.89 (m, 1 H) 3.37 - 3.60 (m, 3 H) 3.89 - 3.97 (m, 2 H) 3.99 - 4.18 (m, 3 H) 4.33 (dd, J=11.89, 4.59 Hz, 1 H) 5.16 (t, J=9.71 Hz, 1 H) 5.35 (t, J=9.71 Hz, 1 H) 5.49 (t, J=8.86 Hz, 1 H) 5.85 (d, J=8.86 Hz, 1 H) 6.62 (dd, J=8.55, 2.64 Hz, 1 H) 6.72 (d, J=2.64 Hz, 1 H) 6.81 (d, J=8.55 Hz, 1 H).
(1) 4- [4- (2-hydroxyethoxy) -2-methylbenzyl] -5-isopropyl-1H-pyrazol-3-yl 2,3,4,6-tetra-O-acetyl-5-thio- β-D-glucopyranoside 2,3,4,6-tetra-O-acetyl-5-thio-D-glucopyranose (51.1 g, 70.1 mmol), 4-{[4- (2-benzyloxyethoxy) -2-methylphenyl] methyl} -1,2-dihydro-5-isopropyl-3H-pyrazol-3-one (26.7 g, 70.1 mmol; 4-bromo-3- with reference to International Publication WO 04/050122) Synthesis from methylphenol) and triphenylphosphine (36.8 g, 140 mmol) in a tetrahydrofuran (175 mL) solution under ice-cooling, diisopropyl azodicarboxyl. A 40% toluene solution of sylate (73.8 mL, 140 mmol) was slowly added dropwise. The mixture was stirred for 30 minutes under ice-cooling, warmed to room temperature, and further stirred for 3 hours. The solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography (n-hexane: ethyl acetate = 1: 1) to obtain a crude compound (44.5 g) as a brown gum. To a solution of this crude compound (28.4 g) in methanol (156 mL) was added 20% palladium hydroxide-activated carbon (10.2 g), and the mixture was stirred overnight at room temperature in a hydrogen atmosphere. The reaction mixture was filtered through celite, the solvent was evaporated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (chloroform: methanol = 40: 1) to give the title compound (9.53 g, 21) as a pale yellow powder. %).
1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.14 (d, J = 6.99 Hz, 6 H) 1.82 (s, 3 H) 1.98 (s, 3 H) 2.02 (s, 3 H) 2.05 (s, 3 H) 2.27 (s, 3 H) 2.72-2.89 (m, 1 H) 3.37-3.60 (m, 3 H) 3.89-3.97 (m, 2 H) 3.99-4.18 (m, 3 H) 4.33 (dd, J = 11.89, 4.59 Hz, 1 H) 5.16 (t, J = 9.71 Hz, 1 H) 5.35 (t, J = 9.71 Hz, 1 H) 5.49 (t, J = 8.86 Hz, 1 H) 5.85 (d, J = 8.86 Hz, 1 H) 6.62 (dd, J = 8.55, 2.64 Hz, 1 H) 6.72 (d, J = 2.64 Hz, 1 H) 6.81 (d, J = 8.55 Hz, 1 H).
(2)4−[4−(2−ヒドロキシエトキシ)−2−メチルベンジル]−5−イソプロピル−1H−ピラゾール−3−イル 5−チオ−β−D−グルコピラノシドの合成
4−[4−(2−ヒドロキシエトキシ)−2−メチルベンジル]−5−イソプロピル−1H−ピラゾール−3−イル 2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシド(0.175g、0.275mmol)のメタノール(3mL)溶液にナトリウムメトキシドの25%メタノール溶液を加え室温で3時間攪拌した。反応液にドライアイスを加え、中和した後に、溶媒を減圧留去した。残渣をシリカゲルカラムクロマトグラフィ−(酢酸エチル:エタノール:水=20:2:1〜15:2:1)にて精製し、白色粉末として表題化合物(0.106g、82%)を得た。得られた化合物の構造、NMRデータ及びMSデータを表1に示す。
(2) Synthesis of 4- [4- (2-hydroxyethoxy) -2-methylbenzyl] -5-isopropyl-1H-pyrazol-3-yl 5-thio-β-D-glucopyranoside 4- [4- (2 -Hydroxyethoxy) -2-methylbenzyl] -5-isopropyl-1H-pyrazol-3-yl 2,3,4,6-tetra-O-acetyl-5-thio-β-D-glucopyranoside (0.175 g, A 25% methanol solution of sodium methoxide was added to a methanol (3 mL) solution of 0.275 mmol) and stirred at room temperature for 3 hours. After dry ice was added to the reaction solution and neutralized, the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate: ethanol: water = 20: 2: 1 to 15: 2: 1) to obtain the title compound (0.106 g, 82%) as a white powder. The structure, NMR data and MS data of the obtained compound are shown in Table 1.
実施例3
4−[4−(2−アミノエトキシ)−2−メチルベンジル]−5−イソプロピル−1H−ピラゾール−3−イル 5−チオ−β−D−グルコピラノシドの合成
Example 3
Synthesis of 4- [4- (2-aminoethoxy) -2-methylbenzyl] -5-isopropyl-1H-pyrazol-3-yl 5-thio-β-D-glucopyranoside
(1)4−[4−(2−アジドエトキシ)−2−メチルベンジル]−5−イソプロピル−1H−ピラゾール−3−イル 2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシドの合成
実施例2(1)で合成した4−[4−(2−ヒドロキシエトキシ)−2−メチルベンジル]−5−イソプロピル−1H−ピラゾール−3−イル 2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシド(8.38g、13.2mmol)、トリエチルアミン(2.8mL、20mmol)のクロロホルム(82mL)溶液に氷冷下、メタンスルホニルクロリド(1.2mL、13mmol)を加え、室温で30分間攪拌した。反応液に0.5N塩酸水溶液を加え、酢酸エチルで抽出後、有機層を飽和重曹水溶液、飽和食塩水で洗浄し、硫酸マグネシウムで乾燥した。乾燥剤をろ別後、溶媒を減圧下留去した。残渣をN,N−ジメチルホルムアミドに溶解させアジ化ナトリウムを加えて100℃で3時間攪拌した。反応液に水を加え、酢酸エチルで2回抽出した後、有機層を飽和食塩水で3回洗浄し、硫酸マグネシウムで乾燥した。乾燥剤をろ別後、溶媒を減圧下留去し、残渣をシリカゲルカラムクロマトグラフィ−(n−ヘキサン:酢酸エチル=1:1)にて精製し、淡黄色粉末として表題化合物(6.98g、80%)を得た。
1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.14 (d, J=6.99 Hz, 6 H) 1.82 (s, 3 H) 1.98 (s, 3 H) 2.03 (s, 3 H) 2.06 (s, 3 H) 2.28 (s, 3 H) 2.76 - 2.89 (m, 1 H) 3.35 - 3.63 (m, 5 H) 4.05 - 4.18 (m, 3 H) 4.34 (dd, J=11.97, 4.66 Hz, 1 H) 5.15 (t, J=9.79 Hz, 1 H) 5.36 (t, J=9.79 Hz, 1 H) 5.50 (t, J=8.86 Hz, 1 H) 5.85 (d, J=8.86 Hz, 1 H) 6.61 (dd, J=8.55, 2.64 Hz, 1 H) 6.72 (d, J=2.64 Hz, 1 H) 6.81 (d, J=8.55 Hz, 1 H).
(1) 4- [4- (2-Azidoethoxy) -2-methylbenzyl] -5-isopropyl-1H-pyrazol-3-yl 2,3,4,6-tetra-O-acetyl-5-thio- Synthesis of β-D-glucopyranoside 4- [4- (2-hydroxyethoxy) -2-methylbenzyl] -5-isopropyl-1H-pyrazol-3-yl synthesized in Example 2 (1) 2,3,4 , 6-Tetra-O-acetyl-5-thio-β-D-glucopyranoside (8.38 g, 13.2 mmol), triethylamine (2.8 mL, 20 mmol) in chloroform (82 mL) under ice-cooling, methanesulfonyl chloride (1.2 mL, 13 mmol) was added and stirred at room temperature for 30 minutes. A 0.5N aqueous hydrochloric acid solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium bicarbonate solution and saturated brine, and dried over magnesium sulfate. After the desiccant was filtered off, the solvent was distilled off under reduced pressure. The residue was dissolved in N, N-dimethylformamide, sodium azide was added, and the mixture was stirred at 100 ° C. for 3 hours. Water was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The organic layer was washed 3 times with saturated brine and dried over magnesium sulfate. After filtering off the desiccant, the solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (n-hexane: ethyl acetate = 1: 1) to give the title compound (6.98 g, 80) as a pale yellow powder. %).
1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.14 (d, J = 6.99 Hz, 6 H) 1.82 (s, 3 H) 1.98 (s, 3 H) 2.03 (s, 3 H) 2.06 (s, 3 H) 2.28 (s, 3 H) 2.76-2.89 (m, 1 H) 3.35-3.63 (m, 5 H) 4.05-4.18 (m, 3 H) 4.34 (dd, J = 11.97, 4.66 Hz, 1 H) 5.15 (t, J = 9.79 Hz, 1 H) 5.36 (t, J = 9.79 Hz, 1 H) 5.50 (t, J = 8.86 Hz, 1 H) 5.85 (d, J = 8.86 Hz, 1 H) 6.61 ( dd, J = 8.55, 2.64 Hz, 1 H) 6.72 (d, J = 2.64 Hz, 1 H) 6.81 (d, J = 8.55 Hz, 1 H).
(2)4−[4−(2−アミノエトキシ)−2−メチルベンジル]−5−イソプロピル−1H−ピラゾール−3−イル 2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシドの合成
4−[4−(2−アジドエトキシ)−2−メチルベンジル]−5−イソプロピル−1H−ピラゾール−3−イル 2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシド(6.98g、10.6mmol)のメタノール溶液に10%パラジウム−活性炭素(0.49g)を加え、水素雰囲気下、室温にて一晩攪拌した。不溶物をセライト濾過後、ろ液を減圧下留去し、得られた残渣をシリカゲルカラムクロマトグラフィ−(クロロホルム:メタノール=30:1)にて精製し、淡黄色粉末として表題化合物(6.16g、91%)を得た。
1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.13 (d, J=6.99 Hz, 6 H) 1.81 (s, 3 H) 1.98 (s, 3 H) 2.02 (s, 3 H) 2.05 (s, 3 H) 2.27 (s, 3 H) 2.75 - 2.91 (m, 1 H) 3.05 (t, J=5.13 Hz, 2 H) 3.34 - 3.69 (m, 3 H) 3.86 - 4.20 (m, 3 H) 4.34 (dd, J=11.97, 4.66 Hz, 1 H) 5.16 (t, J=9.79 Hz, 1 H) 5.36 (t, J=9.79 Hz, 1 H) 5.50 (t, J=8.86 Hz, 1 H) 5.85 (d, J=8.86 Hz, 1 H) 6.60 (dd, J=8.39, 2.64 Hz, 1 H) 6.71 (d, J=2.64 Hz, 1 H) 6.80 (d, J=8.39 Hz, 1 H).
(2) 4- [4- (2-Aminoethoxy) -2-methylbenzyl] -5-isopropyl-1H-pyrazol-3-yl 2,3,4,6-tetra-O-acetyl-5-thio- Synthesis of β-D-glucopyranoside 4- [4- (2-azidoethoxy) -2-methylbenzyl] -5-isopropyl-1H-pyrazol-3-yl 2,3,4,6-tetra-O-acetyl- To a methanol solution of 5-thio-β-D-glucopyranoside (6.98 g, 10.6 mmol) was added 10% palladium-activated carbon (0.49 g), and the mixture was stirred overnight at room temperature in a hydrogen atmosphere. The insoluble material was filtered through Celite, the filtrate was evaporated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (chloroform: methanol = 30: 1) to give the title compound (6.16 g, 91%).
1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.13 (d, J = 6.99 Hz, 6 H) 1.81 (s, 3 H) 1.98 (s, 3 H) 2.02 (s, 3 H) 2.05 (s, 3 H) 2.27 (s, 3 H) 2.75-2.91 (m, 1 H) 3.05 (t, J = 5.13 Hz, 2 H) 3.34-3.69 (m, 3 H) 3.86-4.20 (m, 3 H) 4.34 ( dd, J = 11.97, 4.66 Hz, 1 H) 5.16 (t, J = 9.79 Hz, 1 H) 5.36 (t, J = 9.79 Hz, 1 H) 5.50 (t, J = 8.86 Hz, 1 H) 5.85 ( d, J = 8.86 Hz, 1 H) 6.60 (dd, J = 8.39, 2.64 Hz, 1 H) 6.71 (d, J = 2.64 Hz, 1 H) 6.80 (d, J = 8.39 Hz, 1 H).
(3)4−[4−(2−アミノエトキシ)−2−メチルベンジル]−5−イソプロピル−1H−ピラゾール−3−イル 5−チオ−β−D−グルコピラノシドの合成
4−[4−(2−ヒドロキシエトキシ)−2−メチルベンジル]−5−イソプロピル−1H−ピラゾール−3−イル 2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシドの代わりに4−[4−(2−アミノエトキシ)−2−メチルベンジル]−5−イソプロピル−1H−ピラゾール−3−イル 2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシドを用いて、実施例2(2)に示す方法と同様の方法で表題化合物を合成した。得られた化合物の構造、NMRデータ及びMSデータを表1に示す。
(3) Synthesis of 4- [4- (2-aminoethoxy) -2-methylbenzyl] -5-isopropyl-1H-pyrazol-3-yl 5-thio-β-D-glucopyranoside 4- [4- (2 -Hydroxyethoxy) -2-methylbenzyl] -5-isopropyl-1H-pyrazol-3-yl 2,3,4,6-tetra-O-acetyl-5-thio-β-D-glucopyranoside instead of 4- [4- (2-Aminoethoxy) -2-methylbenzyl] -5-isopropyl-1H-pyrazol-3-yl 2,3,4,6-tetra-O-acetyl-5-thio-β-D-glucopyranoside Was used to synthesize the title compound in the same manner as in Example 2 (2). The structure, NMR data and MS data of the obtained compound are shown in Table 1.
実施例4
ベンジル [イミノ({2−[4−({5−イソプロピル−3−[(5−チオ−β−D−グルコピラノシル)オキシ]−1H−ピラゾール−4−イル}メチル)−3−メチルフェノキシ]エチル}アミノ)メチル]カルバマートの合成
Example 4
Benzyl [imino ({2- [4-({5-isopropyl-3-[(5-thio-β-D-glucopyranosyl) oxy] -1H-pyrazol-4-yl} methyl) -3-methylphenoxy] ethyl } Amino) methyl] carbamate synthesis
(1)ジベンジル [(E)−({2−[4−({5−イソプロピル−3−[(2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシル)オキシ]−1H−ピラゾール−4−イル}メチル)−3−メチルフェノキシ]エチル}アミノ)メチルイリデン]ビスカルバマートの合成
実施例3(2)で合成した4−[4−(2−アミノエトキシ)−2−メチルベンジル]−5−イソプロピル−1H−ピラゾール−3−イル 2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシド(0.503g、0.791mmol)のテトラヒドロフラン(0.3mL)溶液にN、N’−ビス(ベンジルオキシカルボニル)−1H−ピラゾール−1−カルボキシアミジン(0.359g、0.949mmol)を加え、室温で2時間攪拌した。溶媒を減圧下で留去し、得られた残渣をシリカゲルカラムクロマトグラフィ−(n−ヘキサン:酢酸エチル=1:1)にて精製し、淡黄色粉末として表題化合物(0.547g、73%)を得た。
1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.12 (d, J=1.63 Hz, 3 H) 1.15 (d, J=1.63 Hz, 3 H) 1.81 (s, 3 H) 1.97 (s, 3 H) 2.02 (s, 3 H) 2.05 (s, 3 H) 2.27 (s, 3 H) 2.74 - 2.87 (m, 1 H) 3.30 - 3.39 (m, 1 H) 3.44 - 3.61 (m, 2 H) 3.77 - 3.86 (m, 2 H) 3.99 - 4.18 (m, 3 H) 4.34 (dd, J=11.89, 4.90 Hz, 1 H) 5.07 - 5.23 (m, 5 H) 5.36 (t, J=9.79 Hz, 1 H) 5.49 (t, J=8.86 Hz, 1 H) 5.82 (d, J=8.86 Hz, 1 H) 6.59 (dd, J=8.39, 2.64 Hz, 1 H) 6.71 (d, J=2.64 Hz, 1 H) 6.79 (d, J=8.39 Hz, 1 H) 7.34 (m, 10 H) 8.72 (t, J=5.28 Hz, 1 H) 11.72 (br. s., 1 H).
(1) Dibenzyl [(E)-({2- [4-({5-isopropyl-3-[(2,3,4,6-tetra-O-acetyl-5-thio-β-D-glucopyranosyl) Synthesis of Oxy] -1H-pyrazol-4-yl} methyl) -3-methylphenoxy] ethyl} amino) methylylidene] biscarbamate 4- [4- (2-aminoethoxy) synthesized in Example 3 (2) -2-Methylbenzyl] -5-isopropyl-1H-pyrazol-3-yl 2,3,4,6-tetra-O-acetyl-5-thio-β-D-glucopyranoside (0.503 g, 0.791 mmol) N, N′-bis (benzyloxycarbonyl) -1H-pyrazole-1-carboxyamidine (0.359 g, 0.949 mmol) was added to a tetrahydrofuran (0.3 mL) solution of The mixture was stirred for 2 hours at room temperature. The solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography (n-hexane: ethyl acetate = 1: 1) to give the title compound (0.547 g, 73%) as a pale yellow powder. Obtained.
1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.12 (d, J = 1.63 Hz, 3 H) 1.15 (d, J = 1.63 Hz, 3 H) 1.81 (s, 3 H) 1.97 (s, 3 H) 2.02 (s, 3 H) 2.05 (s, 3 H) 2.27 (s, 3 H) 2.74-2.87 (m, 1 H) 3.30-3.39 (m, 1 H) 3.44-3.61 (m, 2 H) 3.77- 3.86 (m, 2 H) 3.99-4.18 (m, 3 H) 4.34 (dd, J = 11.89, 4.90 Hz, 1 H) 5.07-5.23 (m, 5 H) 5.36 (t, J = 9.79 Hz, 1 H ) 5.49 (t, J = 8.86 Hz, 1 H) 5.82 (d, J = 8.86 Hz, 1 H) 6.59 (dd, J = 8.39, 2.64 Hz, 1 H) 6.71 (d, J = 2.64 Hz, 1 H) ) 6.79 (d, J = 8.39 Hz, 1 H) 7.34 (m, 10 H) 8.72 (t, J = 5.28 Hz, 1 H) 11.72 (br. S., 1 H).
(2)ベンジル [イミノ({2−[4−({5−イソプロピル−3−[(5−チオ−β−D−グルコピラノシル)オキシ]−1H−ピラゾール−4−イル}メチル)−3−メチルフェノキシ]エチル}アミノ)メチル]カルバマートの合成
ジベンジル [(E)−({2−[4−({5−イソプロピル−3−[(2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシル)オキシ]−1H−ピラゾール−4−イル}メチル)−3−メチルフェノキシ]エチル}アミノ)メチルイリデン]ビスカルバマート(0.530g、0.560mmol)のベンジルアルコール(1mL)溶液にナトリウムベンジルオキシドのベンジルアルコール溶液(1M、0.34mL、0.34mmol)を室温で加え6時間攪拌した。反応液に水を加え、酢酸エチルで抽出後、硫酸マグネシウムで乾燥した。乾燥剤をろ別後、溶媒を減圧下留去し、得られた残渣をシリカゲルカラムクロマトグラフィ−(酢酸エチル:エタノール:水=20:2:1)にて精製し、淡茶色粉末として表題化合物(0.163g、45%)を得た。得られた化合物の構造、NMRデータ及びMSデータを表1に示す。
(2) benzyl [imino ({2- [4-({5-isopropyl-3-[(5-thio-β-D-glucopyranosyl) oxy] -1H-pyrazol-4-yl} methyl) -3-methyl Synthesis of phenoxy] ethyl} amino) methyl] carbamate dibenzyl [(E)-({2- [4-({5-isopropyl-3-[(2,3,4,6-tetra-O-acetyl-5- Thio-β-D-glucopyranosyl) oxy] -1H-pyrazol-4-yl} methyl) -3-methylphenoxy] ethyl} amino) methylylidene] biscarbamate (0.530 g, 0.560 mmol) in benzyl alcohol (1 mL ) A solution of sodium benzyl oxide in benzyl alcohol (1M, 0.34 mL, 0.34 mmol) was added to the solution at room temperature and stirred for 6 hours. Water was added to the reaction mixture, extracted with ethyl acetate, and dried over magnesium sulfate. After filtering off the desiccant, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography (ethyl acetate: ethanol: water = 20: 2: 1) to give the title compound (light brown powder) 0.163 g, 45%). The structure, NMR data and MS data of the obtained compound are shown in Table 1.
実施例5
N−{2−[4−({5−イソプロピル−3−[(5−チオ−β−D−グルコピラノシル)オキシ]−1H−ピラゾール−4−イル}メチル)−3−メチルフェノキシ]エチル}グアニジンの合成
Example 5
N- {2- [4-({5-isopropyl-3-[(5-thio-β-D-glucopyranosyl) oxy] -1H-pyrazol-4-yl} methyl) -3-methylphenoxy] ethyl} guanidine Synthesis of
実施例4で合成したベンジル [イミノ({2−[4−({5−イソプロピル−3−[(5−チオ−β−D−グルコピラノシル)オキシ]−1H−ピラゾール−4−イル}メチル)−3−メチルフェノキシ]エチル}アミノ)メチル]カルバマート(0.154g、0.239mmol)のメタノール(3mL)溶液に20%水酸化パラジウム−活性炭素(0.03g)を加え、水素雰囲気下、室温にて2時間攪拌した。不溶物をセライト濾過後、ろ液を減圧下留去し、白色粉末として表題化合物(0.108g、85%)を得た。得られた化合物の構造、NMRデータ及びMSデータを表1に示す。 Benzyl synthesized in Example 4 [Imino ({2- [4-({5-isopropyl-3-[(5-thio-β-D-glucopyranosyl) oxy] -1H-pyrazol-4-yl} methyl)- To a solution of 3-methylphenoxy] ethyl} amino) methyl] carbamate (0.154 g, 0.239 mmol) in methanol (3 mL) was added 20% palladium hydroxide-activated carbon (0.03 g) and brought to room temperature under a hydrogen atmosphere. And stirred for 2 hours. The insoluble material was filtered through Celite, and the filtrate was evaporated under reduced pressure to give the title compound (0.108 g, 85%) as a white powder. The structure, NMR data and MS data of the obtained compound are shown in Table 1.
実施例6
4−{4−[2−(N−カルバモイルメチルアミノ)エトキシ]−2−メチルベンジル}−5−イソプロピル−1H−ピラゾール−3−イル 5−チオ−β−D−グルコピラノシドの合成
Example 6
Synthesis of 4- {4- [2- (N-carbamoylmethylamino) ethoxy] -2-methylbenzyl} -5-isopropyl-1H-pyrazol-3-yl 5-thio-β-D-glucopyranoside
(1)4−{4−[2−(N−カルバモイルメチルアミノ)エトキシ]−2−メチルベンジル}−5−イソプロピル−1H−ピラゾール−3−イル 2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシドの合成
実施例3(2)で合成した4−[4−(2−アミノエトキシ)−2−メチルベンジル]−5−イソプロピル−1H−ピラゾール−3−イル 2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシド(0.507g、0.797mmol)のN、N−ジメチルホルムアミド(1.6mL)溶液に2−クロロアセトアミド(0.112g、1.20mmol)、トリエチルアミン(0.17mL、1.2mmol)を加え、50℃で3時間攪拌した。反応液をシリカゲルクロマトグラフィー(クロロホルム:メタノール=60:1)に付し、淡黄色粉末として表題化合物(0.185g、34%)を得た。
1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.13 (d, J=6.99 Hz, 6 H) 1.82 (s, 3 H) 1.97 (s, 3 H) 2.01 (s, 3 H) 2.03 (s, 3 H) 2.26 (s, 3 H) 2.71 - 2.89 (m, 1 H) 2.99 (t, J=4.66 Hz, 2 H) 3.30 - 3.59 (m, 5 H) 3.97 - 4.17 (m, 3 H) 4.30 (dd, J=11.97, 4.66 Hz, 1 H) 5.15 (t, J=9.64 Hz, 1 H) 5.34 (t, J=9.64 Hz, 1 H) 5.47 (t, J=8.78 Hz, 1 H) 5.84 (d, J=8.78 Hz, 1 H) 6.30 - 6.45 (m, 1 H) 6.58 (dd, J=8.39, 2.41 Hz, 1 H) 6.68 (d, J=2.41 Hz, 1 H) 6.80 (d, J=8.39 Hz, 1 H) 7.18 - 7.30 (m, 1 H).
(1) 4- {4- [2- (N-carbamoylmethylamino) ethoxy] -2-methylbenzyl} -5-isopropyl-1H-pyrazol-3-yl 2,3,4,6-tetra-O— Synthesis of acetyl-5-thio-β-D-glucopyranoside 4- [4- (2-aminoethoxy) -2-methylbenzyl] -5-isopropyl-1H-pyrazole-3-synthesized in Example 3 (2) Yl 2,3,4,6-tetra-O-acetyl-5-thio-β-D-glucopyranoside (0.507 g, 0.797 mmol) in N, N-dimethylformamide (1.6 mL) in 2-chloro Acetamide (0.112 g, 1.20 mmol) and triethylamine (0.17 mL, 1.2 mmol) were added, and the mixture was stirred at 50 ° C. for 3 hours. The reaction solution was subjected to silica gel chromatography (chloroform: methanol = 60: 1) to give the title compound (0.185 g, 34%) as a pale yellow powder.
1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.13 (d, J = 6.99 Hz, 6 H) 1.82 (s, 3 H) 1.97 (s, 3 H) 2.01 (s, 3 H) 2.03 (s, 3 H) 2.26 (s, 3 H) 2.71-2.89 (m, 1 H) 2.99 (t, J = 4.66 Hz, 2 H) 3.30-3.59 (m, 5 H) 3.97-4.17 (m, 3 H) 4.30 ( dd, J = 11.97, 4.66 Hz, 1 H) 5.15 (t, J = 9.64 Hz, 1 H) 5.34 (t, J = 9.64 Hz, 1 H) 5.47 (t, J = 8.78 Hz, 1 H) 5.84 ( d, J = 8.78 Hz, 1 H) 6.30-6.45 (m, 1 H) 6.58 (dd, J = 8.39, 2.41 Hz, 1 H) 6.68 (d, J = 2.41 Hz, 1 H) 6.80 (d, J = 8.39 Hz, 1 H) 7.18-7.30 (m, 1 H).
(2)4−{4−[2−(N−カルバモイルメチルアミノ)エトキシ]−2−メチルベンジル}−5−イソプロピル−1H−ピラゾール−3−イル 5−チオ−β−D−グルコピラノシドの合成
4−[4−(2−ヒドロキシエトキシ)−2−メチルベンジル]−5−イソプロピル−1H−ピラゾール−3−イル 2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシドの代わりに4−{4−[2−(N−カルバモイルメチルアミノ)エトキシ]−2−メチルベンジル}−5−イソプロピル−1H−ピラゾール−3−イル 2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシドを用いて、実施例2(2)に示す方法と同様の方法で表題化合物を合成した。得られた化合物の構造、NMRデータ及びMSデータを表1に示す。
(2) Synthesis of 4- {4- [2- (N-carbamoylmethylamino) ethoxy] -2-methylbenzyl} -5-isopropyl-1H-pyrazol-3-yl 5-thio-β-D-glucopyranoside 4 -[4- (2-hydroxyethoxy) -2-methylbenzyl] -5-isopropyl-1H-pyrazol-3-yl 2,3,4,6-tetra-O-acetyl-5-thio-β-D- 4- {4- [2- (N-carbamoylmethylamino) ethoxy] -2-methylbenzyl} -5-isopropyl-1H-pyrazol-3-yl 2,3,4,6-tetra-O instead of glucopyranoside The title compound was synthesized in the same manner as in Example 2 (2) using -acetyl-5-thio-β-D-glucopyranoside. The structure, NMR data and MS data of the obtained compound are shown in Table 1.
実施例7
N−(2−ヒドロキシ−1,1−ジメチルエチル)−N’−{2−[4−({5−イソプロピル−3−[(5−チオ−β−D−グルコピラノシル)オキシ]−1H−ピラゾール−4−イル}メチル)−3−メチルフェノキシ]エチル}ウレアの合成
Example 7
N- (2-hydroxy-1,1-dimethylethyl) -N ′-{2- [4-({5-isopropyl-3-[(5-thio-β-D-glucopyranosyl) oxy] -1H-pyrazole Synthesis of -4-yl} methyl) -3-methylphenoxy] ethyl} urea
実施例3(2)で合成した4−[4−(2−アミノエトキシ)−2−メチルベンジル]−5−イソプロピル−1H−ピラゾール−3−イル 2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシド(0.145g、0.228mmol)のクロロホルム(1.5mL)溶液にトリエチルミン(0.043mL、0.308mmol)、クロロギ酸 4−ニトロフェニル(0.053g、0.262mmol)を加え、室温で1時間攪拌した。さらにトリエチルアミン(0.064mL、0.456mmol)と2−アミノ−2−メチル−1−プロパノール(0.033mL、0.342mmol)を加え、室温で1時間攪拌した。溶媒を減圧下留去し、得られた残渣にメタノール(2.3mL)とナトリウムメトキシド(25%メタノール溶液、0.20mL、0.912mmol)を加え、室温で4時間攪拌した。反応液にドライアイスを加え、中和した後に、溶媒を減圧留去した。得られた残渣をシリカゲルカラムクロマトグラフィ−(酢酸エチル:エタノール:水=10:2:1)で精製し、白色粉末として表題化合物(0.064g、48%)を得た。得られた化合物の構造、NMRデータ及びMSデータを表1に示す。 4- [4- (2-Aminoethoxy) -2-methylbenzyl] -5-isopropyl-1H-pyrazol-3-yl 2,3,4,6-tetra-O— synthesized in Example 3 (2) A solution of acetyl-5-thio-β-D-glucopyranoside (0.145 g, 0.228 mmol) in chloroform (1.5 mL) was added to triethylamine (0.043 mL, 0.308 mmol), 4-nitrophenyl chloroformate (0. 053 g, 0.262 mmol) was added, and the mixture was stirred at room temperature for 1 hour. Further, triethylamine (0.064 mL, 0.456 mmol) and 2-amino-2-methyl-1-propanol (0.033 mL, 0.342 mmol) were added, and the mixture was stirred at room temperature for 1 hour. The solvent was evaporated under reduced pressure, methanol (2.3 mL) and sodium methoxide (25% methanol solution, 0.20 mL, 0.912 mmol) were added to the resulting residue, and the mixture was stirred at room temperature for 4 hr. After dry ice was added to the reaction solution and neutralized, the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography (ethyl acetate: ethanol: water = 10: 2: 1) to obtain the title compound (0.064 g, 48%) as a white powder. The structure, NMR data and MS data of the obtained compound are shown in Table 1.
実施例8
4−[4−(2−{ビス[2−(ベンジルオキシ)エチル]アミノ}エトキシ)−2−メチルベンジル]−5−イソプロピル−1H−ピラゾール−3−イル 5−チオ−β−D−グルコピラノシドの製造
Example 8
4- [4- (2- {Bis [2- (benzyloxy) ethyl] amino} ethoxy) -2-methylbenzyl] -5-isopropyl-1H-pyrazol-3-yl 5-thio-β-D-glucopyranoside Manufacturing of
(1)4−[4−(2−{ビス[2−(ベンジルオキシ)エチル]アミノ}エトキシ)−2−メチルベンジル]−5−イソプロピル−1H−ピラゾール−3−イル 5−チオ−β−D−グルコピラノシドの合成
2−クロロアセトアミドの代わりにベンジル-2-ブロモエチルエーテルを用いて実施例6(1)と同様に表題化合物(0.213g、33%)を得た。
1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.11 (d, J=2.33 Hz, 3 H) 1.13 (d, J=2.33 Hz, 3 H) 1.80 (s, 3 H) 1.97 (s, 3 H) 2.02 (s, 3 H) 2.04 (s, 3 H) 2.25 (s, 3 H) 2.71 - 3.05 (m, 5 H) 3.51 (d, J=5.44 Hz, 1 H) 3.55 - 3.63 (m, 3 H) 3.99 (t, J=6.06 Hz, 2 H) 4.12 (dd, J=11.89, 3.81 Hz, 1 H) 4.34 (dd, J=11.89, 4.66 Hz, 1 H) 4.51 (s, 3 H) 5.13 (t, J=9.17 Hz, 1 H) 5.30 - 5.41 (m, 1 H) 5.50 (t, J=8.86 Hz, 1 H) 5.83 (d, J=8.86 Hz, 1 H) 6.55 (dd, J=8.39, 2.49 Hz, 1 H) 6.66 (d, J=2.49 Hz, 1 H) 6.77 (d, J=8.39 Hz, 1 H) 7.22 - 7.35 (m, 5 H).
(1) 4- [4- (2- {Bis [2- (benzyloxy) ethyl] amino} ethoxy) -2-methylbenzyl] -5-isopropyl-1H-pyrazol-3-yl 5-thio-β- Synthesis of D-glucopyranoside The title compound (0.213 g, 33%) was obtained in the same manner as in Example 6 (1) using benzyl-2-bromoethyl ether instead of 2-chloroacetamide.
1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.11 (d, J = 2.33 Hz, 3 H) 1.13 (d, J = 2.33 Hz, 3 H) 1.80 (s, 3 H) 1.97 (s, 3 H) 2.02 (s, 3 H) 2.04 (s, 3 H) 2.25 (s, 3 H) 2.71-3.05 (m, 5 H) 3.51 (d, J = 5.44 Hz, 1 H) 3.55-3.63 (m, 3 H ) 3.99 (t, J = 6.06 Hz, 2 H) 4.12 (dd, J = 11.89, 3.81 Hz, 1 H) 4.34 (dd, J = 11.89, 4.66 Hz, 1 H) 4.51 (s, 3 H) 5.13 ( (t, J = 9.17 Hz, 1 H) 5.30-5.41 (m, 1 H) 5.50 (t, J = 8.86 Hz, 1 H) 5.83 (d, J = 8.86 Hz, 1 H) 6.55 (dd, J = 8.39 , 2.49 Hz, 1 H) 6.66 (d, J = 2.49 Hz, 1 H) 6.77 (d, J = 8.39 Hz, 1 H) 7.22-7.35 (m, 5 H).
(2)4−[4−(2−{ビス[2−(ベンジルオキシ)エチル]アミノ}エトキシ)−2−メチルベンジル]−5−イソプロピル−1H−ピラゾール−3−イル 5−チオ−β −D−グルコピラノシドの合成
4−[4−(2−ヒドロキシエトキシ)−2−メチルベンジル]−5−イソプロピル−1H−ピラゾール−3−イル 2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシドの代わりに4−[4−(2−{ビス[2−(ベンジルオキシ)エチル]アミノ}エトキシ)−2−メチルベンジル]−5−イソプロピル−1H−ピラゾール−3−イル 5−チオ−β−D−グルコピラノシドを用いて実施例2(2)と同様の方法で表題化合物を得た(0.052g、94%)。得られた化合物の構造、NMRデータ及びMSデータを表1に示す。
(2) 4- [4- (2- {Bis [2- (benzyloxy) ethyl] amino} ethoxy) -2-methylbenzyl] -5-isopropyl-1H-pyrazol-3-yl 5-thio-β- Synthesis of D-glucopyranoside 4- [4- (2-hydroxyethoxy) -2-methylbenzyl] -5-isopropyl-1H-pyrazol-3-yl 2,3,4,6-tetra-O-acetyl-5 4- [4- (2- {bis [2- (benzyloxy) ethyl] amino} ethoxy) -2-methylbenzyl] -5-isopropyl-1H-pyrazole-3- instead of thio-β-D-glucopyranoside The title compound was obtained in the same manner as in Example 2 (2) using yl 5-thio-β-D-glucopyranoside (0.052 g, 94%). The structure, NMR data and MS data of the obtained compound are shown in Table 1.
実施例9
N−[2−ヒドロキシ−1−(ヒドロキシメチル)−1−メチルエチル]−N’−{2−[4−({5−イソプロピル−3−[(5−チオ−β−D−グルコピラノシル)オキシ]−1H−ピラゾール−4−イル}メチル)−3−メチルフェノキシ]エチル}尿素の製造
Example 9
N- [2-hydroxy-1- (hydroxymethyl) -1-methylethyl] -N ′-{2- [4-({5-isopropyl-3-[(5-thio-β-D-glucopyranosyl) oxy] ] -1H-pyrazol-4-yl} methyl) -3-methylphenoxy] ethyl} urea
2−アミノ−2−メチル−1−プロパノールの代わりに2−アミノ−2−メチル−1,3−プロパンジオールを用い、実施例7と同様の方法で表題化合物を得た(0.123g、86%)。得られた化合物の構造、NMRデータ及びMSデータを表1に示す。 The title compound was obtained in the same manner as in Example 7 except that 2-amino-2-methyl-1,3-propanediol was used instead of 2-amino-2-methyl-1-propanol (0.123 g, 86 %). The structure, NMR data and MS data of the obtained compound are shown in Table 1.
実施例10
4−(4−{2−[(2−ヒドロキシ−1,1−ジメチルエチル)アミノ]エトキシ}−2−メチルベンジル)−5−イソプロピル−1H−ピラゾール−3−イル 5−チオ−β −D−グルコピラノシドの製造
Example 10
4- (4- {2-[(2-hydroxy-1,1-dimethylethyl) amino] ethoxy} -2-methylbenzyl) -5-isopropyl-1H-pyrazol-3-yl 5-thio-β-D -Production of glucopyranoside
実施例2(1)で合成した4−[4−(2−ヒドロキシエトキシ)−2−メチルベンジル]−5−イソプロピル−1H−ピラゾール−3−イル 2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシド(0.40g、0.63mmol)、トリエチルアミン(0.13mL、0.94mmol)のクロロホルム(2.5mL)溶液に氷冷下、メタンスルホニルクロリド(0.075mL、0.91mmol)を加え、室温で30分間攪拌した。反応液に0.5N塩酸水溶液を加え、酢酸エチルで抽出後、有機層を飽和重曹水溶液、飽和食塩水で洗浄し、硫酸マグネシウムで乾燥した。乾燥剤をろ別後、溶媒を減圧下留去した。残渣をアセトニトリル−エタノール混合溶媒に溶解させ、2−アミノ−2−メチル−1−プロパノール(0.060mL、0.63mmol)、よう化ナトリウム(9mg、0.06mmol)を加えて60℃で4日間攪拌した。反応液を減圧濃縮後、残渣をメタノール(1mL)に溶解させ、ナトリウムメトキシド(25%メタノール溶液)を加えて室温で2時間攪拌した。反応液にドライアイスを加え、中和した後に、溶媒を減圧留去した。残渣をシリカゲルカラムクロマトグラフィ−(酢酸エチル:エタノール:水=3:2:1)で精製した。得られた残渣を再度シリカゲルカラムクロマトグラフィ−(酢酸エチル:エタノール:水=5:2:1)にて精製し、0.070gの残渣を得た。この残渣をメタノール(3mL)に溶解させ、ナトリウムメトキシド(25%メタノール溶液)を加えた後に、この溶液をシリカゲルカラムクロマトグラフィ−(酢酸エチル:エタノール:水=5:2:1)にて精製し、表題化合物(0.023g、14%)を得た。得られた化合物の構造、NMRデータを表1に示す。 4- [4- (2-Hydroxyethoxy) -2-methylbenzyl] -5-isopropyl-1H-pyrazol-3-yl 2,3,4,6-tetra-O— synthesized in Example 2 (1) A solution of acetyl-5-thio-β-D-glucopyranoside (0.40 g, 0.63 mmol) and triethylamine (0.13 mL, 0.94 mmol) in chloroform (2.5 mL) under ice cooling with methanesulfonyl chloride (0. 075 mL, 0.91 mmol) was added and stirred at room temperature for 30 minutes. A 0.5N aqueous hydrochloric acid solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium bicarbonate solution and saturated brine, and dried over magnesium sulfate. After the desiccant was filtered off, the solvent was distilled off under reduced pressure. The residue was dissolved in an acetonitrile-ethanol mixed solvent, and 2-amino-2-methyl-1-propanol (0.060 mL, 0.63 mmol) and sodium iodide (9 mg, 0.06 mmol) were added thereto at 60 ° C. for 4 days. Stir. The reaction mixture was concentrated under reduced pressure, the residue was dissolved in methanol (1 mL), sodium methoxide (25% methanol solution) was added, and the mixture was stirred at room temperature for 2 hr. After dry ice was added to the reaction solution and neutralized, the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate: ethanol: water = 3: 2: 1). The obtained residue was purified again by silica gel column chromatography (ethyl acetate: ethanol: water = 5: 2: 1) to obtain 0.070 g of residue. This residue was dissolved in methanol (3 mL), sodium methoxide (25% methanol solution) was added, and the solution was purified by silica gel column chromatography (ethyl acetate: ethanol: water = 5: 2: 1). To give the title compound (0.023 g, 14%). Table 1 shows the structure and NMR data of the obtained compound.
実施例11
N−[4−({5−イソプロピル−3−[(5−チオ−β−D−グルコピラノシル)オキシ]−1H−ピラゾール−4−イル}メチル)フェニル]尿素の製造
Example 11
Preparation of N- [4-({5-isopropyl-3-[(5-thio-β-D-glucopyranosyl) oxy] -1H-pyrazol-4-yl} methyl) phenyl] urea
(1)4−(4−アミノベンジル)−5−イソプロピル−1H−ピラゾール−3−イル 2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシドの合成
2,3,4,6−テトラ−O−アセチル−5−チオ−D−グルコピラノース(25.2g、69.0mmol)、4−[(4−ニトロフェニル)メチル]−1,2−ジヒドロ−5−イソプロピル−3H−ピラゾール−3−オン(9.02g、34.5mmol;国際特許公開WO2004/019958号を参考にニトロベンジルブロミドより合成)及びトリフェニルホスフィン(18.1g、69.0mmol)のテトラヒドロフラン(43mL)溶液に氷冷下、ジイソプロピルアゾジカルボキシレートの40%トルエン溶液(36.3mL、69.0mmol)をゆっくりと滴下した。氷冷下で30分間攪拌し、室温に昇温後、さらに3時間攪拌した。溶媒を減圧下留去し、得られた残渣をシリカゲルカラムクロマトグラフィ−(n−ヘキサン:酢酸エチル=1:1)で精製した。さらに、得られた残渣をシリカゲルカラムクロマトグラフィ−(クロロホルム:メタノール=50:1)にて精製し、11.9gの残渣を得た。この残渣のメタノール(195mL)溶液に10%パラジウム−活性炭素(3.9g)を加え、水素雰囲気下、室温にて一晩攪拌した。反応液をセライト濾過後、溶媒を減圧下留去し、得られた残渣をシリカゲルカラムクロマトグラフィ−(ヘキサン:酢酸エチル=1:3)で精製した。得られた残渣を再度シリカゲルクロマトグラフィー(クロロホルム:メタノール=20:1)にて精製し、淡黄色液体として表題化合物 (2.68g、13%)を得た。
1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.15 (d, J=1.24 Hz, 3 H) 1.18 (d, J=1.24 Hz, 3 H) 1.89 (s, 3 H) 1.99 (s, 3 H) 2.03 (s, 3 H) 2.06 (s, 3 H) 2.84 - 2.98 (m, 1 H) 3.29 - 3.38 (m, 1 H) 3.44 - 3.60 (m, 2 H) 4.07 - 4.17 (m, 1 H) 4.34 (dd, J=11.97, 4.66 Hz, 1 H) 5.09 - 5.19 (m, 1 H) 5.38 (dd, J=10.10, 9.33 Hz, 1 H) 5.54 (t, J=8.70 Hz, 1 H) 5.82 (d, J=8.70 Hz, 1 H) 6.58 (d, J=8.55 Hz, 2 H) 6.90 (d, J=8.55 Hz, 2 H).
(1) Synthesis of 4- (4-aminobenzyl) -5-isopropyl-1H-pyrazol-3-yl 2,3,4,6-tetra-O-acetyl-5-thio-β-D-glucopyranoside 3,4,6-tetra-O-acetyl-5-thio-D-glucopyranose (25.2 g, 69.0 mmol), 4-[(4-nitrophenyl) methyl] -1,2-dihydro-5 Isopropyl-3H-pyrazol-3-one (9.02 g, 34.5 mmol; synthesized from nitrobenzyl bromide with reference to WO 2004/019958) and triphenylphosphine (18.1 g, 69.0 mmol) in tetrahydrofuran ( 43 mL) was slowly added dropwise to a 40% toluene solution of diisopropyl azodicarboxylate (36.3 mL, 69.0 mmol) under ice cooling. The mixture was stirred for 30 minutes under ice-cooling, heated to room temperature, and further stirred for 3 hours. The solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography (n-hexane: ethyl acetate = 1: 1). Furthermore, the obtained residue was purified by silica gel column chromatography (chloroform: methanol = 50: 1) to obtain 11.9 g of residue. 10% Palladium-activated carbon (3.9 g) was added to a methanol (195 mL) solution of this residue, and the mixture was stirred overnight at room temperature under a hydrogen atmosphere. The reaction mixture was filtered through celite, the solvent was evaporated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 1: 3). The obtained residue was purified again by silica gel chromatography (chloroform: methanol = 20: 1) to obtain the title compound (2.68 g, 13%) as a pale yellow liquid.
1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.15 (d, J = 1.24 Hz, 3 H) 1.18 (d, J = 1.24 Hz, 3 H) 1.89 (s, 3 H) 1.99 (s, 3 H) 2.03 (s, 3 H) 2.06 (s, 3 H) 2.84-2.98 (m, 1 H) 3.29-3.38 (m, 1 H) 3.44-3.60 (m, 2 H) 4.07-4.17 (m, 1 H) 4.34 (dd, J = 11.97, 4.66 Hz, 1 H) 5.09-5.19 (m, 1 H) 5.38 (dd, J = 10.10, 9.33 Hz, 1 H) 5.54 (t, J = 8.70 Hz, 1 H) 5.82 (d, J = 8.70 Hz, 1 H) 6.58 (d, J = 8.55 Hz, 2 H) 6.90 (d, J = 8.55 Hz, 2 H).
(2)N−[4−({5−イソプロピル−3−[(5−チオ−β−D−グルコピラノシル)オキシ]−1H−ピラゾール−4−イル}メチル)フェニル]尿素の合成
4−[4−(2−アミノエトキシ)−2−メチルベンジル]−5−イソプロピル−1H−ピラゾール−3−イル 2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシドの代わりに4−(4−アミノベンジル)−5−イソプロピル−1H−ピラゾール−3−イル 2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシドを、2−アミノ−2−メチル−1−プロパノ−ルの代わりにアンモニア(7Mメタノール溶液)を用いて実施例7と同様の方法で表題化合物(0.125g、73%)を得た。得られた化合物の構造、NMRデータ及びMSデータを表1に示す。
(2) Synthesis of N- [4-({5-isopropyl-3-[(5-thio-β-D-glucopyranosyl) oxy] -1H-pyrazol-4-yl} methyl) phenyl] urea 4- [4 -(2-aminoethoxy) -2-methylbenzyl] -5-isopropyl-1H-pyrazol-3-yl instead of 2,3,4,6-tetra-O-acetyl-5-thio-β-D-glucopyranoside 4- (4-aminobenzyl) -5-isopropyl-1H-pyrazol-3-yl 2,3,4,6-tetra-O-acetyl-5-thio-β-D-glucopyranoside to 2-amino- The title compound (0.125 g, 73%) was obtained in the same manner as in Example 7 using ammonia (7 M methanol solution) instead of 2-methyl-1-propanol. The structure, NMR data and MS data of the obtained compound are shown in Table 1.
実施例12
N−[4−({5−イソプロピル−3−[(5−チオ−β−D−グルコピラノシル)オキシ]−1H−ピラゾール−4−イル}メチル)フェニル]−N’−(ピリジン−3−イルメチル)尿素の製造
Example 12
N- [4-({5-isopropyl-3-[(5-thio-β-D-glucopyranosyl) oxy] -1H-pyrazol-4-yl} methyl) phenyl] -N ′-(pyridin-3-ylmethyl) ) Production of urea
アンモニア(7Mメタノール溶液)の代わりに3−(アミノメチル)ピリジンを用いて実施例11と同様の方法で表題化合物(0.087g、46%)を得た。得られた化合物の構造、NMRデータ及びMSデータを表1に示す。 The title compound (0.087 g, 46%) was obtained in the same manner as in Example 11 using 3- (aminomethyl) pyridine in place of ammonia (7M methanol solution). The structure, NMR data and MS data of the obtained compound are shown in Table 1.
実施例13
(3E)−N−(2−ヒドロキシ−1,1−ジメチルエチル)−4−[4−({5−イソプロピル−3−[(5−チオ−β−D−グルコピラノシル)オキシ]−1H−ピラゾール−4−イル}メチル)フェニル]ブタ−3−エンアミドの製造
Example 13
(3E) -N- (2-hydroxy-1,1-dimethylethyl) -4- [4-({5-isopropyl-3-[(5-thio-β-D-glucopyranosyl) oxy] -1H-pyrazole Preparation of -4-yl} methyl) phenyl] but-3-enamide
(1)4−(4−ブロモベンジル)−5−イソプロピル−1H−ピラゾール−3−イル 5−チオ−β−D−グルコピラノシドの合成
4−[(4−ニトロフェニル)メチル]−1,2−ジヒドロ−5−イソプロピル−3H−ピラゾール−3−オンの代わりに4−[(4−ブロモフェニル)メチル]−1,2−ジヒドロ−5−イソプロピル−3H−ピラゾール−3−オン(国際特許公開WO2004/014932号を参考に4−ブロモベンジルブロミドより合成)を用い、実施例11(1)と同様の方法で23.4gの残渣を得た。
(1) Synthesis of 4- (4-bromobenzyl) -5-isopropyl-1H-pyrazol-3-yl 5-thio-β-D-glucopyranoside 4-[(4-nitrophenyl) methyl] -1,2- 4-[(4-Bromophenyl) methyl] -1,2-dihydro-5-isopropyl-3H-pyrazol-3-one instead of dihydro-5-isopropyl-3H-pyrazol-3-one (International Patent Publication WO2004 2014 g of residue was obtained in the same manner as in Example 11 (1) using / 014932 as a reference and synthesizing from 4-bromobenzyl bromide.
この残渣をメタノール(170mL)に溶解させ、ナトリウムメトキシド(4.6Mメタノール溶液、15mL、68mmol)を加え、3時間攪拌した。反応液を濃縮後、残渣をシリカゲルクロマトグラフィー(クロロホルム:メタノール=17:3)にて精製し、表題化合物(6.74g、27%)を得た。
1H NMR (600 MHz, METHANOL-d4) δ ppm 1.14 (dd, J=7.11, 3.90 Hz, 6 H) 2.82 - 2.93 (m, 2 H) 3.26 (t, J=8.94 Hz, 1 H) 3.52 - 3.68 (m, 2 H) 3.68 - 3.81 (m, 3 H) 3.90 (dd, J=11.46, 3.67 Hz, 1 H) 5.45 (d, J=8.71 Hz, 1 H) 7.11 (d, J=8.25 Hz, 2 H) 7.36 (d, J=8.25 Hz, 2 H).
This residue was dissolved in methanol (170 mL), sodium methoxide (4.6 M methanol solution, 15 mL, 68 mmol) was added, and the mixture was stirred for 3 hr. The reaction mixture was concentrated, and the residue was purified by silica gel chromatography (chloroform: methanol = 17: 3) to give the title compound (6.74 g, 27%).
1H NMR (600 MHz, METHANOL-d4) δ ppm 1.14 (dd, J = 7.11, 3.90 Hz, 6 H) 2.82-2.93 (m, 2 H) 3.26 (t, J = 8.94 Hz, 1 H) 3.52-3.68 (m, 2 H) 3.68-3.81 (m, 3 H) 3.90 (dd, J = 11.46, 3.67 Hz, 1 H) 5.45 (d, J = 8.71 Hz, 1 H) 7.11 (d, J = 8.25 Hz, 2 H) 7.36 (d, J = 8.25 Hz, 2 H).
(2)4−(4−ブロモベンジル)−5−イソプロピル−1H−ピラゾール−3−イル 2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシドの合成
4−(4−ブロモベンジル)−5−イソプロピル−1H−ピラゾール−3−イル 5−チオ−β−D−グルコピラノシド(6.25g、13.2mmol)のピリジン(50mL)溶液に無水酢酸(25mL)を加え、2時間攪拌した。反応液に水を加え、酢酸エチルで2回抽出後、有機層を1N塩酸、飽和重曹水溶液、飽和食塩水で洗浄し、硫酸マグネシウムで乾燥した。乾燥剤をろ別後、溶媒を減圧下留去した。残渣をシリカゲルクロマトグラフィー(ヘキサン:酢酸エチル=3:2)にて精製し、表題化合物(6.08g、72%)を得た。
1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.15 - 1.22 (m, 6 H) 1.87 (s, 3 H) 1.99 (s, 3 H) 2.03 (s, 3 H) 2.06 (s, 3 H) 2.84 - 2.99 (m, 1 H) 3.32 - 3.44 (m, 1 H) 3.50 - 3.66 (m, 2 H) 4.05 - 4.20 (m, 1 H) 4.34 (dd, J=11.97, 4.82 Hz, 1 H) 5.07 - 5.22 (m, 9.09 Hz, 1 H) 5.32 - 5.45 (m, 1 H) 5.52 (t, J=8.70 Hz, 1 H) 5.85 (d, J=8.70 Hz, 1 H) 7.00 (d, J=8.39 Hz, 2 H) 7.35 (d, J=8.39 Hz, 2 H).
(2) Synthesis of 4- (4-bromobenzyl) -5-isopropyl-1H-pyrazol-3-yl 2,3,4,6-tetra-O-acetyl-5-thio-β-D-glucopyranoside 4- Acetic anhydride (25 mL) was added to a solution of (4-bromobenzyl) -5-isopropyl-1H-pyrazol-3-yl 5-thio-β-D-glucopyranoside (6.25 g, 13.2 mmol) in pyridine (50 mL). Stir for 2 hours. Water was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The organic layer was washed with 1N hydrochloric acid, saturated aqueous sodium hydrogen carbonate solution and saturated brine, and dried over magnesium sulfate. After the desiccant was filtered off, the solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography (hexane: ethyl acetate = 3: 2) to give the title compound (6.08 g, 72%).
1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.15-1.22 (m, 6 H) 1.87 (s, 3 H) 1.99 (s, 3 H) 2.03 (s, 3 H) 2.06 (s, 3 H) 2.84 -2.99 (m, 1 H) 3.32-3.44 (m, 1 H) 3.50-3.66 (m, 2 H) 4.05-4.20 (m, 1 H) 4.34 (dd, J = 11.97, 4.82 Hz, 1 H) 5.07 -5.22 (m, 9.09 Hz, 1 H) 5.32-5.45 (m, 1 H) 5.52 (t, J = 8.70 Hz, 1 H) 5.85 (d, J = 8.70 Hz, 1 H) 7.00 (d, J = 8.39 Hz, 2 H) 7.35 (d, J = 8.39 Hz, 2 H).
(3)(3E)−4−[4−({5−イソプロピル−3−[(2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシル)オキシ]−1H−ピラゾール−4−イル}メチル)フェニル]ブタ−3−エン酸の合成
4−(4−ブロモベンジル)−5−イソプロピル−1H−ピラゾール−3−イル 2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシド(0.66g、1.03mmol)のアセトニトリル(10mL)溶液にビニル酢酸(0.21mL、2.47mmol)、酢酸パラジウム(II)(22mg、0.10mmol)、トリ−O−トリルホスフィン(60mg、0.20mmol)、トリエチルアミン(0.72mL、5.15mmol)を加え、biotage社製マイクロウェーブを用いて120℃、20分間反応を行った。反応液を減圧下留去し、得られた残渣をシリカゲルカラムクロマトグラフィ−(クロロホルム:メタノール=20:1)にて精製した。得られた残渣を再度シリカゲルクロマトグラフィー(ヘキサン:酢酸エチル=1:4)にて精製し、淡黄色粉末として表題化合物(301mg、56%)を得た。
1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.13 - 1.20 (m, J=6.99, 2.95 Hz, 6 H) 1.85 (s, 3 H) 1.99 (s, 3 H) 2.03 (s, 3 H) 2.05 (s, 3 H) 2.82 - 2.96 (m, 1 H) 3.21 - 3.37 (m, 3 H) 3.54 - 3.68 (m, J=3.89 Hz, 2 H) 4.09 - 4.18 (m, J=12.59, 3.73 Hz, 1 H) 4.33 (dd, J=11.73, 4.90 Hz, 1 H) 5.09 - 5.19 (m, 1 H) 5.31 - 5.42 (m, 1 H) 5.53 (t, J=8.55 Hz, 1 H) 5.73 (d, J=8.55 Hz, 1 H) 6.16 - 6.30 (m, 1 H) 6.41 - 6.55 (m, 1 H) 7.06 (d, J=7.77 Hz, 2 H) 7.22 - 7.28 (m, 2 H).
(3) (3E) -4- [4-({5-isopropyl-3-[(2,3,4,6-tetra-O-acetyl-5-thio-β-D-glucopyranosyl) oxy] -1H Synthesis of -Pyrazol-4-yl} methyl) phenyl] but-3-enoic acid 4- (4-Bromobenzyl) -5-isopropyl-1H-pyrazol-3-yl 2,3,4,6-tetra-O -Acetyl-5-thio-β-D-glucopyranoside (0.66 g, 1.03 mmol) in acetonitrile (10 mL) in a solution of vinyl acetic acid (0.21 mL, 2.47 mmol) and palladium (II) acetate (22 mg, 0.2 mg). 10 mmol), tri-O-tolylphosphine (60 mg, 0.20 mmol), triethylamine (0.72 mL, 5.15 mmol) were added, and a biotage microwave was used. 20 ° C., was carried out for 20 minutes the reaction. The reaction solution was evaporated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (chloroform: methanol = 20: 1). The obtained residue was purified again by silica gel chromatography (hexane: ethyl acetate = 1: 4) to obtain the title compound (301 mg, 56%) as a pale yellow powder.
1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.13-1.20 (m, J = 6.99, 2.95 Hz, 6 H) 1.85 (s, 3 H) 1.99 (s, 3 H) 2.03 (s, 3 H) 2.05 (s, 3 H) 2.82-2.96 (m, 1 H) 3.21-3.37 (m, 3 H) 3.54-3.68 (m, J = 3.89 Hz, 2 H) 4.09-4.18 (m, J = 12.59, 3.73 Hz , 1 H) 4.33 (dd, J = 11.73, 4.90 Hz, 1 H) 5.09-5.19 (m, 1 H) 5.31-5.42 (m, 1 H) 5.53 (t, J = 8.55 Hz, 1 H) 5.73 ( (d, J = 8.55 Hz, 1 H) 6.16-6.30 (m, 1 H) 6.41-6.55 (m, 1 H) 7.06 (d, J = 7.77 Hz, 2 H) 7.22-7.28 (m, 2 H).
(4)(3E)−N−(2−ヒドロキシ−1,1−ジメチルエチル)−4−[4−({5−イソプロピル−3−[(2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシル)オキシ]−1H−ピラゾール−4−イル}メチル)フェニル]ブタ−3−エンアミドの合成
(3E)−4−[4−({5−イソプロピル−3−[(2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシル)オキシ]−1H−ピラゾール−4−イル}メチル)フェニル]ブタ−3−エン酸(0.144g、0.223mmol)のN,N−ジメチルホルムアミド(1.5mL)溶液に、2−アミノ−2−メチル−1−プロパノ−ル(31.9μL、0.334mmol)、1−ヒドロキシベンゾトリアゾール1水和物(90mg、0.668mmol)、N−エチル−N′−3−ジメチルアミノプロピルカルボジイミド塩酸塩(128mg、0.668mmol)を加え、室温にて2時間攪拌した。反応液をシリカゲルカラムクロマトグラフィ−(クロロホルム:メタノール=20:1)にて精製し、淡黄色粉末として表題化合物(138mg、88%)を得た。
1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.18 (d, J=7.15 Hz, 6 H) 1.28 (s, 6 H) 1.87 (s, 3 H) 1.99 (s, 3 H) 2.03 (s, 3 H) 2.05 (s, 3 H) 3.06 - 3.16 (m, 2 H) 3.32 - 3.44 (m, 1 H) 3.53 - 3.70 (m, 4 H) 4.05 - 4.18 (m, 2 H) 4.33 (dd, J=11.97, 4.82 Hz, 1 H) 5.11 - 5.22 (m, 1 H) 5.32 - 5.42 (m, 1 H) 5.53 (t, J=8.70 Hz, 1 H) 5.86 (d, J=8.70 Hz, 1 H) 6.11 - 6.26 (m, 1 H) 6.48 (d, J=15.85 Hz, 1 H) 7.08 (d, J=8.24 Hz, 2 H) 7.25 (d, J=8.24 Hz, 2 H).
(4) (3E) -N- (2-hydroxy-1,1-dimethylethyl) -4- [4-({5-isopropyl-3-[(2,3,4,6-tetra-O-acetyl) Synthesis of (5-thio-β-D-glucopyranosyl) oxy] -1H-pyrazol-4-yl} methyl) phenyl] but-3-enamide (3E) -4- [4-({5-isopropyl-3- [(2,3,4,6-Tetra-O-acetyl-5-thio-β-D-glucopyranosyl) oxy] -1H-pyrazol-4-yl} methyl) phenyl] but-3-enoic acid (0. 144 g, 0.223 mmol) in a solution of N, N-dimethylformamide (1.5 mL), 2-amino-2-methyl-1-propanol (31.9 μL, 0.334 mmol), 1-hydroxybenzotriazole 1 Hydrate (90 mg, 0. 68 mmol), N-ethyl--N'-3- dimethylaminopropyl carbodiimide hydrochloride (128 mg, 0.668 mmol) and the mixture was stirred for 2 hours at room temperature. The reaction solution was purified by silica gel column chromatography (chloroform: methanol = 20: 1) to obtain the title compound (138 mg, 88%) as a pale yellow powder.
1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.18 (d, J = 7.15 Hz, 6 H) 1.28 (s, 6 H) 1.87 (s, 3 H) 1.99 (s, 3 H) 2.03 (s, 3 H) 2.05 (s, 3 H) 3.06-3.16 (m, 2 H) 3.32-3.44 (m, 1 H) 3.53-3.70 (m, 4 H) 4.05-4.18 (m, 2 H) 4.33 (dd, J = 11.97, 4.82 Hz, 1 H) 5.11-5.22 (m, 1 H) 5.32-5.42 (m, 1 H) 5.53 (t, J = 8.70 Hz, 1 H) 5.86 (d, J = 8.70 Hz, 1 H ) 6.11-6.26 (m, 1 H) 6.48 (d, J = 15.85 Hz, 1 H) 7.08 (d, J = 8.24 Hz, 2 H) 7.25 (d, J = 8.24 Hz, 2 H).
(5)(3E)−N−(2−ヒドロキシ−1,1−ジメチルエチル)−4−[4−({5−イソプロピル−3−[(5−チオ−β−D−グルコピラノシル)オキシ]−1H−ピラゾール−4−イル}メチル)フェニル]ブタ−3−エンアミドの合成
(3E)−N−(2−ヒドロキシ−1,1−ジメチルエチル)−4−[4−({5−イソプロピル−3−[(2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシル)オキシ]−1H−ピラゾール−4−イル}メチル)フェニル]ブタ−3−エンアミド(0.124g、0.176mmol)のメタノール(2mL)溶液に、ナトリウムメトキシド(25%メタノール溶液;0.38mL、0.18mmol)を加え、室温で2時間攪拌した。反応液を減圧濃縮後、残渣をシリカゲルカラムクロマトグラフィ−(酢酸エチル:エタノール:水=20:2:1)で精製し、表題化合物(63mg、65%)を合成した。得られた化合物の構造、NMRデータ及びMSデータを表1に示す。
(5) (3E) -N- (2-hydroxy-1,1-dimethylethyl) -4- [4-({5-isopropyl-3-[(5-thio-β-D-glucopyranosyl) oxy]- Synthesis of 1H-pyrazol-4-yl} methyl) phenyl] but-3-enamide (3E) -N- (2-hydroxy-1,1-dimethylethyl) -4- [4-({5-isopropyl-3 -[(2,3,4,6-Tetra-O-acetyl-5-thio-β-D-glucopyranosyl) oxy] -1H-pyrazol-4-yl} methyl) phenyl] but-3-enamide (0. Sodium methoxide (25% methanol solution; 0.38 mL, 0.18 mmol) was added to a methanol (2 mL) solution of 124 g, 0.176 mmol), and the mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (ethyl acetate: ethanol: water = 20: 2: 1) to synthesize the title compound (63 mg, 65%). The structure, NMR data and MS data of the obtained compound are shown in Table 1.
実施例14
(3E)−N−(2−アミノ−1,1−ジメチル−2−オキソエチル)−4−[4−({5−イソプロピル−3−[(5−チオ−β−D−グルコピラノシル)オキシ]−1H−ピラゾール−4−イル}メチル)フェニル]ブタ−3−エンアミドの製造
Example 14
(3E) -N- (2-amino-1,1-dimethyl-2-oxoethyl) -4- [4-({5-isopropyl-3-[(5-thio-β-D-glucopyranosyl) oxy]- 1H-pyrazol-4-yl} methyl) phenyl] but-3-enamide
(1)(3E)−N−(2−アミノ−1,1−ジメチル−2−オキソエチル)−4−[4−({5−イソプロピル−3−[(2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシル)オキシ]−1H−ピラゾール−4−イル}メチル)フェニル]ブタ−3−エンアミドの合成
2−アミノ−2−メチル−1−プロパノ−ルの代わりに2−メチルアラニンアミドを用いて、実施例13(4)と同様の方法で表題化合物(0.120g、70%)を得た。
1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.15 (d, J=6.68 Hz, 6 H) 1.58 (d, J=2.80 Hz, 6 H) 1.85 (s, 3 H) 2.00 (s, 3 H) 2.03 (s, 1 H) 2.05 (s, 3 H) 2.79 - 3.03 (m, 2 H) 3.12 (d, J=7.15 Hz, 2 H) 3.36 - 3.71 (m, 3 H) 4.05 - 4.19 (m, 2 H) 4.33 (dd, J=11.97, 4.66 Hz, 1 H) 5.13 - 5.27 (m, 1 H) 5.32 - 5.44 (m, 1 H) 5.49 - 5.60 (m, 1 H) 5.86 (d, J=8.70 Hz, 1 H) 6.13 - 6.29 (m, 1 H) 6.46 (d, J=15.85 Hz, 1 H) 7.06 (d, J=7.93 Hz, 2 H) 7.23 (d, J=7.93 Hz, 2 H).
(1) (3E) -N- (2-amino-1,1-dimethyl-2-oxoethyl) -4- [4-({5-isopropyl-3-[(2,3,4,6-tetra- Synthesis of O-acetyl-5-thio-β-D-glucopyranosyl) oxy] -1H-pyrazol-4-yl} methyl) phenyl] but-3-enamide of 2-amino-2-methyl-1-propanol Instead, the title compound (0.120 g, 70%) was obtained in the same manner as in Example 13 (4) using 2-methylalaninamide.
1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.15 (d, J = 6.68 Hz, 6 H) 1.58 (d, J = 2.80 Hz, 6 H) 1.85 (s, 3 H) 2.00 (s, 3 H) 2.03 (s, 1 H) 2.05 (s, 3 H) 2.79-3.03 (m, 2 H) 3.12 (d, J = 7.15 Hz, 2 H) 3.36-3.71 (m, 3 H) 4.05-4.19 (m, 2 H) 4.33 (dd, J = 11.97, 4.66 Hz, 1 H) 5.13-5.27 (m, 1 H) 5.32-5.44 (m, 1 H) 5.49-5.60 (m, 1 H) 5.86 (d, J = 8.70 Hz, 1 H) 6.13-6.29 (m, 1 H) 6.46 (d, J = 15.85 Hz, 1 H) 7.06 (d, J = 7.93 Hz, 2 H) 7.23 (d, J = 7.93 Hz, 2 H ).
(2)(3E)−N−(2−アミノ−1,1−ジメチル−2−オキソエチル)−4−[4−({5−イソプロピル−3−[(5−チオ−β−D−グルコピラノシル)オキシ]−1H−ピラゾール−4−イル}メチル)フェニル]ブタ−3−エンアミドの合成
(3E)−N−(2−ヒドロキシ−1,1−ジメチルエチル)−4−[4−({5−イソプロピル−3−[(2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシル)オキシ]−1H−ピラゾール−4−イル}メチル)フェニル]ブタ−3−エンアミドの代わりに(3E)−N−(2−アミノ−1,1−ジメチル−2−オキソエチル)−4−[4−({5−イソプロピル−3−[(2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシル)オキシ]−1H−ピラゾール−4−イル}メチル)フェニル]ブタ−3−エンアミドを用いて、実施例13(5)と同様の方法で表題化合物(0.067g、73%)を得た。得られた化合物の構造、NMRデータ及びMSデータを表1に示す。
(2) (3E) -N- (2-amino-1,1-dimethyl-2-oxoethyl) -4- [4-({5-isopropyl-3-[(5-thio-β-D-glucopyranosyl)) Synthesis of (oxy) -1H-pyrazol-4-yl} methyl) phenyl] but-3-enamide (3E) -N- (2-hydroxy-1,1-dimethylethyl) -4- [4-({5- Isopropyl-3-[(2,3,4,6-tetra-O-acetyl-5-thio-β-D-glucopyranosyl) oxy] -1H-pyrazol-4-yl} methyl) phenyl] but-3-enamide (3E) -N- (2-amino-1,1-dimethyl-2-oxoethyl) -4- [4-({5-isopropyl-3-[(2,3,4,6-tetra- O-acetyl-5-thio-β-D-glucopyranosyl) oxy] -1 - using a pyrazol-4-yl} methyl) phenyl] but-3-enamide, to give Example 13 The title compound was prepared in a similar manner as in (5) (0.067g, 73%). The structure, NMR data and MS data of the obtained compound are shown in Table 1.
実施例15
N−(2−ヒドロキシ−1,1−ジメチルエチル)−4−[4−({5−イソプロピル−3−[(5−チオ−β−D−グルコピラノシル)オキシ]−1H−ピラゾール−4−イル}メチル)フェニル]ブタンアミドの製造
Example 15
N- (2-hydroxy-1,1-dimethylethyl) -4- [4-({5-isopropyl-3-[(5-thio-β-D-glucopyranosyl) oxy] -1H-pyrazol-4-yl } Methyl) phenyl] butanamide
(1)4−[4−({5−イソプロピル−3−[(2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシル)オキシ]−1H−ピラゾール−4−イル}メチル)フェニル]ブタン酸の合成
実施例13(3)で合成した(3E)−4−[4−({5−イソプロピル−3−[(2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシル)オキシ]−1H−ピラゾール−4−イル}メチル)フェニル]ブタ−3−エン酸(0.728g、1.13mmol)のメタノール(5mL)溶液に10%パラジウム−活性炭(70mg)を加え、水素雰囲気下で一晩攪拌した。反応液をセライト濾過後、ろ液を濃縮し、表題化合物(0.670g、91%)を得た。
1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.15 (d, J=2.33 Hz, 3 H) 1.18 (d, J=2.33 Hz, 3 H) 1.84 - 1.95 (m, 2 H) 1.86 (s, 3 H) 1.99 (s, 3 H) 2.01 - 2.02 (m, 3 H) 2.04 (s, 3 H) 2.27 - 2.37 (m, 2 H) 2.54 - 2.67 (m, 2 H) 2.84 - 2.99 (m, 1 H) 3.27 - 3.38 (m, 1 H) 3.53 - 3.68 (m, 2 H) 4.13 (dd, J=11.97, 3.96 Hz, 1 H) 4.32 (dd, J=11.97, 4.82 Hz, 1 H) 5.09 - 5.19 (m, 1 H) 5.30 - 5.44 (m, 1 H) 5.53 (t, J=8.55 Hz, 1 H) 5.75 (d, J=8.55 Hz, 1 H) 7.03 (s, 4 H).
(1) 4- [4-({5-Isopropyl-3-[(2,3,4,6-tetra-O-acetyl-5-thio-β-D-glucopyranosyl) oxy] -1H-pyrazole-4 Synthesis of -yl} methyl) phenyl] butanoic acid (3E) -4- [4-({5-isopropyl-3-[(2,3,4,6-tetra-O) synthesized in Example 13 (3) -Acetyl-5-thio-β-D-glucopyranosyl) oxy] -1H-pyrazol-4-yl} methyl) phenyl] but-3-enoic acid (0.728 g, 1.13 mmol) in methanol (5 mL). 10% palladium-activated carbon (70 mg) was added, and the mixture was stirred overnight under a hydrogen atmosphere. The reaction mixture was filtered through celite, and the filtrate was concentrated to give the title compound (0.670 g, 91%).
1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.15 (d, J = 2.33 Hz, 3 H) 1.18 (d, J = 2.33 Hz, 3 H) 1.84-1.95 (m, 2 H) 1.86 (s, 3 H) 1.99 (s, 3 H) 2.01-2.02 (m, 3 H) 2.04 (s, 3 H) 2.27-2.37 (m, 2 H) 2.54-2.67 (m, 2 H) 2.84-2.99 (m, 1 H) 3.27-3.38 (m, 1 H) 3.53-3.68 (m, 2 H) 4.13 (dd, J = 11.97, 3.96 Hz, 1 H) 4.32 (dd, J = 11.97, 4.82 Hz, 1 H) 5.09- 5.19 (m, 1 H) 5.30-5.44 (m, 1 H) 5.53 (t, J = 8.55 Hz, 1 H) 5.75 (d, J = 8.55 Hz, 1 H) 7.03 (s, 4 H).
(2)N−(2−ヒドロキシ−1,1−ジメチルエチル)−4−[4−({5−イソプロピル−3−[(5−チオ−β−D−グルコピラノシル)オキシ]−1H−ピラゾール−4−イル}メチル)フェニル]ブタンアミドの合成
(3E)−4−[4−({5−イソプロピル−3−[(2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシル)オキシ]−1H−ピラゾール−4−イル}メチル)フェニル]ブタ−3−エン酸の代わりに4−[4−({5−イソプロピル−3−[(2,3,4,6−テトラ−O−アセチル−5−チオ−β−D−グルコピラノシル)オキシ]−1H−ピラゾール−4−イル}メチル)フェニル]ブタン酸を用いて、実施例13(4)と同様の方法で0.154gの残渣を得た。
(2) N- (2-hydroxy-1,1-dimethylethyl) -4- [4-({5-isopropyl-3-[(5-thio-β-D-glucopyranosyl) oxy] -1H-pyrazole- Synthesis of 4-yl} methyl) phenyl] butanamide (3E) -4- [4-({5-isopropyl-3-[(2,3,4,6-tetra-O-acetyl-5-thio-β-) D-glucopyranosyl) oxy] -1H-pyrazol-4-yl} methyl) phenyl] but-3-enoic acid instead of 4- [4-({5-isopropyl-3-[(2,3,4,6) -Tetra-O-acetyl-5-thio-β-D-glucopyranosyl) oxy] -1H-pyrazol-4-yl} methyl) phenyl] butanoic acid was used in the same manner as in Example 13 (4). Obtained 154 g of residue.
この残渣のメタノール(2mL)溶液に、ナトリウムメトキシド(25%メタノール溶液;52μL、0.24mmol)を加え、室温で2時間攪拌した。反応液を減圧濃縮後、残渣をシリカゲルカラムクロマトグラフィ−(酢酸エチル:エタノール:水=15:2:1)で精製し、表題化合物(90mg、68%)を合成した。得られた化合物の構造、NMRデータ及びMSデータを表1に示す。 Sodium methoxide (25% methanol solution; 52 μL, 0.24 mmol) was added to a methanol (2 mL) solution of the residue, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (ethyl acetate: ethanol: water = 15: 2: 1) to synthesize the title compound (90 mg, 68%). The structure, NMR data and MS data of the obtained compound are shown in Table 1.
実施例16
N−(2−アミノ−1,1−ジメチル−2−オキソエチル)−4−[4−({5−イソプロピル−3−[(5−チオ−β−D−グルコピラノシル)オキシ]−1H−ピラゾール−4−イル}メチル)フェニル]ブタンアミドの製造
Example 16
N- (2-amino-1,1-dimethyl-2-oxoethyl) -4- [4-({5-isopropyl-3-[(5-thio-β-D-glucopyranosyl) oxy] -1H-pyrazole- 4-Il} methyl) phenyl] butanamide
2−アミノ−2−メチル−1−プロパノ−ルの代わりに2−メチルアラニンアミドを用い、実施例15(2)と同様の方法で表題化合物(69mg、54%)を得た。得られた化合物の構造、NMRデータ及びMSデータを表1に示す。 The title compound (69 mg, 54%) was obtained in the same manner as in Example 15 (2) using 2-methylalaninamide instead of 2-amino-2-methyl-1-propanol. The structure, NMR data and MS data of the obtained compound are shown in Table 1.
実施例17
N−[2−ヒドロキシ−1,1−ビス(ヒドロキシメチル)エチル]−4−[4−({5−イソプロピル−3−[(5−チオ−β−D−グルコピラノシル)オキシ]−1H−ピラゾール−4−イル}メチル)フェニル]ブタンアミドの製造
Example 17
N- [2-hydroxy-1,1-bis (hydroxymethyl) ethyl] -4- [4-({5-isopropyl-3-[(5-thio-β-D-glucopyranosyl) oxy] -1H-pyrazole Preparation of -4-yl} methyl) phenyl] butanamide
2−アミノ−2−メチル−1−プロパノ−ルの代わりにトリス(ヒドロキシメチル)アミノメタンを用い、実施例15(2)と同様の方法で表題化合物(9mg、6%)を得た。得られた化合物の構造、NMRデータ及びMSデータを表1に示す。 The title compound (9 mg, 6%) was obtained in the same manner as in Example 15 (2) using tris (hydroxymethyl) aminomethane in place of 2-amino-2-methyl-1-propanol. The structure, NMR data and MS data of the obtained compound are shown in Table 1.
実施例18
N−[1,1−ジメチル−2−(4−メチルピペラジン−1−イル)−2−オキソエチル]−4−{4−({5−イソプロピル−3−[(5−チオ−β−D−グルコピラノシル)オキシ]−1H−ピラゾール−4−イル}メチル)フェニル}ブタンアミドの製造
Example 18
N- [1,1-dimethyl-2- (4-methylpiperazin-1-yl) -2-oxoethyl] -4- {4-({5-isopropyl-3-[(5-thio-β-D- Preparation of glucopyranosyl) oxy] -1H-pyrazol-4-yl} methyl) phenyl} butanamide
2−アミノ−2−メチル−1−プロパノ−ルの代わりに2−メチル−1−(4−メチルピペラジン−1−イル)−1−オキソプロパン−2−アミンを用い、実施例15(2)と同様の方法で表題化合物(69mg、54%)を得た。得られた化合物の構造、NMRデータ及びMSデータを表1に示す。 Example 15 (2) using 2-methyl-1- (4-methylpiperazin-1-yl) -1-oxopropan-2-amine instead of 2-amino-2-methyl-1-propanol To give the title compound (69 mg, 54%). The structure, NMR data and MS data of the obtained compound are shown in Table 1.
製剤実施例 Formulation examples
製造方法
薬物(本発明化合物)を乳糖一水和物、結晶セルロ−ス、カルボキシメチルセルロ−スカルシウム及びヒドロキシプロピルセルロ−スと混合し、この混合物を粉砕機で粉砕する。粉砕された混合物を撹拌造粒機で1分間混合し、その後、水で4〜8分間造粒する。得られた造粒物を70℃、40分間乾燥する。造粒乾燥末を500μmの篩で篩過する。篩過後の造粒乾燥末とステアリン酸マグネシウムを、V型混合機を用いて30rpmで3分間混合する。ロ−タリ−式打錠機を用いて得られた打錠用顆粒を圧縮成形し製錠する。
Production Method The drug (the compound of the present invention) is mixed with lactose monohydrate, crystalline cellulose, carboxymethyl cellulose calcium and hydroxypropyl cellulose, and this mixture is pulverized with a pulverizer. The pulverized mixture is mixed for 1 minute with a stirring granulator and then granulated with water for 4-8 minutes. The obtained granulated product is dried at 70 ° C. for 40 minutes. The granulated dry powder is sieved with a 500 μm sieve. The granulated dry powder after sieving and magnesium stearate are mixed for 3 minutes at 30 rpm using a V-type mixer. The tableting granules obtained using a rotary tableting machine are compression-molded and tableted.
試験例1
(1)ヒトSGLT1とヒトSGLT2のクローニングと発現ベクターへの導入
ヒト小腸由来mRNAからヒトSGLT1配列(NM_000343)を逆転写の後増幅し、pCMV−tag5A(ストラタジーン社)に導入した。また、ヒトSGLT2配列(NM_003041)はヒト腎由来mRNAから同様な方法で調製し、pcDNA3.1+hygro(インビトロジェン社)に導入した。それぞれのクローンの配列が、報告されている配列と一致することを確認した。
Test example 1
(1) Cloning of human SGLT1 and human SGLT2 and introduction into expression vector Human SGLT1 sequence (NM_000343) was amplified from human small intestine-derived mRNA after reverse transcription and introduced into pCMV-tag5A (Stratagene). The human SGLT2 sequence (NM_003041) was prepared from human kidney-derived mRNA by the same method and introduced into pcDNA3.1 + hygro (Invitrogen). It was confirmed that the sequence of each clone matched the reported sequence.
(2)ヒトSGLT1及びヒトSGLT2を安定に発現するCHO−k1細胞の作成
ヒトSGLT1およびヒトSGLT2発現ベクターを、リポフェクトアミン2000(インビトロジェン社)を用いてCHO−K1細胞へトランスフェクションした。SGLT発現細胞は、500μg/mLの濃度のジェネティシン(SGLT1)またはハイグロマイシンB(SGLT2)の存在下で培養し耐性株を選択し、下記に示す系により糖取り込み比活性を指標に取得した。
(2) Preparation of CHO-k1 cells stably expressing human SGLT1 and human SGLT2 Human SGLT1 and human SGLT2 expression vectors were transfected into CHO-K1 cells using Lipofectamine 2000 (Invitrogen). SGLT-expressing cells were cultured in the presence of geneticin (SGLT1) or hygromycin B (SGLT2) at a concentration of 500 μg / mL, resistant strains were selected, and the sugar uptake specific activity was obtained using the system shown below as an index.
(3)細胞におけるナトリウム依存的糖取り込み阻害試験
ヒトSGLT1又はヒトSGLT2を安定に発現する細胞をナトリウム依存的グルコース取り込み活性阻害試験に用いた。
(3) Sodium-dependent glucose uptake inhibition test in cells Cells stably expressing human SGLT1 or human SGLT2 were used in sodium-dependent glucose uptake activity inhibition tests.
前処理用緩衝液(140mM 塩化コリン、2mM KCl、1mM CaCl2、1mM MgCl2、10mM HEPES/5mM Tris、pH7.4)200μLをヒトSGLT1発現細胞に又は2mLをヒトSGLT2発現細胞に加え、20分間インキュベーションした。前処理用緩衝液を除去し、試験化合物を含む取り込み用緩衝液([14C]メチル α−D−グルコピラノシドを含むメチル α−D−グルコピラノシド(1mM)、145mM NaCl、2mM KCl、1mM CaCl2、1mM MgCl2、10mM HEPES/5mM Tris、pH7.4)を75μL(SGLT1の場合)又は200μL(SGLT2の場合)加え、37℃にて30分(SGLT1の場合)又は1時間(SGLT2の場合)取り込み反応を行った。反応後細胞を洗浄用緩衝液(10mM メチル α−D−グルコピラノシド、140mM 塩化コリン2mM KCl、1mM CaCl2、1mM MgCl2、10mM HEPES/5mM Tris、pH7.4)200μL(SGLT1の場合)又は2mL(SGLT2の場合)で2回洗浄し、0.2M NaOH溶液75μL(SGLT1の場合)又は400μL(SGLT2の場合)に溶かした。液体シンチレーター(パーキンエルマー社)を加えよく混和した後、microBETA(SGLT1の場合)又は液体シンチレーションカウンター(SGLT2の場合)(ベックマンコールター社)で放射活性を測定した。対照群として試験化合物を含まない取り込み用緩衝液を調製した。また基礎取り込み用としてNaClに代えて塩化コリンを含む取り込み用緩衝液を調製した。 Add 200 μL of pretreatment buffer (140 mM choline chloride, 2 mM KCl, 1 mM CaCl 2 , 1 mM MgCl 2 , 10 mM HEPES / 5 mM Tris, pH 7.4) to human SGLT1-expressing cells or 2 mL to human SGLT2-expressing cells for 20 minutes Incubated. The pretreatment buffer is removed and the uptake buffer containing the test compound ([ 14 C] methyl α-D-glucopyranoside containing methyl α-D-glucopyranoside (1 mM), 145 mM NaCl, 2 mM KCl, 1 mM CaCl 2 , Add 75 μL (for SGLT1) or 200 μL (for SGLT2) and add 30 mM (for SGLT1) or 1 hour (for SGLT2) at 37 ° C. with 1 mM MgCl 2 , 10 mM HEPES / 5 mM Tris, pH 7.4) Reaction was performed. After the reaction, the cells were washed with a washing buffer (10 mM methyl α-D-glucopyranoside, 140 mM choline chloride 2 mM KCl, 1 mM CaCl 2 , 1 mM MgCl 2 , 10 mM HEPES / 5 mM Tris, pH 7.4) 200 μL (for SGLT1) or 2 mL ( Washed twice with SGLT2) and dissolved in 75 μL 0.2M NaOH solution (for SGLT1) or 400 μL (for SGLT2). After adding a liquid scintillator (Perkin Elmer) and mixing well, the radioactivity was measured with a microBETA (for SGLT1) or a liquid scintillation counter (for SGLT2) (Beckman Coulter). As a control group, an uptake buffer containing no test compound was prepared. For basal uptake, an uptake buffer containing choline chloride instead of NaCl was prepared.
IC50値を求めるにあたり、適当な6濃度の試験化合物を用い、対照群の糖取り込み量(100%)に対し、糖取り込み量が50%阻害される試験化合物濃度(IC50値)を算出した。試験結果を表4に示す。 In determining the IC 50 value, the test compound concentration (IC 50 value) at which the sugar uptake amount was inhibited by 50% relative to the sugar uptake amount (100%) of the control group was calculated using appropriate 6 concentrations of the test compound. . The test results are shown in Table 4.
試験例2
ストレプトゾトシン糖尿病モデルラットにおける血糖値上昇抑制作用確認試験
(1)糖尿病モデルラットの作製
7週齢のSD/IGSラット(日本チャールスリバー株式会社,雄性)について約16時間の絶食後、エーテル麻酔下でストレプトゾトシン(STZ)50mg/kgを尾静脈内投与し、糖尿病モデルラットを作製した.同様にエーテル麻酔下,1.25mmol/Lクエン酸生理食塩液1mL/kgを尾静脈内投与し、正常対照ラットを作製した。STZまたは1.25mmol/Lクエン酸生理食塩液投与1週後(8週齢)、経口グルコース負荷試験に供した。
Test example 2
Test for confirming inhibitory effect on blood glucose level in streptozotocin diabetic model rats (1) Preparation of diabetic model rats Seven-week-old SD / IGS rats (Nippon Charles River Co., Ltd., male) were fasted for about 16 hours and then streptozotocin under ether anesthesia. (STZ) 50 mg / kg was administered into the tail vein to prepare diabetes model rats. Similarly, 1 mL / kg of 1.25 mmol / L citric acid physiological saline was administered into the tail vein under ether anesthesia to produce normal control rats. One week after administration of STZ or 1.25 mmol / L citrate physiological saline (8 weeks of age), it was subjected to an oral glucose tolerance test.
(2)経口グルコース負荷試験
ラットを約16時間の絶食後、薬物投与群には、0.5%カルボキシメチルセルロース(CMC)水溶液に懸濁した薬物(1mg/kg)を,対照群には0.5%CMC水溶液のみ経口投与した。薬物投与5分後に、グルコース溶液(2g/kg)を経口投与し、薬物投与前(0time)、及び、経口投与0.25、0.5、1、2時間後の計5点で採血した。
(2) Oral glucose tolerance test After fasting rats for about 16 hours, the drug-administered group received a drug (1 mg / kg) suspended in 0.5% carboxymethylcellulose (CMC) aqueous solution, and the control group received 0. Only 5% CMC aqueous solution was orally administered. Five minutes after drug administration, glucose solution (2 g / kg) was orally administered, and blood was collected at a total of 5 points before drug administration (0 time) and 0.25, 0.5, and 1, 2 hours after oral administration.
採血は、エーテル麻酔下でラット眼窩静脈洞よりヘパリンコート採血管を用いて行い、遠心分離後、血漿を分取した。血漿中グルコース濃度の定量は、グルコースCIIテストワコー(和光純薬株式会社)を用いて測定した。血糖値上昇抑制作用強度は、各薬物投与群の0から1時間までの血糖値より台形法を用いて血糖値-時間曲線下面積(AUC)を算出し、basalを差し引いた血糖増加面積(ΔAUC)として表記し、対照群のそれに対する降下の割合で表記した。結果を表5に示す。 Blood collection was performed under ether anesthesia using a heparin-coated blood collection tube from the rat orbital sinus, and after centrifugation, plasma was collected. The plasma glucose concentration was measured using Glucose CII Test Wako (Wako Pure Chemical Industries, Ltd.). The increase in blood glucose level is calculated by calculating the area under the blood glucose level-time curve (AUC) using the trapezoidal method from the blood glucose level from 0 to 1 hour in each drug administration group, and the area of increased blood glucose (ΔAUC) after subtracting basal ) And expressed as the rate of descent relative to that of the control group. The results are shown in Table 5.
本発明により、小腸上皮に発現するSGLT1(ナトリウム依存性グルコース共輸送体1)を選択的に阻害し、小腸からの糖吸収を阻害することによって、IGT(耐糖能異常)を制御するピラゾリル 5−チオグルコシド化合物を有効成分として含有する糖尿病の予防又は治療剤を提供することが期待される。 According to the present invention, pyrazolyl 5 regulates IGT (abnormal glucose tolerance) by selectively inhibiting SGLT1 (sodium-dependent glucose cotransporter 1) expressed in the small intestine epithelium and inhibiting sugar absorption from the small intestine. It is expected to provide a preventive or therapeutic agent for diabetes containing a thioglucoside compound as an active ingredient.
Claims (10)
R1、R2及びR3は同一または異なって、水素原子、ハロゲン原子、C1-6アルコキシ基またはC1-6アルキル基であり、
Yは単結合、C1-6アルキレン基、C2-6アルケニレン基または−O−(CH2)n−(nは1から4の整数を示す)であり、
Qは水酸基、−OC1-4アルキルフェニル、−N(RA)RBまたは−CONHRCである、
但し、Qが水酸基、−OC1-4アルキルフェニルまたは−NH2のとき、Yは単結合ではない。
RA及びRBは同一または異なって、水素原子、−CONHRD(RDは水素原子または、水酸基及びピリジル基からなる群から選択される置換基で置換されてもよいC1-6アルキル基を示す)、−C(=NH)NHRE(REは水素原子、または−CO2C1-4アルキルフェニルである)、あるいは、C1-6アルキル基(該C1-6アルキル基は、水酸基、−CONH2及び−OC1-4アルキルフェニルからなる群から選択される置換基で置換されてもよい)であり、
RCは水酸基及び−CON(RF)RGからなる群より選択される置換基で置換されたC1-6アルキル基であり、
RF及びRGは、同一または異なって、水素原子またはC1-6アルキル基であるか、あるいはRF及びRGが結合している窒素原子と一緒になって、さらに環構成原子として、酸素原子、硫黄原子及び窒素原子から選択されるヘテロ原子を含んでも良い5〜6員のヘテロシクロアルキル基(該ヘテロシクロアルキル基は水酸基で置換されても良いC1-6アルキル基で置換されてもよい)を形成してもよい。 A prophylactic or therapeutic agent for diabetes comprising a pyrazolyl 5-thioglucoside compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof or a hydrate thereof as an active ingredient.
R 1 , R 2 and R 3 are the same or different and are a hydrogen atom, a halogen atom, a C 1-6 alkoxy group or a C 1-6 alkyl group,
Y is a single bond, a C 1-6 alkylene group, a C 2-6 alkenylene group or —O— (CH 2 ) n — (n represents an integer of 1 to 4);
Q is a hydroxyl group, a -OC 1-4 alkyl phenyl, -N (R A) R B or -CONHR C,
However, when Q is a hydroxyl group, —OC 1-4 alkylphenyl or —NH 2 , Y is not a single bond.
R A and R B are the same or different and are a hydrogen atom, —CONHR D (R D is a hydrogen atom or a C 1-6 alkyl group which may be substituted with a substituent selected from the group consisting of a hydroxyl group and a pyridyl group. ), —C (═NH) NHR E (R E is a hydrogen atom, or —CO 2 C 1-4 alkylphenyl), or a C 1-6 alkyl group (the C 1-6 alkyl group is Which may be substituted with a substituent selected from the group consisting of a hydroxyl group, —CONH 2 and —OC 1-4 alkylphenyl),
R C is a C 1-6 alkyl group substituted with a substituent selected from the group consisting of a hydroxyl group and —CON (R F ) RG ;
R F and R G are the same or different and are a hydrogen atom or a C 1-6 alkyl group, or together with the nitrogen atom to which R F and R G are bonded, A 5- to 6-membered heterocycloalkyl group which may contain a heteroatom selected from an oxygen atom, a sulfur atom and a nitrogen atom (the heterocycloalkyl group is substituted with a C 1-6 alkyl group which may be substituted with a hydroxyl group) May be formed).
から4の整数である)である、請求項1記載のピラゾリル 5−チオグルコシド化合物若しくはその製薬学的に許容される塩又はそれらの水和物を有効成分として含有する、糖尿病の予防又は治療剤。 Y is a C 1-6 alkylene group, a C 2-6 alkenylene group or —O— (CH 2 ) n — (n is 2
Or a pharmaceutically acceptable salt thereof, or a hydrate thereof, as an active ingredient, which is an integer from 1 to 4). .
Yは、−O−(CH2)n−(nは1から4の整数である)であり、
Qは、水酸基、−OC1-4アルキルフェニル、又は−N(RA)RBであり、
RA及びRBは、同一又は異なって、水素原子、−CONH2で置換されたC1-6アルキル基、−CONHRD(RDは、水酸基で置換されたC1-6アルキル基である)、あるいは−C(=NH)NHRE(REは、水素原子または−CO2C1-4アルキルフェニルである)である、請求項1記載のピラゾリル 5−チオグルコシド化合物若しくはその製薬学的に許容される塩又はそれらの水和物を有効成分として含有する、糖尿病の予防又は治療剤。 R 1 , R 2 and R 3 are the same or different and each represents a hydrogen atom or a C 1-6 alkyl group;
Y is -O- (CH 2) n- (n is an integer of 1 to 4),
Q is a hydroxyl group, —OC 1-4 alkylphenyl, or —N (R A ) R B ;
R A and R B are the same or different and are a hydrogen atom, a C 1-6 alkyl group substituted with —CONH 2 , or —CONHR D (R D is a C 1-6 alkyl group substituted with a hydroxyl group. , Or -C (= NH) NHR E (R E is a hydrogen atom or -CO 2 C 1-4 alkylphenyl), or a pharmacological compound thereof A prophylactic or therapeutic agent for diabetes, which contains a salt or hydrate thereof as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007279690A JP2009107947A (en) | 2007-10-26 | 2007-10-26 | Agent for treating diabetes, containing pyrazolyl 5-thioglucoside compound as active ingredient |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007279690A JP2009107947A (en) | 2007-10-26 | 2007-10-26 | Agent for treating diabetes, containing pyrazolyl 5-thioglucoside compound as active ingredient |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2009107947A true JP2009107947A (en) | 2009-05-21 |
Family
ID=40776866
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007279690A Pending JP2009107947A (en) | 2007-10-26 | 2007-10-26 | Agent for treating diabetes, containing pyrazolyl 5-thioglucoside compound as active ingredient |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2009107947A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011039338A3 (en) * | 2009-10-02 | 2011-08-25 | Sanofi | Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone diseases |
WO2012023600A1 (en) * | 2010-08-20 | 2012-02-23 | 大正製薬株式会社 | 4-isopropyl-6-methoxyphenyl glucitol compound |
-
2007
- 2007-10-26 JP JP2007279690A patent/JP2009107947A/en active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011039338A3 (en) * | 2009-10-02 | 2011-08-25 | Sanofi | Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone diseases |
WO2012023600A1 (en) * | 2010-08-20 | 2012-02-23 | 大正製薬株式会社 | 4-isopropyl-6-methoxyphenyl glucitol compound |
US9161945B2 (en) | 2010-08-20 | 2015-10-20 | Taisho Pharmaceutical Co., Ltd. | 4-isopropyl-6-methoxyphenyl glucitol compound |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5067644B2 (en) | C-phenylglycitol compound | |
JP5152519B2 (en) | C-phenyl 1-thioglucitol compound | |
WO2007129668A1 (en) | Pyrazolyl 5-thioglucoside compound | |
JPWO2008072726A1 (en) | 1-Phenyl 1-thio-D-glucitol derivative | |
WO2007126117A1 (en) | Phenyl 5-thioglucoside compound | |
TWI298071B (en) | ||
TW200533349A (en) | Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs | |
JP2007145786A (en) | Pyrazine derivative and nephritis-treating medicine containing the same as active ingredient | |
JP2009120553A (en) | Therapeutic agent for diabetes containing c-phenyl glucitol compound as effective ingredient | |
JP2009107947A (en) | Agent for treating diabetes, containing pyrazolyl 5-thioglucoside compound as active ingredient | |
JP2009107948A (en) | Agent for treating diabetes, containing phenyl 5-thioglucoside compound as active ingredient | |
JP2009155212A (en) | Therapeutic agent for diabetes comprising c-phenyl 1-thioglucitol compound as active ingredient | |
JP2010018611A (en) | Preventive or therapeutic agent for diabetes, diabetes-related diseases or diabetic complications containing 1-phenyl 1-thio-d-glucitol derivative as effective ingredient | |
JP2014070051A (en) | Nipecotic acid derivative, and its medicinal use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20090624 |